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Abstract 
 
Nanomedicine utilises biocompatible nanomaterials for therapeutic as well as imaging 
purposes, for the treatment of various diseases including cancer, neurological disorders 
and wound infections. Graphene, a material composed of a single layer of carbon atoms, 
has recently shown great potential to improve diagnostics and therapeutics, owing to its 
small size, large surface-area-to-volume ratio and unique physicochemical properties. 
However, the limited fabrication, in vitro and in vivo functionalities published in the 
literature indicate inconsistencies regarding the factors affecting metabolic fate, 
biodistribution as well as toxicity patterns of graphene. This thesis focuses on the 
biological effects of graphene-based materials, including graphene oxide (GO), reduced 
graphene oxide (rGO), graphene nanopores (GNPs), graphene quantum dots (GQDs) 
and three-dimensional graphene foam (GF). These can be used to closely mimic 
therapeutic functions and thereby open up new pathways to anticancer nanomedicine. In 
this work, a biocompatible GO-based anti-metastatic enzyme cancer therapy approach 
has been introduced for the first time to target the extracellular pro-metastatic and pro- 
tumourigenic enzymes of cathepsin D and cathepsin L, which are typically overexpressed 
in ovarian and breast cancers. Definitive binding and modulation of cathepsin- D and -L 
with GO has revealed that both of the enzymes were adsorbed onto the surface of GO 
through its cationic and hydrophilic residues under the biologically relevant condition of 
acidic pH. It has been demonstrated that low concentrations of rGO were shown to 
significantly produce late apoptosis and necrosis rather than early apoptotic events in 
lung cancer cells (A549 and SKMES-1), suggesting that it was able to disintegrate the 
cellular membranes in a dose-dependent manner. GNPs at lower concentrations 
(250µg/ml) induce upregulation of phosphatidylserine on cell surface membrane (i.e. 
early apoptotic event), which does not significantly disintegrate the cell membrane in the 
aforementioned lung cancer cells, while higher concentrations of GNPs (5 and 15 mg/kg) 
in rats (when intraperitoneally injected) exhibited sub-chronic toxicity in a period of 27 
days. The interaction of GQDs and trypsin has revealed the strong bonding capacity of 
GQDs with trypsin, owing to their surface charge and surface functionalities evidencing 
the high bioavailability of GQDs in enzyme engineering. Finally, 3D GF was developed 
to probe the role of graphene-based scaffold cues in the field of regenerative medicine 
revealing their cell attachment to in vitro cell cultures. Furthermore, GF was shown to 
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maintain remarkable biocompatibility with in vitro and in vivo toxicity screening models 
when exposed for 7 days at doses of 5, 10 and 15 mg/l. Taken together, graphene and 
its modified structures developed in this thesis promise to revolutionise clinical settings 
across the board in nanomedicine which include, but are not limited to, ultra-high 
sensitive enzyme adsorbents, high throughput biosensors, enzyme modulators and 
smart scaffolds for tissue regeneration.  
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Chapter 1 
Introduction  
1.1 Background  
 
The use of graphene is becoming well established in the fields of photonics and 
electronics, but it is only now, with the technologies maturing, that it is branching out into 
new areas such as nanomedicine and synthetic biology. Its use promises to revolutionise 
clinical settings across the board in areas including, but not limited to, drug delivery 
systems for theranostics, high throughput biosensors and bioassay, smart scaffolds for 
tissue regeneration, and ultra-high sensitivity biomarkers [1-3]. Graphene is the 
archetypal monolayer framework of carbon atoms, forming the basis of carbon 
nanotubes, fullerenes, and graphite [4]. Graphite is composed of stacked graphene 
layers, each layer being one atom thick and composed of sp2 hybridised carbon atoms 
packed in a hexagonal lattice [5]. The unique and tunable features of different derivatives 
of graphene (including pristine graphene, graphene oxide, reduced graphene oxide, 
graphene quantum dots, nanoribbons and nanoplatelets, three dimensional graphene 
foam, and many others) promises many new approaches in medical interventions, where 
its high specific surface area, exceptional electrical and thermal charateristics, and high 
strength could be a boon for drug delivery techniques [6-8] (See scheme 1.1). Their 
lateral dimensions and thickness can be tuned between nano- to milli-metres and mono- 
to few-layers, respectively. In addition, their two-dimensional nature can be modified to 
zero, one and three-dimensional assemblies [9]. Graphene-based materials are perhaps 
the first systems that allow us to take advantage of such a tunability approach, improving 
the accumulation of drug vehicles and contrast agents at specific target sites in different 
diseases. Applications of graphene in the biomedical field are currently in their early 
stages, and over the past decade, the use of nanostructured graphene in cancer 
diagnosis and therapy along with their potential toxic effects have become increasingly 
important. The continuous and widespread exposure of graphene-based materials raises 
urgent occupational, environmental and health concerns to living organisms. The first 
study on graphene in drug delivery was reported by the Hongjie Dai group in 2008, 
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demonstrating that doxorubicin, a widely utlilised anticancer drug, can be loaded to nano-
graphene oxide (tagged with antibody) for in vitro targeting of tumors [10]. Since then, 
many significant studies on graphene-based materials for drug delivery systems, bio-
imaging, and biosensors have been reported [11,12].  
  
 
Scheme 1.1: A schematic diagram of the biological applications of graphene-based materials, the 
potential mechanism of toxicity and graphene-mediated reactive oxygen and nitrogen species (RONS) 
generation. The lower panel represents the preparation and structures of graphene oxide and reduced 
graphene oxide. Chemical preparation of graphene is generally carried out by oxidation and exfoliation 
of graphite flakes while reduced graphene oxide is prepared by reduction of graphene oxide using a 
variety of reducing agents, such as sulphur, hydrazine and nitrogen, which helps eliminate the functional 
groups existing on the surface of graphene. The upper right panel refers to the applications of graphene 
in the biomedical field such as cancer, infectious, inflammatory, and cardiovascular and 
neurodegenerative diseases and the middle panel represents the oxygen and nitrogen centred radicals 
such as hydroxyl radical (•OH), hydrogen peroxide (H2O2),superoxide (•O−2), singlet oxygen (1O2), 
ONOO− (peroxynitrite), nitric oxide (NO). The left panel shows the potential toxic pathways of graphene 
within a cell such as cell cycle arrest, apoptosis, damage to the cell membrane, mitochondrial and DNA 
damages.  
 
25 
 
Nanomedicine refers to the application of nanotechnology to healthcare management, 
which aims to develop and implement new mechanisms, platforms, and treatment 
options for the diagnosis and treatment of human diseases. This paradigm has widely 
been benefited by cancer research and care in recent years [13]. The prepartion of 
graphene nanostructures is at the forefront of anticancer nanomedicine. Graphene-
based materials have extensively been exploited for standard treatment options, 
including surgical resection, alongside therapeutic strategies (such as chemotherapy, 
radiotherapy, and photodynamic therapy) [14-16]. The graphene nanostructures 
designed and reported so far in the literature reveal remarkable efficacy for their in vitro 
and in vivo applicability against several malignant tumors and cell lines; nevertheless, 
the physiochemical interaction of graphene nanostructures with cells and biological 
tissues needs to be explored to better achieve their bio functionality and reduced side 
effects [17-19]. Some of these studies have reported higher toxicity levels of graphene 
compared to other nanoparticles [20]. Although recent studies have demonstrated their 
in vitro and in vivo anti-cancer applicability in nanomedicine, there still exists a critical 
need to explore the potential health benefits and risks of these materials in living models 
[21,22]. In vivo toxicity findings for acute, sub-chronic and chronic circulation, 
biodistribution, and clearance of nanomedicines are not fully understood. Furthermore, 
the influence of surface chemistry of graphene-based materials for protein adsorption 
has not been studied [23]. 
 
It has become evident that the protein adsorption is vital in biomedical engineering to 
determine the hemo‐ and biocompatibility and biological relevant properties of 
nanomaterials [24]. The high adsorption capacities of such nanomaterials could make 
them an ideal candidate for progressive loading of high molecular weight drugs and their 
control release at targeted sites. Similarly, high specific adsorption of pro-metastatic 
enzymes can be a promising strategy to remove and clear out such enzymes in various 
cancers. For example, cathepsin D and cathepsin L are overexpressed extracellular 
enzymes in several human cancers [25]. Each enzyme plays an important role in 
directing cancer development, proliferation, and metastasis within the tumor 
microenvironment [26, 27]. Therefore, it is important to discover novel therapeutic 
treatment strategies to target such pro-metastatic enzymes to impede metastasis. With 
further discoveries on innovative biocompatible adsorbent interactions with enzymes 
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and advances in adsorbent delivery to tumor microenvironments, the class of graphene 
nanostructures could prove to be important vehicles to deliver, deactivate and clear out 
pro-metastatic enzymes used as novel therapies for disease management. Taken 
together, the current challenges in developing the next generation of graphene-based 
platform for cancer therapeutics are: 1) toxic effect of graphene nanostructures on 
cancer cells and biological tissues; 2) Interaction of the most abundant proteins with 
graphene; and 3) adsorption of extracellularly found pro-metastatic enzymes by 
graphene-based materials for their selective and targeted clearance for the point-of-care 
management and treatment of cancer. This thesis takes these challenges into account 
to contribute to the contemporary anticancer nanomedicine research. 
 
1.2 Specific aims and overview of the thesis 
 
The translation of current advances in graphene-based anticancer nanomedicine have 
the potential to address important unmet needs and to transform healthcare. To make 
it happen via this project, it is hypothesised that the development of graphene 
structures could play an important role in cancer treatment.  
 
Sub-hypotheses: (i) Graphene oxide could target and adsorb extracellular cathepsin 
D and cathepsin L in anti-metastatic enzyme cancer therapy; (ii) reduced graphene 
oxide could cause toxic effects on cancer cells by inducing programmed cell death; (iii) 
graphene nanopores could affect biological tissues at sub-chronic levels, affirming the 
limited biosafety of such nanopores which are not bioavailable for healthcare 
management; (iv) the interaction of graphene quantum dots and trypsin (the most 
abundant digestive protein) could lead to the formation of protein coronas and nano-
bio-interfaces, which in turn could determine the ultimate fate of graphene quantum 
dots in enzyme engineering; (v) the bioavailability of three-dimensional graphene foam 
based scaffolds in biological tissues could allow cells to attach and regrow in a 3D 
microenvironment , as well as facilitate the development of novel regenerative medical 
treatments to help restore and strengthen lost functionality. 
 
The primary research component of this thesis is focused on testing these hypotheses 
to achieve the aims of the project. The following were the set aims: 
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Aim 1: To demonstrate selective targeting of biocompatible graphene oxide for anti-
metastatic enzyme cancer therapy, by assessing the adsorption capacity of graphene 
oxide to target and remove extracellular pro-metastatic and -tumourigenic enzymes 
cathepsin D and cathepsin L when exposed under different acidic conditions. This aim 
is to test sub-hypothesis (i). 
 
Aim 2: To investigate the mechanism of cell death induced by reduced graphene oxide 
in lung cancer cells. This aim is to test sub-hypothesis (ii). 
 
Aim 3: To develop a facile and scalable route for graphene nanopores preparation and 
to correlate targeting, intracellular destination, and local dissolution of as-prepared 
graphene nanopores with their toxicity mechanism in lung cancer cells and biological 
tissues. This aim is to test sub-hypothesis (iii). 
 
Aim 4: To assess the integrative physiochemical interaction between trypsin and 
graphene quantum dots to determine their potential biological identity in enzyme 
engineering at different conditions of enzyme activity and concentration of quantum 
dots, as well as nature of their binding. This aim is to test sub-hypothesis (iv). 
 
Aim 5: To investigate the in vitro and in vivo bioavailability of 3D graphene foam based 
scaffolds, and to address the role of physicochemical properties of graphene scaffolds 
in cell attachment and regrowth to reduce the side effects associated with cell 
regeneration, leading to potential effectiveness of stem cell therapy.  This aim is to test 
sub-hypothesis (v). 
 
1.3 Structure of the thesis 
 
This thesis is divided into 9 chapters. Chapter 1 presents an overview of this thesis 
and defines the hypothesis, aims and significance of the work. Chapter 2 will describe 
the features, development, toxicity mechanism and application of graphene-based 
materials in cancer treatment. Chapter 3 will present the various analysis techniques 
used in this thesis. Chapter 4 is the first experimental chapter. It will discuss the 
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development of highly adaptable and straightforward GO-based strategies for the rapid 
and facile removal of pro-metastasis enzymes that could effectively rescue the 
disease. Chapter 5 will present the in vitro toxic effects and limited bioavailability of 
unmodified reduced graphene oxide on lung cancer cells. Chapter 6 will present the 
novel synthesis of graphene nanopores and further in vitro and in vivo investigations 
into the toxicity and biocompatibility of graphene nanopores on lung cancer cells and 
organs of rats. This is to elucidate the toxicity mechanism by analysing the oxidative 
stress and subsequent programmed cell death in time and dose dependent manner. 
Chapter 7 will describe the interactions of graphene quantum dots with trypsin to 
elucidate the general fate of these dots in biological systems as a potential substrate 
for efficient enzyme immobilisation, separation, and purification approaches. Chapter 
8 will focus on the fabrication and biocompatibility of three-dimensional porous 
graphene foam-based scaffolds to investigate cell viability, attachment and growth 
within 3D microenvironments promoting their potential biostability, survival, integration, 
enhanced differentiation, and synergistic cell control signals. Chapter 9 will summarise 
the key findings, their impact, and future directions of this work for the progress of 
nanomedicine and biomedical engineering fields. 
 
1.4 Significance of the thesis 
 
The overall goal of this research work is to contribute to the fundamental understanding 
of graphene nanostructures in anticancer nanomedicine, enabling a biomedical 
research market that would allow these translational technologies to solve real-world 
clinical problems. Current state-of-the-art methodologies based on graphene 
nanostructures are limited primarily through pre-clinical constraints as outlined earlier, 
such as non-specific targeting of malignant tumors alongside side effects on normal 
cells, as well as cost effectiveness of such materials [28]. This thesis involves zero to 
three-dimensional sized structures of graphene. The research work will contribute in 
four broad and valuable ways to expanding the knowledge of anticancer 
nanomedicine. Firstly, this work has revealed that graphene oxide, with its variable 
zeta potential, variety of functional groups and very large (and in principle fully 
accessible) surface area, is an ideal candidate for the adsorption and inhibition of 
cathepsin D and cathepsin L, which in turn could enhance the anti-metastatic 
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challenges faced in breast and ovarian cancers. Given the therapeutic challenges 
posed by secreted cathepsin D and L in breast and ovarian cancers, a fuller clearance 
of these proteins before their involvement in secondary tumour formation may aid 
development of new treatment modalities. Additionally, graphene oxide nanostructures 
are easy to manufacture and are stable, which simplifies long-term storage and 
correspondingly reduces the cost. Secondly, this work demonstrates the toxicological 
effects of reduced graphene oxide and graphene nanopores to look at their biosafety 
profile for clinical applications. Furthermore, the novel, facile and scalable synthesis of 
graphene nanopores was carried out via thermal treatment of reduced graphene oxide. 
Graphene nanopores are also promising candidates for DNA sequencing, but their 
toxicological implications have not been studied before. In vivo toxicity findings for long 
term acute, sub-chronic and chronic circulation, biodistribution, specific targeting within 
diseased cells and clearance of nanomedicines have not been fully understood. 
Thirdly, for the first time, the interaction of graphene quantum dots with trypsin and the 
impact of graphene quantum dots on the adsorption of enzymes was evaluated. 
Investigation into such interactions could play an increasingly important role in 
bionanotechnology and enzyme engineering to assess the biocompatibility of such 
biomaterials in applications of blood purification, biocatalysis, and in drug delivery as 
a vehicle for loading of high molecular weight drugs and metabolites. Lastly, a 
biocompatible 3D graphene-based scaffold was designed to be used in cell 
regeneration and growth. Currently, there is no in vivo and in vitro toxicity study 
available for the side effects of this type of scaffold on biological tissues for potential 
applications in stem cell and regenerative therapies. 
 
In summary, this work is a key step in the roadmap for the progressive integration of 
graphene nanostructures to be practical in a clinical setting. With further discoveries 
arising from the interplay between nanostructured graphene and biological systems, 
and advances in the delivery of graphene-based materials to tumor 
microenvironments, the class of graphene nanostructures described here will prove to 
be important vehicles to deliver nanodrugs and clear out pro-metastatic enzymes in 
the point-of-care management and treatment of cancer. 
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Chapter 2 
Literature Review 
 
 Graphene has a promising future in applications such as disease diagnosis, cancer 
therapy, and drug/gene delivery, bio-imaging and antibacterial approaches owing to 
graphene’s unique physiochemical and mechanical features alongside minimal 
toxicity, and photo-stability. However, these unique features and bioavailability of 
graphene are fraught with uncertainties and concerns for environmental and 
occupational exposure. Changes in the physicochemical properties of graphene affect 
biological responses including reactive oxygen species (ROS) production. Lower 
production of ROS by currently available theranostic agents, e.g. magnetic 
nanoparticles, carbon nanotubes, gold nanostructures or polymeric nanoparticles, 
restricts their clinical application. Oxidative stress induced by graphene accumulated 
in living organs is due to acellular factors which may affect physiological interactions 
between graphene and target biological tissues and cells. Acellular factors include 
particle size, shape, surface charge, surface containing functional groups, and light 
activation. Cellular responses such as mitochondrial respiration, graphene-cell 
interactions and pH of the medium are also determinants of ROS production. The 
mechauism of toxicity for nanostructured graphene is poorly understood. This chapter 
describes the structures, properties, preparation methods, mechanism of toxicity and 
biomedical applications of graphene. 
 
2.1 Structures and properties of graphene nanostructures 
 
 Cancer is one of the leading causes of morbidity and mortality worldwide, with more 
than 14 million new cases and 8.8 million deaths in 2012 [1]. Globally, cancer accounts 
for nearly one of every six deaths. Cancer elicits a significant economic cost. The total 
annual economic cost of cancer in 2010 was estimated at approximately US$ 1.16 
trillion [2]. Conventional therapeutic options including chemotherapy and radiation 
therapy are most commonly used in the treatment of cancer. However, these 
modalities yield low success rates and have profound adverse side effects on patients' 
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physical and mental health [3]. Therefore less invasive, and more effectively targeted, 
treatments need to be developed for palliative care and improvement of quality of life. 
Novel regimes for simultaneous diagnosis and therapy, known as theranostics, have 
changed the cancer treatment algorithm by the combination of bio-imaging with site-
specific and site-selective targeting of tumors, without damaging normal cells [4]. A 
schematic representation of the components of a typical theranostic platform is given 
in Figure 2.1.  
 
 The two key components of this theranostic platform are: first, targeted diagnostic 
imaging modalities and, secondly, targeted delivery of therapies such as photodynamic 
therapy (PDT). An excellent review of targeted diagnostic imaging has recently been 
contributed by Cope et al (2016) [5]. PDT has evolved into a practical, effective and 
systematic theranostic option comprising of the multiple-exposure, guided, non-
invasive, treatment of tumors in combination with real-time detection and tracking of 
malignant tissue by fluorescence imaging. The basis of PDT is that light is utilised to 
trigger a photosensitizer, leading to the generation and localization of highly toxic 
reactive oxygen species (ROS) at the targeted site of cancerous tissue. PDT offers 
several advantages over traditional treatment options, typically including low toxicity of 
the photosensitizer in the absence of light interaction/irradiation, better efficacy, low 
side effects, selective and specific accumulation, and deep penetration of 
photosensitizer into the tumors [6]. Nevertheless, the mechanism of the selective and 
specific killing of tumor cells by ROS remains unclear. A better understanding of this 
phenomenon will empower patients and clinicians with a greater confidence in this 
treatment option.  
 
 A key feature of PDT is to exploit the light source for selective activation of the 
photosensitizer within the tumor cells. A light source of appropriate wavelength (visible 
or near-infrared) is utilised to activate a photosensitizer that generates and releases 
ROS, for the selective killing of tumors [7]. The photo-activation of the photosensitizer 
initially enables its excitation to a triplet state through a short-lived intermediate called 
the ‘singlet state’. The electron and energy transfer to the surrounding free oxygen 
produces ROS, such as singlet oxygen, the superoxide anion radical, the hydroxyl 
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species, and hydrogen peroxide. Highly toxic ROS cause tumor cell death by oxidative 
stress.  
 
 Historically, the development of photosensitizers has resulted in three eminent 
generations of photosensitizer types. The first generation was porphyrins [8]. The 
clinical limitations of porphyrins are poor selectivity, poor photosensitivity, a low 
clearance rate, and a low light penetration within tumors. The second generation of 
photosensitizers - including chlorins, porphyrinoids and transition metal complexes - 
also have several problems such as: high hydrophobicity, poor tumor selectivity, 
complex surface chemistry, and aggregation in aqueous media. The third generation 
includes biomolecule conjugates and covalently attached peptides [8]. The selection 
of biomolecules is critical for their clinical efficacy because of the selective targeting 
capability, the structural and photochemical properties of these conjugates, and the 
degree of receptor expression in the targeted tumors.  
 
Scheme 2.1: Schematic representation of a typical theranostic platform for the combined use 
of a range of imaging and therapeutic approaches. Imaging modalities include: ultrasonography, 
positron electron tomography, fluorescence imaging, magnetic resonance imaging and single-photon 
emission computed tomography. Therapeutic approaches include: drug delivery, photothermal therapy, 
photodynamic therapy, or a combination of two therapies. Based on its unique properties, graphene can 
be employed as a theranostic agent that combines the capabilities of diverse imaging and therapeutic 
modalities to target tumors.  
 
 Recently, novel photosensitizers have been fabricated to improve the selective 
tissue penetration of incident light, and to improve the clinical efficacy of PDT. Among 
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such novel developments, graphene has also recently been fabricated and utilised as 
a photosensitizer and theranostic agent [9]. Graphene is a two-dimensional single-
layer-thin material with sp2-bonded carbon atoms composed in a honeycomb lattice. 
This material has gained significant attention in many disciplines of life science, owing 
to its electronic, optical and structural properties. Graphene has been applied as a drug 
vechicle in chemotherapy, and as a photosensitizer for photothermal therapy and PDT. 
A graphene nanohybrid showed improved anticancer PDT effects compared with the 
conventional photosensitizers [10]. Graphene has significant potential for use in 
theranostic agents owing to its unique characteristics, including a high surface area, 
appropriate energy and/or electron transfer features, a high fluorescence quantum 
yield, π−π stacking, good water dispersibility, good biocompatibility, enhanced drug-
loading efficiency, selective tumor uptake, minimal side effects and a high yield of ROS 
production. Graphene has a variety of derivatives including graphene oxide (GO), 
reduced graphene oxide, graphene quantum dots, graphene nanoribbons, three 
dimensional graphene foam and graphene nanopores. The structural models of 
several graphene derivatives are shown in Figure 2.2. GO is a highly efficient long-
range quencher for various fluorescence processes [11]. 
 
 
Scheme 2.2 Summary of structural models of various derivatives of graphene. (a) Graphene, (b) 
graphene oxide (GO), (c) reduced graphene oxide, (d) porous graphene, (e) graphene quantum 
dots and (f) three dimensional graphene foam. Graphene is a sp2 hybridized model of carbon atoms 
in a repeated manner, forming a regular lattice structure (as shown in panel a), while GO and reduced 
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GO have functional groups and defects in their basal planes (panels b and c). The physicochemical 
properties and structures of different graphene variants depend on the fabrication method and 
conditions. The presence of both defects and functional groups provides potential advantages for the 
efficient utilisation of graphene variants in the production of ROS. The chemical exfoliation method is 
thought to be an efficient route for synthesizing graphene on a large scale and at low cost. Porous 
graphene is a graphene sheet that is missing carbon atoms from its plane. The various forms of porous 
graphene provides fascinating materials for biological applications owing to their high specific surface 
areas, hydrophobic nature and biocompatibility. Graphene nanopores usually have pore sizes of 1-30 
nm. Pores and vacancies can clearly be seen in the porous graphene sheet, as shown in panel (d). 
Graphene quantum dots are luminescent nanocrystals having a size less than 50 nm. These have 
attractive properties and potential applications in cancer diagnosis and treatment. Water soluble 
graphene quantum dots, shown in panel (e), have functional groups (C–OH, C=O, C–O–C, C–H) on 
their surface. Three-dimensional graphene networks in the form of a foam, sponge or aerogel have 
recently been assembled from individual graphene sheets using chemical vapour deposition templated 
methods, which also preserve the unique properties of individual graphene sheets. [Panel f is adapted 
from [12], with permission of MDPI Publishing Group, Copyright 2015.]  
 
 The therapeutic responses of different derivatives of graphene such as GO and 
graphene quantum dots revealed them as promising treatment agents and showed the 
possibility of exploiting ROS in cancer treatment. A better understanding of the role of 
ROS in the therapeutic mode of action of graphene, in cancer treatment, will facilitate 
the development of improved graphene-based theranostic platforms.  
2.2 Methods for graphene preparation 
The methods of preparing graphene-based materials mainly include mechanical 
exfoliation [13,14], chemical exfoliation [15,16], chemical reduction [17,18], bottom up 
and top-down approaches [19,20], unzipping of carbon nanotubes [21,22], chemical 
vapour deposition (CVD) methods [23-26], and epitaxial growth of graphene [27-29]. 
The methods employed for the production of graphene nanostructures (used in this 
work) are as follows: 
 
2.2.1 Modified Hummer’s Method 
 
There are several methods reported for the preparation of GO. In 1958, Hummer and 
his colleagues developed a method for preparing graphite oxide by the oxidation 
process of graphite flakes with the addition of sulfuric acid, sodium nitrate and 
potassium permanganate maintained below 45 °C for 2 h [31]. A combination of 
concentrated sulfuric acid, sodium nitrate and potassium permanganate lead to the 
formation of a highly oxidized product. The product was termed as graphite oxide, 
which was obtained after washing and centrifuging the oxidised product. This method 
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is also considered as a green route to prepare GO by exfoliation of graphite oxide to 
graphene oxide since 2004 [32]. The chemical exfoliation of GO is commonly carried 
out by using graphite flakes in H2SO4 and NaNO3 to oxidize graphite flakes into 
graphite oxide. The chemical reaction for this step is: 2 NaNO3 + H2SO4 = 2 HNO3 + 
Na2SO4. Oxidation by HNO3 may liberate gaseous NO2 and/or N2O4. The addition of 
NaNO3 increases the interlayer distance marginally, with improved basal planes 
oxidation of graphite. As a result, graphite flakes are broken into the smallest sheets 
(single or few layers) with the maximum functionalization on the basal planes. 
However, many modifications have recently been carried out to this technique to 
enhance the product yield and to increase the reproducibility of properties of single or 
few layered graphene [33].  
 
2.2.2 Chemical reduction of graphene oxide 
 
Chemical reduction of GO is considered as one of the most promising and extensively 
used method to prepare reduced graphene oxide, owing to its scalability and relative 
ease of reduction flexibility [34, 35]. After the exfoliation of GO, several reducing agents 
have been employed to reduce the functional groups and achieve ‘graphene’ such as 
sodium borohydride [36], oxygen-containing reducing agents [37], ascorbic acid [38], 
hydrohalic acid [39] and sulfur [40]. However, technical drawbacks related to these 
reduction methods, such as insufficient reducing capability, agglomeration and poor 
wetting properties of graphene, have been reported in literature [41]. Hydrazine is the 
commonly used reducing agent to reduce the functional groups and also to enhance 
surface area and porosity [42, 43]. In this thesis, hydrazine has been used to prepare 
reduced GO.  
 
2.2.3 Heat treatment of reduced graphene oxide 
 
Recent developments in the preparation of porous graphene and graphene nanopores 
(GNPs) offer new opportunities to design advanced materials with enhanced 
adsorption capacities and improved sequencing of DNA [44-46]. Available routes to 
prepare GNPs include electron beam irradiation [47], ion bombardment [48], doping 
[49], chemical etching [50], chemical methods [51] and solution deposition method [52]. 
Unfortunately, these methods are very expensive and not viable for practical 
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applications due to non-uniform amounts of porous nanostructured graphene. In this 
thesis, GNPs have been developed by a facile and scalable conversion of reduced GO 
into porous reduced graphene oxide via thermal treatment. Theoretically, graphene 
has a surface area of 2630 m2 g-1. However, experimentally determined values for 
porous rGO are generally less than 200 m2 g-1 [53-57]. This method includes the 
oxidisation of graphite flakes to form graphite oxide and further exfoliation for 2 h in an 
ultrasonic bath to attain GO, followed by reduction using hydrazine as a reducing 
agent. To obtain GNPs, the filtered product was oven-dried in a vacuum overnight and 
then thermally treated at 200 ºC in Ar for 12 h. Additionally, the temperature range 
involved in this treatment process was (190–200 ° C), which was lower than that 
previously reported for the synthesis of porous rGO (800 ºC) [54-56]. 
2.2.4 Bottom–up approach 
 
Currently, the methods to prepare GQDs include bottom-up and top-down approaches 
[58, 59], hydrothermal processes [60], lithography [61] and electrochemical routes [62, 
63]. Many of these methods suffer from low product yield, high number of layers and 
agglomerated dots and cost-effectiveness, and the problems associated with the 
separation and purification of the condensed amorphous carbon phase from low 
crystalline carbon blacks and fibres [64-66]. The resultant product of this partial 
separation and purification is an oxidized graphite framework and graphene oxide QDs 
rather than GQDs [67]. In this thesis we have used a bottom-up approach to prepare 
GQDs by tuning the carbonization degree of citric acid, which is a commonly used 
organic precursor. This process involved heating citric acid to 200 °C, using a heating 
mantle, for 30 mins to obtain a GQDs solution. In this method, citric acid can be 
carbonized to form water soluble photo luminescent GQDs which contain small sp2 
clusters in a uniform size and excitation-dependent photoluminescence features [68].  
 
2.2.5 CVD method 
 
It is evident that CVD is an efficient route to prepare high quality graphene on a 
substrate, making efficient growth possible using a carbon source as precursor on a 
substrate under high temperature conditions [69-72]. The CVD preparation of 
graphene has several advantages over other methods, such as the large size and high 
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quality of the graphene [73]. The only drawback of this kind of method is that this is 
only suitable for experimental purposes because of its low production along with high 
cost [74]. This is an effective approach to prepare 3D graphene foam [75-77]. In this 
work, we have used the CVD method to prepare graphene foam. This method involves 
heating and stabilizing Cu film, following by introducing a carbon precursor, cooling 
down the durance and etching in a solution. The last step involves the transference of 
prepared graphene to an appropriate substrate [78]. 
 
2.3 Toxic potential of graphene family nanomaterials  
 
 ROS generation by nanoparticles has been considered as the primary source of 
their toxicity [79]. Potential adverse effects of ROS include the downregulation of 
defensive systems to disrupt the structure and function of normal cells. ROS cause 
damage to cellular components such as proteins, DNA and lipids, resulting in the 
release of inflammatory cytokines and chemokines. ROS generation by graphene is 
dependent on several factors that strongly define the extent of graphene-induced 
toxicity, such as: size and shape, particle surface, surface charges, surface-associated 
chemical groups, solubility and dispersion, ions released from graphene, photo-
activation, aggregation, mode of interaction with cells, the presence of inflammation in 
tissues, and the pH of the system. In addition, the conditions of experiments in which 
graphene is administered, either in vivo or in vitro, affect the interactions between 
graphene and targeted biological tissues and cells. Such conditions include the time of 
exposure, dose, and (in the case of in vitro experiments) the cell type and the criterion 
used for examining cell viability. For in vivo models, the method of administration is 
also of course crucial [9]. Graphene can cause an inflammatory response that 
produces relatively large amounts of free radicals such as hydroxyl radicals [80]. GO 
at a low concentration (< 4 μg/ml) resulted in a perturbation of mitochondrial structure 
and function in Hep G2 cells, as measured by a decrease in the mitochondrial 
membrane potential and the dysregulation of mitochondrial Ca2 + homeostasis, while 
higher concentrations of graphene quantum dots (< 200 μg/ml) also caused decreases 
in the mitochondrial membrane potential by increased ROS generation, in association 
with apoptotic and autophagic cell deaths, with an increase in the expression caspase 
3, caspase 9, beclin 1, and microtubule-associated protein 1A/1B-light chain 3 [81, 82]. 
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Apoptosis and autophagy are two key modes of cancer cell death, in addition to 
necrosis. Apoptosis is a widely studied form of cell death and mainly originates through 
the activation of death receptors (extrinsic pathway) or through mitochondrial 
permeabilization (intrinsic pathway). ROS play a key role in both the extrinsic and 
intrinsic pathways of apoptosis, as initiators and in enabling signaling events. The 
apoptosis-inducing ligand, Fas, produces ROS in the extrinsic pathway of the apoptotic 
process [83]. Activation of the extrinsic pathway requires an inflammatory response to 
tissue injury and may cause a delay in intrinsic pathway initiation that responds 
immediately to calcium and ROS. Oxidative stress may be associated with the 
intracellular accumulation of ROS. Moreover, increased intracellular ROS levels, with 
associated increases in apoptosis, were detected in murine RAW 264.7 macrophages 
exposed to graphene (20-100 µg/ml) [84]. Chang et al reported a concentration-
dependent toxicity of GO on A549 cells in vitro, a concentration of 200 µg/ml causing 
a dose-dependent oxidative stress in cells and inducing a loss of cell viability [85]. 
However it was also found that a low concentration of GO (10 μg/ml) did not enter A549 
cells and had no obvious toxicity. The higher concentration of GO (200 µg/ml) caused 
oxidative stress and induced a slight loss of cell viability. Oxidative stress as a result 
of graphene-cell interactions may cause cell mutagenesis, carcinogenesis and ageing 
[86]. Graphene may cause mitochondrial toxicity that includes changes in 
mitochondrial calcium levels and depletion of the mitochondrial membrane potential. 
Graphene subsequently triggers apoptosis by the activation of mitochondrial pathways, 
namely the mitogen-activated protein kinase (MAPKs) and transforming growth factor-
β (TGF-beta)-related signaling pathways. Graphene has the potential to adsorb 
aromatic amino acids by π-π stacking [87]. Recent in vivo and in vitro studies have 
shown the role of ROS in mediating the toxicity of graphene [12, 80-86, 88, 89]. A 
schematic illustration of the potential ROS-mediated mechanisms manifested by 
graphene in the cell is shown in Figure 2.3. 
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Scheme 2.3 Schematic illustration of the potential mechanisms by which reactive 
oxygen species (ROS) are associated with the cellular toxicity of graphene. Graphene 
may affect biological behaviour at the cellular, subcellular, protein and gene levels. The 
toxicity of graphene depends on its physicochemical interactions and its accumulation 
in specific organs. Uptake of graphene into specific organs also affects cell function as 
a result of cellular changes within the organs. The deposition, distribution and 
clearance of graphene after entering into a living system is a major knowledge gap in 
understanding the toxicity of graphene. Graphene circulating in the bloodstream is 
internalized into cells through the plasma membrane. The plasma membrane is a 
selectively permeable membrane that transfers materials such as ions and nano-sized 
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proteins. Graphene (depending on its size, shape, and surface chemistry) enters the 
cell via different pathways such as clathrin/caveolar-mediated endocytosis, 
phagocytosis, macropinocytosis, and pinocytosis and exits the cell via the pathways of 
lysosome secretion, vesicle-related secretion, and non-vesicle-related secretion. The 
nature of plasma membrane interaction with graphene determines the fate of graphene 
in a wide range of potential applications with high biocompatibility, including drug- and 
gene-delivery, photothermal and photodynamic therapy. This interaction may lead to 
the possibility of events such as adsorption or incorporation of graphene onto the 
surfaces of cells. Furthermore, the entrapped biomolecules on the surface of 
graphene, when graphene is present within the extracellular matrix, may influence the 
tertiary structure of a protein - resulting in the formation of a protein-graphene interface 
and malfunction. The extracellular mechanisms causing the accumulation of graphene 
in the extracellular matrix and the subsequent effects of graphene on the extracellular 
matrix remain undefined. Graphene-induced ROS may cause oxidative stress, loss of 
cell function, mitochondrial damage, initiation of lipid peroxidation, covalent chemical 
modifications of nucleic acids, DNA-strand breaks, induction of gene expression via 
the activation of transcription factors, and modulation of inflammation via signal 
transduction, leading to toxicity, cell death and genotoxicity. The specific minerals in 
the secondary antioxidants are being referred to selenium, zinc, molybdenum, iron and 
copper. The antioxidant defence system is overwhelmed by high levels of ROS, leading 
to oxidative stress, inflammation and toxicity. One potential way to minimize the toxicity 
of graphene is to functionalize the graphene with biodegradable agents. 
 
 
2.4 Graphene in enzyme engineering and cancer treatment 
 
 
Interaction of nanomaterials with proteins plays a critical role in investigating their 
biocompatibility for enzyme purification and wound healing applications. Recent 
developments in nanostructured graphene reveal promising approaches to bind and 
adsorb proteins which in turn influences their extracellular toxic potential. Pristine 
graphene, GO and rGO have recently been reported to show their interactions with 
enzymes [90-94]. Recent studies in this area reveal the binding capacity of graphene 
to influence the chemical changes and breakdown in the structures of enzymes by 
making protein coronas and nano-biointerfaces. Surface functionalities of GO make 
them an ideal candidate for enzyme adsorption. The electrostatic binding capacity, π-
π stacking and ionic/covalent bonding have been reported as main factors influencing 
their interactions with enzymes. High adsorption of enzymes onto the surface of 
graphene can lead to the adsorption of high molecular weight carrying drugs and 
biomarkers. Therefore, investigations into these interactions is of critical importance 
for practical applications of graphene in biomarkers, biosensing and medical devices. 
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 The proof-of-concept investigations of graphene in cancer theranostics are still at a 
preclinical stage. An early report on GO as theranostic agent was published by Cho 
and his group [95]. They synthesized a GO-based photosensitizer with a redox-
responsive disulfide linker which was activated by glutathione. This photosensitizer 
exhibited a remarkable fluorescence emission and singlet oxygen generation in the 
presence of glutathione as a reducing agent. There was efficient cellular internalization 
and preferential accumulation of the photosensitizer inside cancer cells, and 
glutathione was then able to cleave the disulfide linkers. Cho et al demonstrated in 
vitro cellular uptake and fluorescence activation of the photosensitizer, but they did not 
report the role of ROS in phototoxicity towards A549 cells. As mentioned earlier, 
ascertaining the type of ROS produced, the nature of intracellular ROS signaling, ROS 
localization, and cancer cell-specific ROS-sensing mechanisms are the most important 
challenges in relation to understanding the role of the ROS in cell killing by graphene. 
The molecular targets of ROS in cancer are shown in Figure 2.4. ROS may induce 
both transcription factors/activators and genes associated with tumor suppression [96]. 
 
 
Scheme 2.4: Cell signaling and molecular targets of ROS in cancer. ROS may induce 
both transcriptional factors/activators and genes associated with tumor suppression: 
HIF-1α (hypoxia-inducible factor-1 alpha); NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells); PTEN  (phosphatase and tensin homolog deleted on 
chromosome 10); AP-1 (activator protein-1); Hh (hedgehog protein); STAT3 (signal 
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transducer and activator of transcription 3); Rb (retinoblastoma protein); Nrf2 ( nuclear 
factor (erythroid-derived 2)-like 2); Sp1 (specificity protein 1). NF-κB and AP-1 are 
transcription factors that play key roles in the expression of many genes involved in 
inflammation as well as many other significant events such as embryonic development, 
lymphoid differentiation and apoptosis. HIF-1α plays an essential role in embryonic 
vascularization and tumor angiogenesis. Nrf2, a redox-sensitive transcription factor, 
regulates genes which bind antioxidant response elements in DNA. PTEN is a tumor 
suppressor gene, which is deleted or mutated at high frequency in a large number of 
cancers. Rb protein is a tumor suppressor gene which controls cell cycle progression. 
Sp1 is a transcription factor which contributes to overexpression of MDM2 in 
rhabdomyosarcoma tumors. Stat 3 is a transcription factor which plays an important 
role in cell growth and apoptosis. ROS-mediated signaling through activation of these 
transcription factors controls the expression of genes involved in inflammation, 
metastasis, cell proliferation and tumor angiogenesis, as well as tumor cell death or 
survival. 
 
 
 Cancer cells possess an inherent nature of survival and re-growth [97]. Thus, the 
effectiveness of a therapy depends on the selective and specific targeting of tumors 
without producing chronic, severe, harm to vital organs and normal cells. Caspase 
activation by the intrinsic pathway leads to the release of: cytochrome c, a family of 
proteins known as “inhibitors of apoptosis proteins”, and endonuclease G. Release of 
these factors leads to the disintegration of mitochondrial membrane to form 
mitochondrial permeability transition pore complex. Cao et al prepared a 
multifunctional theranostic agent based on porphyrin-conjugated polyethylene glycol-
functionalized graphene quantum dots [98]. These functionalized graphene quantum 
dots demonstrated a clear discrimination (as observed by the use of a cell imaging 
label and intracellular micro RNA detection) of cancer cells from somatic cells. The 
functionalized graphene quantum dots also exhibited a high production of singlet 
oxygen (quantum yield ≤ 1.08) with 28.58% photothermal conversion efficiency. 
Apoptotic events and cell membrane destruction were observed in A549 cells exposed 
to these porphyrin-conjugated polyethylene glycol-functionalized graphene quantum 
dots. However, porphyrin-based functionalized graphene quantum dots revealed a 
slightly slower 1O2 production rate compared with porphyrin alone. Wei et al prepared 
a nanodrug pyropheophorbide-a-nano GO-monoclonal antibody conjugate, within 
which the monoclonal antibody was directed against integrin αvβ3 as a mechanism for 
tumor targeting [99]. The authors demonstrated that the phototoxicity of GO-bound 
pyropheophorbide can be switched on and off in both organic and aqueous 
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environments after the conjugation of pyropheophorbide with polyethylene-glycol. The 
functionalized GO efficiently targets the cancer cells’ surface ligand (i.e. integrin αvβ3). 
Once endocytozed by the cells, and having then escaped from lysosomes, the 
functionalized GO subsequently moves to the mitochondria. The two-fold on/off 
switching of this functionalized GO considerably increases the intrinsic pathway of 
apoptosis.  
 
H2O2-induced apoptosis usually occurs in lymphoma cells via activation of cysteine 
proteases such as caspase-3 [100]. H2O2 is a precursor of highly reactive hydroxyl 
radicals, while H2O2 itself has relatively low reactivity. H2O2 produced by nanoparticles 
has shown great potential to initiate apoptosis in the cells of osteosarcoma, breast, 
bladder, and lung cancer cells. He et al reported a nanoagent based on iron 
hydroxide/oxide-modified GO and showed a higher generation of superoxide anion 
radicals under near-infrared light irradiation, compared with GO alone [101]. In respect 
of this composite, it was proved that near-infrared light irradiation promoted electron 
transfer from GO to Fe(III) (endogenously present within the cells) and accelerated the 
formation of superoxide radicals. H2O2 then reacted with Fe(II) and gave an improved 
yield of hydroxyl radicals. Excessive generation of ROS may contribute to necrotic cell 
death by inducing degradation of biomolecules and resulting in mitochondrial 
membrane permeabilization [102]. ROS may also cause both apoptosis and necrosis 
in tumors. Qu et al desrcibed GO-induced macrophagic cell death through 
programmed necrosis in J774A.1 cells and showed that GO toxicity is facilitated by 
activation of toll-like receptor 4 (TLR4) signalling [103]. Macrophage cell death linked 
to GO exposure was attributed to programmed necrosis mediated by a receptor-
relating protein kinase 1 and 3 complex, downstream of TNF-α induction. A schematic 
illustration of the mechanisms by which photosensitizers generate 1O2, and the 
mechanism by which the hybrid of folic acid polyethylene glycol and C60 (a spherical 
fullerene molecule with the formula C60 called buckminsterfullerene) conjugated onto 
GO (FA-GO-PEG/C60) achieves the combined synergistic effects of photothermal 
therapy and PDT are shown in Figure 2.5 a & b. 
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Scheme 2.5: Schematic representations of the mechanism involved in singlet oxygen 
production and their synergistic effects in programmed cell death induced by combined 
photodynamic and photothermal therapies using a graphene nanocomposite as a 
photosensitizer. Panel (a) shows a schematic illustration of the mechanisms of singlet 
oxygen (1O2) generation by a photosensitizer, in the form of a Jablonski diagram 
representing the electronic states of a photosensitizer after light absorption, followed 
by energy transfer to an oxygen molecule to generate 1O2. The photosensitizer 
displays intersystem crossing to the triplet state when the photosensitizer is excited to 
the singlet state. The electronic states are shown in the diagram. Internal conversion: 
transitions between states of similar electronic spin, where the electronic states are 
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singlet and triplet. Fluorescence: The emitted photon has energy resembling the 
energy difference between the initial and final states of the non-toxic photosensitizer. 
The emitting and final states have similar electronic spin states, either singlet or triplet. 
Intersystem crossing: the change of electronic spin in the excited state, from singlet 
to triplet. Phosphorescence: the emitted photon has energy resembling the energy 
difference between the initial and final states of the photosensitizer. The emitting and 
final states have different electronic spin states, such as one in the singlet state and 
the other in the triplet state. Panel (b) is a schematic illustration of the mechanism of 
cancer cell killing induced by a functionalized hybrid of folic acid (FA), polyethylene 
glycol (PEG) and C60 (a spherical fullerene molecule with the formula C₆0 called 
buckminsterfullerene) non-covalently conjugated to GO for synergistic combined 
photothermal therapy and photodynamic therapy. Thus, the functionalized hybrid 
consists of FA-GO-PEG/C60 [FA (cancer targeting moiety) and C60 (photosensitizer) 
conjugated to PEGylated graphene oxide]. Functionalized GO was exposed to near 
infrared light (808 nm) for enhanced cellular uptake of C60 in cancer cells. The GO 
nanocomposite showed effective cell apoptosis and death and exhibited a synergistic 
effect of combined photodynamic and photothermal therapies. [Panel (b) is adapted 
from [10], with permission of the Royal Society of Chemistry, Inc., Copyright 2015]. 
 
2.5  Summary 
 
 In summary, recent studies underpin the potential of graphene in the theranostic 
field. Many groups have utilised graphene in PDT, photothermal therapy and 
fluorescent imaging for cancer treatment. The combination of imaging and therapy 
could produce synergistic effects to increase the targeted killing with minimal side 
effects and with the maintenance of biocompatibility. The scope for functionalization 
and conjugation of graphene can potentially generate a promising array of theranostic 
agents. Further in vivo studies are obligatory to better understand the real-world 
applications of nanostructured graphene. Moreover, the ROS generation, toxicity and 
potential cancer theranostic approaches for other derivatives of graphene such as 
graphene nanoribbons, graphene nanoplatelets, three dimensional graphene foams, 
and graphene nanopores need to be studied. Oxidative stress induced by graphene 
accumulated in living organs is due to acellular factors including particle size, particle 
shape, surface charge, surface functional groups, and light activation, while cellular 
responses such as mitochondrial respiration, and immune cell activation, pH of the 
medium and physiological redox-regulated functions are critical determinants affecting 
the production of ROS. To date, the mechanisms and roles of ROS production by most 
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forms of graphene in relation to cancer treatment, are not understood. A basic 
understanding of graphene-cell interactions, as well as the optimal conditions for their 
proper use, will provide new theranostic platforms in the future. 
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Chapter 3 
Raw Materials and Analysis Techniques 
 
The generic experimental methodology and procedures applied for this research will 
be presented in this chapter. 
 
3.1 Raw materials 
 
The reagents used throughout this thesis were of analytical grade and purchased from 
indicated sources. H2SO4 (95.0-98.0%, Product No. 320501), KMnO4 (Product No. 
223468), NaNO3 (product no. S5506), H2O2 (30 wt%, Product No. 216763), hydrazine 
(35 wt%, product No. 309400), potassium nitrate salt (product No.: 542040), 0.1 M 
Tris-HCl buffer (product No. 07066), Diiodomethane (product number 158429), 
potassium bromide (product number P0838), disodium hydrogen phosphate (product 
no. 7558-79-4) and styrene (product no. 100-42-5) were purchased from Sigma-
Aldrich. HCl (36 wt%, product No.: 7647-01-0), was purchased from Acros. Graphite 
flake (GFs, product No.17346-25) and 0.2 micron membrane filter were purchased 
from Thermo and Fisher Scientific suppliers. Reagent kits for measuring the 
concentrations of enzymes were purchased from Chemelex, S.A., Canovelles, Spain. 
Citric acid was purchased from Alfa Aesar. Trypsin (1%), Boc-Gln-Ala-Arg-AMC 
fluorogenic substrate for trypsin (kcat/Km=2.0 x 107 M-1sec-1; Km=6.0 µM), cathepsin L 
fluorogenic substrate Z-Val-Val-Arg-AMC (ZVA) and cathepsin D fluorogenic substrate 
were obtained from Enzo Life Sciences (UK) Ltd and was stored at -20 ºC. Ni foam 
was purchased from Inco. Ltd, Canada. Annexin binding buffer and propidium iodide 
were purchased from BioLegend, UK and Sigma-Aldrich, UK respectively. 
AlamarBlue® cell viability assay was purchased from Thermofisher Scientific, Italy. 
 
3.2 Scanning electron microscopy 
 
Scanning Electron Microscopes (SEM) makes this form of microscopy an appropriate 
tool for characterizing surface morphology. In standard SEM, a filament produces an 
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electron stream which is then directed at the sample using a positive electron potential 
– this thin, monochromatic beam is focused by metal apertures and lenses, as shown 
in Scheme 3.1 [1]. Secondary electrons (SE) and X-rays are produced when these 
interact with the specimen; the secondary electrons are produced only from the top 
layer of the sample (10 nm), so the images produced by these can provide topographic 
details of the specimen surface. 
In this work, SEM images of the samples were were taken on a Philips XL-30 SEM 
under high vacuum conditions with accelerating voltage 20 kV. Both the powder 
samples and liquid samples were mounted onto carbon sticky tape, with the latter first 
dried before mounting. 
 
Scheme 3.1:  Schematic diagram of a SEM [1]. 
 
3.3 Transmission electron microscopy 
 
Transmission Electron Microscopy (TEM) has an ultra-high resolution down to 0.2 nm, 
making it an efficient technique for obtaining highly detailed images. Unlike SEM, 
where electrons only hit the specimen surface, the electrons beams utilised in TEM 
travel through the entire sample and can provide information on internal structures of 
materials. STEM bright field (BF) and dark field (DF) imaging and Elemental Mapping 
are all possible using TEM; Scheme 3.2 illustrates the TEM system. Electron diffraction 
can be used to analyze the crystal structures of samples, making this method of 
microscopy indispensable in nanomaterial analysis; some researchers have even used 
TEM to observe adatoms (atoms which lie on a crystal surface), which is an important 
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advancement in this field [2]. In this work high resolution microstructural images were 
also taken, on a JEOL-2100 TEM operating at a voltage of 200 kV. The powder sample 
was dispersed in acetone, after which the sample was dropped on the centre of a 
carbon Cu grid using a micro pipet. 
 
Scheme 3.2: Illustration of TEM system [2]. 
 
3.4 Ultraviolet/Visible (UV/Vis) spectroscopy 
 
Ultraviolet–visible spectroscopy (UV-Vis) is a spectroscopic tool that uses an 
ultraviolet-visible beam to analyse a samples chemical composition. As the electronic 
transition energy of the molecules move from ground state to the excited state, the UV-
visible beam is absorbed (Scheme 3.3) [3]. By analysing the absorption peaks, 
chemical composition of the sample can be determined; the instrument used for this is 
a UV-visible spectrophotometer. It gives the measurement of the intensity of light going 
through a sepecimen (I), and associates this to the lights intensity before passing 
through the specimen (Io), typically light from the visible and adjacent ranges.  
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In this work, UV–Vis absorbance were obtained by using a Jenway 6715 UV/Vis 
spectrophotometer. Most of the samples used in this thesis were in liquid form, while 
powder samples were dispersed in water before using this machine. 
 
 
Scheme 3.3: Schematic layout of UV/Vis spectrometer [3]. 
 
3.5 Raman spectroscopy 
 
Raman Spectroscopy is a spectroscopic tool used to analyse the chemical composition 
of a sample. It uses lasers to do this – lasers with different ranges, typically visible, 
near infrared and near ultraviolet, are emitted to interact with molecular vibrations. This 
leads to the generation of up or down shifts of the energy of laser photons (Scheme 
3.4); these shifts are analysed to measure the vibration modes of a sample. Each 
molecule has a different set of vibrational energy levels, so when the lasers are focused 
on a particular molecule, the photon can be scattered either elastically or inelastically. 
Only a small amount of scattered light is inelastically scattered – about 1 in every 30 
million photons. The vast majority is therefore the same as the excitation source, sop 
shows no Raman effect (Rayleigh). Raman spectroscopy is also an effective tecnique 
to characterise graphene intensity and number of its layers [4].  
In this work, the Raman spectra were collected using a 532 nm laser excitation 
operating at 6 mW power. The power of the laser was kept at 6 mW.  The 2D and 
quantum dots samples were prepared by dropping their solution on a glass slide while  
the 3D sample was prepared by grinding them into fine powder. 
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Scheme 3.4: Energy diagrams for light scattering: Rayleigh (elastic) vs. Raman 
(inelastic) [4].  
 
3.6 Fourier Transform Infrared (FT-IR) spectroscopy 
 
Fourier transform infrared spectroscopy (FTIR) is often utilised to acquire an infrared 
spectrum by absorption or transmission through a solid, liquid, or gas. When infrared 
(IR) radiation passes through a sample, some electromagnetic radiation is absorbed 
and some transmitted, resulting an infrared spectrum characteristic of the specific 
sample. The FTIR and assisting computer software can then measure and decode all 
infrared frequencies, generating the spectral information of the sample in question 
(Scheme 3.5). It also shows the molecular finger-print of the sample [5]. In our 
experiment, FTIR spectra were obtained using an Alpha Bruker system. The samples 
were measured in the wavenumber range of 4000–450 cm-1. Samples used in this 
thesis were prepared by mixing the original samples with KBr. 
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Scheme 3.5: A schematic of an interferometer used in a Fourier Transfer Infrared 
Spectrometer (FTIR) [6]. 
 
3.7 X-Ray diffraction (XRD) 
 
X-ray Diffraction (XRD) is a powerful tool utilised for the identification of phases of a 
crystalline material, providing key evidences on a variety of characteristics, such as 
unit cell dimensions, crystal perfection, lattice spacing, d, grain size, and texture. XRD 
is typically based on the productive interfering of monochromatic X-rays and a 
crystalline specimen [7]. These X-rays are produced by a cathode tube, which is filtered 
to generate monochromatic radiation, and focused toward the specimen. The 
crystallite features of samples can be identified from the XRD peaks. An interference 
formed by the interaction of the incident beam with the specimen, and thus following 
the Bragg's Law which is given as below [8]: 
 
𝑛𝜆=2𝑑 𝑠𝑖𝑛𝜃      ……………..  (3.1)  
 
In this work, X-ray diffraction (XRD) analysis was performed using Cu Kα radiation (at 
40 kV and –40 mA). Powdered samples were prepared for XRD analysis. As prepared 
sample, was inserted into the sample holder and scanned from10 - 80° 2θ with a step 
size of 0.02°, and 1 s step time. 
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3.8 Photoluminescence spectroscopy 
 
Photoluminescence (PL) Spectroscopy is an efficient technique for analysing the 
electronic structure of nanostructed materials [9]. Light is focused onto the specimen 
and directs excessive energy into the samples, causing electrons within the materials 
to reach an excited state. (It can be noted that this is like the process of UV-visible 
spectrometry, as decribed in section 3.3.) When the excited electrons return back to 
their equilibrium positions, excessive energy is emitted in form of light (radiative 
process) or thermal energy (non-radiative process) [9]. If it is the former, the process 
is photoluminescence; the energy of this is reliant on the energy difference between 
the excited and equilibrium states of the electrons. This process of absorption and 
emission can be clarified using a Jablonski diagram (Scheme 2.5 a). In this schematic 
representation, S0, S1 and S2 show the singlet ground, first and second electronic 
states, respectively.  
 
In this work, PL features were obtained by using an Edinburgh Instruments 
Spectrofluorometer FS5 at 350 nm of excitation wavelength. The sample used for PL 
was in liquid form. 
 
3.9 BET Surface area analyser 
 
The Brunauer-Emmett-Teller method (BET) is a technique used to determine the 
physical adsorption of gases in solid materials that have complicated shapes, e.g. 
porous materials. Adsorption and desorption isotherms are used to find the number of 
gas molecules adsorbed on the material [10]. The BET equation describes an 
adsorption where the adsorbate contains multiple layers. It has several main 
assumptions: (1) The adsorbed molecules are fixed in the material; (2) The enthalpy 
of adsorption of all the layers is the same; (3) The energy of absorption for all layers is 
the same, except for the first layer; (4) A new layer can start before the one before has 
finished. 
In this work surface area was calculated by using Brunauer–Emmett–Teller (BET) 
theory method. The total pore volume (Vt) was measured from the amount of adsorbed 
nitrogen (at P/Po = ca. 0.99). 
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3.10 Contact angle goniometer 
 
The measurements of contact angle and surface energy of materials are of critical 
importance in surface science [11]. The most popular approach to measure the contact 
angle is direct measurement of the shape of liquid drop on a flat surface [12]. It involves 
straightforward measurement of a sessile drop profile. The equipment contains a stage 
to hold sample, a pipette to form a liquid drop profile, a light source, and a digital 
camera to record the image of drop profile.  
 
In this work, the wettability of samples was determined using a contact angle 
goniometer. A digital camera was used to record the images and the contact angle 
was calculated (using PolyPro). The surface of the sample was prepared for wetting 
by gently drop casting it onto a glass slide. The surface energy was determined by 
measuring the contact angle of a 10 µl drop of diiodomethane (DIIO) on the surface. 
The equations used in the surface energy calculations are given in chapter 4. 
 
3.11 Zeta potential probe 
 
Zeta potential is used to investigate the nature of the elctrstatic potential on the surface 
of a material. Suspended partcles generally carry a surface charge which is typically 
negative or positive. Functional groups existing on the surface of any sheet of particle 
can also cause to produce a surafce charge. Surface charge is a crital feature in 
graphene to investigating the adsorption capacity and nature of interactions with 
proteins, cells and biological tissues.  
 
In this work, zeta potential measurements were carried out using a colloidal dynamics 
zeta probe to identify the surface charge of rGO as a function of pH, balanced in the 
acidic–basic ranges using 10−1M HCl and KOH solutions, respectively. 
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3.12 Cell Viability evaluation and flow cytometry analysis 
 
A549 and SKMES-1 lung cancer cells were seeded in 6 well plates at a density of 
350,000 per well. After overnight incubation, cells were treated with or without 5, 50, 
250, 500 and 1000 µg/ml of GO for 24 h. Then, cells were trypsinised and centrifuged 
at 200 g for 5 min. Cell pellets were then re-suspended in 100µl of annexin binding 
buffer containing annexin (BioLegend, UK) and propidium iodide (PI) (Sigma-Aldrich, 
UK), and incubated for 15 min in the dark. Flow cytometry was performed using a 
Guava flow cytometer. The data were analysed using Guava 3.1.1 software. The early 
and late apoptotic populations of the cells were analysed by flow cytometer Alexa 
Fluor647 Annexin V (apoptosis) – F2, Propidium iodide necrosis –F3 YEL. The criteria 
for early and late apoptotic cells are Annexin V-positive, PI-negative and Annexin V-
positive, and PI-positive, respectively. Signals were detected using Alexa Fluor® 647, 
a bright far-red–fluorescent dye with excitation ideally suited for the 594 nm or 633 nm 
laser lines. PI is yellow-fluorescent dye with excitation ideally suited to the 532 nm laser 
line. Toxicity assays were repeated 3 times. 
 
In cell attachment experiment, cytotoxicity was determined using AlamarBlue® cell 
viability assay (Thermofisher Scientific, Italy) following the guideline provided by 
manufacturer [13]. The cell culture medium was changed with fresh medium which 
contains 10% of AlamarBlue® reagent. Then, fluorescence (ʎex = 540 nm; ʎem = 595 
nm) was measured by using plate reader after 2 h of incubation at 37 °C. Experiments 
were repeated for 3 times and cell viability was presented as percentage of control 
cells. A fluorescence microscope (Olympus MODEL BX51WIF) was employed for 
imaging assessment of cell attachment to 3D graphene foam. 
 
3.13 In Vivo studies 
 
All animal experiments were carried out following the regulations of the institutional 
ethics committee on animal welfare (Animal Care and Use Program Guidelines of 
Government College University, Faisalabad, Pakistan), and with their prior approval 
for using the animal models. Sprague-Dawley adult male rats (average age of 6-7 
weeks, 230-250g weight) were obtained from the animal house of institution, and 
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housed in groups in ventilated cages under standard lighting conditions and natural 
day/night cycle after approval from the ethical committee of the institution. Common 
carp (Cyprinus carpio) (50 ± 2 g weight and 29 ± 0.9 cm in length) was procured from 
the Fish Hatchery Satiana Road Faisalabad Punjab, Pakistan and held there for two 
weeks in a stock aquarium with flowing aerated dechlorinated tap water. They were 
given free access to water and food and the surrounding humidity and temperature 
(25 °C ± 2 °C) was controlled. After a period of acclimatization for 7 days, the animals 
of similar mean initial body weights were divided into five groups, n=8 per group. The 
body weights of the control group and all the experimental groups were observed and 
recorded weekly to note changes in body weights. The body weight and behaviour 
were also noted every day after graphene exposure. Blood samples were collected at 
the start and end of the experiments and used for the analysis of complete blood count 
(CBC), selected serum biochemical parameters, haematology and oxidative stress 
enzymes. 
 
3.14 Statistical Analysis 
 
The data of cell viability were analysed in GraphPad Prism 5.04, and expressed as % 
cell count ± standard deviation, Mann Whitney. The in vivo data was statistically 
analysed in GraphPad Prism 5.04 to determine the GNPs treatment effects on various 
parameters of cell count, body weight, liver and kidney function tests, complete blood 
count and oxidative stress biomarkers. P < 0.05 was considered as statistically 
significant. Results have been shown as the mean ± standard deviation (SD). 
 
3.15 Regression analysis 
 
We investigated the relationship between concentration of graphene sample and cell 
death rate, so that the most appropriate concentration levels could be determined for 
biological applications. Standard non-linear regression methods will only capture the 
general trend without taking into account the uncertainties in measurements and 
predictions. Therefore, we used a Gaussian process (GP) to model the relationships 
and readily incorporate the uncertainties in measurements to produce a Bayesian 
posterior predictive distribution [14, 15]. A GP is essentially a collection of random 
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variables, and any finite number of these have joint Gaussian distribution. Given a 
dataset 𝐷 =  {(𝑥𝑖, 𝑦𝑖)}𝑖=1
𝑛  with 𝑛 data points, where 𝑥𝑖 is the 𝑖th graphene sample 
concentration and 𝑦𝑖 is the associated cell count, the posterior predictive distribution is 
𝑃(𝑦𝑛+1|𝑥𝑛+1, 𝐷, 𝜃) ~ ℵ(𝑦𝑛+1|𝜇(𝑥𝑛+1), 𝜎(𝑥𝑛+1)). Here, the mean prediction 𝜇(. ) and the 
standard deviation 𝜎(. ) are functions of the covariance matrix. The covariance matrix 
captures the covariance between observed concentrations, which is governed by the 
specific covariance function and the set of hyper-parameters 𝜃. In this study, we used 
the Matern52 covariance function. The hyper-parameters are set by maximising the 
likelihood of the data. 
3.16 Adsorption kinetic model 
Adsorption kinetic models are typically employed to study and better understand the 
kinetics of the adsorption mechanism. Such models are uselful to determine the 
performance and capacity of an adsorbent. In this study, we have used intrapartcile 
model to better understand the adsorption mechanism of graphene oxide. Fick's 
second law was used to reveal if intraparticle diffusion is adsorption controlling 
phenomena involved in our study, which is given below [16,17]: 
𝑞𝑡 = 𝑘𝑖𝑑√𝑡 + 𝐼,  
where I represents the boundary layer effect and kid shows the intraparticle rate 
constant.  
Intrapacticle plot indicates a multi-linear trend, representing two or more shapes. The 
first segment typically shows the instantaneous surface adsorption [18,19]. The second 
part of the plot represents the slow adsorption step. The third segment shows the final 
equilibrium stage where intraparticle diffusion gradually becomes slow due to the less 
available sites of adsorbate. 
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Chapter 4 
Graphene Oxide Based Targeting Extracellular 
Cathepsin D and Cathepsin L in Novel Anti-
Metastatic Enzyme Cancer Therapy 
 
Overexpression and secretion of the enzymes cathepsin D (CathD) and cathepsin L 
(CathL) is associated with metastasis in several human cancers. As a superfamily, 
extracellularly, these proteins may act within the tumor microenvironment to drive 
cancer progression, proliferation, invasion and metastasis. Therefore, it is important to 
discover novel therapeutic treatment strategies to target CathD and CathL and impede 
metastasis. Graphene oxide (GO) could form the basis of such a strategy by acting as 
an adsorbent for pro-metastatic enzymes. In this chapter, we have conducted research 
into the potential of anti-metastatic target therapy using GO to adsorb these pro-
tumourigenic enzymes. Definitive binding and modulation of CathD/L-GO revealed that 
CathD/L were adsorbed onto the surface of GO through its cationic and hydrophilic 
residues.  The work described in this chapter could provide a roadmap for the rational 
integration of CathD/L-targeting agents into clinical settings.  
 
4.1 Introduction 
 
Every year more than 2.28 million new cases of breast and ovarian cancers are 
diagnosed, principally in developed countries and 807,440 women die of these 
worldwide, with these cancers representing the first and fifth most common cause of 
female malignancies, respectively [1-5]. Although these diseases have different 
pathologies they share a common set of molecular mechanisms such as the 
misfolding/aggregation, overexpression and hypersecretion of specific proteins 
typically involved in degrading cross-linked, abnormal, short-lived self- and foreign- 
proteins in lysosomes and phagocytosis. The intracellular and extracellular responses 
of the tumor microenvironment tend to be more prominent in response to conditions 
such as acidic pH [6], the enhanced permeability and retention effect [7], the enzyme 
abundance in the tumor extracellular matrix, [8] and overexpression of particular cell 
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membrane receptors [9]. Typically, this emanates from the misfolding-prone proteins 
forming potentially pathogenic aggregates, either because they lose their ability to 
execute their physiological functions efficiently in certain regions of their sequence or 
because they form harmful oligomeric and/or cytotoxic species in the molecular 
etiology of these diseases [10]. The upregulated activity of lysosomal proteases such 
as cathepsin D (CathD) and cathepsin L (CathL) have long been known for their 
intracellular protein-degrading activities usually regulated within acidic 
endosomal/lysosomes compartments. However, in tumor invasion and development, 
these enzymes play a significant role extracellularly influencing cell proliferation, 
differentiation, apoptosis, angiogenesis, inflammation and extracellular tissue 
remodelling [11, 12].  
Elevated levels of CathL and CathD are reported to be associated with an increased 
risk of metastasis [13]. For example, CathL is considered to be involved in tumor 
invasion and metastasis, by degrading subunits of extracellular matrix such as 
proteoglycans, elastin, laminin, fibronectin, perlecan and interstitial and basement-
membrane collagens. Recently, we showed a significant expression of CathL in the 
omentum hosting metastatic ovarian high-grade serous carcinoma compared with 
omentum from control patients with benign ovarian cystadenoma, and that exogenous 
CathL induced pro-angiogenic effects on omental microvascular endothelial cells 
which may aid metastasis [14, 15]. Recent immunohistochemical studies have 
demonstrated that enhanced CathD expression is an indicator of potential malignancy 
in serous ovarian cancer [13], for example Losch et al. demonstrated that CathD was 
detected in more than 70% of invasive ovarian cancers [16]. Secreted CathD from 
breast cancer cells and its proteolytic role in degrading extracellular matrix (ECM) 
proteins and subsequently releasing growth factors such as bFGF, have also been 
reported, which are important steps for cancer cells to invade surrounding tissue [17]. 
Misfolding, overexpression and hypersecretion of CathD and CathL have now been 
demonstrated in numerous cancer types including ovarian, breast, endometrial, lung 
and prostate, as well as malignant glioma and melanoma and are recognized as critical 
players in cancer biology by regulating diverse proteolytic functions in fuelling the 
breakdown of the extracellular matrix and facilitating tumor invasion [18-21]. 
Adsorption of these enzymes to two-dimensional materials opens a window of 
opportunity to develop a wide range of new approaches in the prevention of cancer.  
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Nanotechnology and its underpinning sciences have significantly contributed to the 
improvement of nanodrug bioavailability and therapeutic index in cancer therapy [22]. 
Recently, graphene oxide (GO) formulations have been developed into adaptable 
nanoscale platforms for medical interventions as one of the most sophisticated and 
minimally toxic tools [23] that permit direct contact and manipulation of the intracellular 
environment. This could offer a potential therapeutic tool by adsorbing the pro-
metastatic enzymes, which are cancer associated stimuli. GO has a large interfacial 
area and spatial constraints for biological interaction, ideally suited to constructing a 
robust and cost-effective extracellular tumor-specific enzyme binding method [24]. This 
capability of GO to bind and track an active enzyme could open the door to new clinical 
algorithms based on ‘enzyme-targeted therapy’. GO nanoformulations that uptake 
these enzymes could be key enablers of novel anti-metastatic enzyme therapy by 
breaking down the functional and structural integrity of extracellular enzymes. These 
GO nanoplatfoms offer a simple, safe and robust strategy in boosting the concept of 
‘anti-metastatic enzyme targeted therapy’, a neologism coined to indicate an innovative 
and revolutionary approach useful to adsorb and treat ‘pro-tumourigenic’ with a number 
of outcomes, notably the clearance of these enzymes, their structural breakdown, their 
digestion to active site-directed specific adsorbents and deregulation. It is generally 
understood that the biocompatibility of graphene-based materials is limited by their 
sharp edges and 2D monolayered structures, which is evident from concentration-
dependent toxic effects in numerous cell lines. Notable exceptions however need to 
be taken into account to find an appropriate biocompatible concentration whose 
adsorption efficiency is not the outcome of obvious toxic alterations. Targeting and 
therapeutic adsorption of CathD and CathL in cancer treatment are currently unknown 
and undefined. The process of enzyme adsorption, and its therapeutic efficacy are 
effected by several factors such as the properties of proteins and concentration in 
solution, pH, ionic strength, temperature of the medium, pH-dependent adsorption 
performance, structural stability of proteins, the selection and nature of adsorbent, 
porous sites/vacancies in adsorbents to uptake the proteins and strength/stability of 
adsorbate-adsorbent interface. The mechanistic aspects of protein adsorption and/or 
protein corona formation as a result of their interaction with graphene may be via 
electrostatic and hydrophobic interactions [25]. The intrinsic stability of adsorbent 
matrix structure, which can be revealed by undergoing structural rearrangements, and 
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conformational alteration resulting protein denaturation and/or loss of functional 
activities and change in surface energy allows a wide range of chemical changes in 
functional groups and wettabilities. The established method of fluorescence quenching 
and absorbance, together with vibrational spectrometry, wetting transparency, 
adsorption kinetics, and regression analysis can be used to reveal the fundamental 
aspects of the enzyme-graphene interaction and to address a variety of pre-clinical 
unknowns in the same theranostic session. 
Given the therapeutic challenges posed by secreted CathD and CathL in breast and 
ovarian cancers, a fuller clearance of these proteins before their involvement in 
secondary tumour formation may aid development of treatment modalities. We have 
previously published expression and secretion of CathL and CathD in the omentum 
and ascites of ovarian malignant patients, as well as in the tumour conditioned media 
of ovarian cancer cells [14]. In this chapter, we use GO to investigate whether CathD 
and CathL might be cleared out through an adsorption process. To help visualize the 
role that GO plays, we use cost-effective and scalable batch adsorption approach, 
where complementary information is channelled via multimodal kinetic and regression 
models as an analogy of a multiplexed toxicity-dependent clearance of pro-metastasis 
enzymes. This chapter reveals that inhibition of CathD and CathL could indeed 
enhance the therapeutic challenges faced in breast and ovarian cancers. The idea of 
enzyme targeting therapy is illustrated in Figure 4.1. 
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Figure 4.1: Proposed mechanism of cathepsin function in cancer metastasis and 
use of graphene oxide (GO) as an adsorbent to remove cathepsin from a living 
system. There are three panels in this diagram: (1) role of cathepsins in cancer 
progression: (2) structure of graphene oxide and its parameters relevant to the 
adsorption of cathepsins: and (3) the mechanism of adsorption. The left panel (1) 
illustrates the potential roles of tumor cell-secreted cathepsin D (CathD) and cathepsin 
L (CathL) on extracellular matrix (ECM), tumor, fibroblast and endothelial cells (EC) in 
the tumor microenvironment. CathD is synthesized and processed in the rough 
endoplasmic reticulum (rER) and Golgi bodies (G), and subsequently transported to 
lysosomes (LY). Overexpressed CathD/CathL is secreted into the extracellular space 
by tumor cells. Mature cathepsin cleaves ECM and releases basic fibroblast growth 
factor that may induce angiogenesis. Both CathD and CathL induce tumor cell 
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proliferation, and hence invasion. CathD induces proliferation of fibroblasts and 
migration of endothelial cells. RCP represents the Rab-coupling protein in the scheme 
which, together with EC, is involved in inducing proliferative effects. The bottom panel 
(2) shows the structure of graphene oxide. This is prepared from graphite using the 
modified Hummer’s method [26, 27, 28]. GO has good properties to adsorb these 
enzymes such as surface charge, surface area, functional groups, electronic and 
chemical properties. The right panel (3) shows the potential mechanism involved in 
particle internalization, their interaction to CathD/CathL and their further breakdown 
which may lead to cathepsin removal. Electrostatic and van der Waals forces, osmotic 
depletion and solvophobicity play a pivotal role in adsorption of such enzymes. 
 
4.2 Materials and methods 
 
4.2.1 Synthesis and characterization 
Exfoliated graphene oxide (GO) flakes were prepared following the modified Hummer’s 
method previously reported by us [27-29]. 2 g graphite flake,1.5 g NaNO3 and 150 ml 
H2SO4 (98%) were added in an 800 ml flask and mixed under magnetic stirring. The 
flask was immersed in an oil bath which was warmed to 35 ºC, before 9 g KMnO4 had 
been added into the flask. The mixture was continuously stirred for 24 h, followed by 
further addition of 280 ml H2SO4 (5%) and increasing the temperature to 85-95 ºC. 
After 2 h further stirring, the bath was removed and the flask was allowed to cool down 
to around 60 ºC before further addition of 15 ml H2O2 (30 wt%) into it. After another 2 
h stirring, the solid product in the suspension was collected, and washed repeatedly 
with diluted HCl (3 wt%) and distilled water to remove any residual Mn4+ and other 
impurities. The resultant GO was dispersed in water under stirring to the concentration 
of 0.25 mg ml−1. The resultant GO was then used for further characterization. High 
resolution microstructural images were taken on a JEOL-2100 transmission electron 
microscope (TEM) operating at an accelerating voltage of 200 kV. TEM samples were 
prepared by dropping onto a holey carbon Cu grid using a micropipette. X-ray 
diffraction (XRD) analysis was performed using Cu Kα radiation (at 40 kV and 40 mA). 
Spectra were collected with a step size of 0.02° (2) and a step time of 1 s. Fourier-
transform infrared (FTIR) spectra were recorded in the wavenumber range of 4000–
500 cm−1 using a Bruker Optics Tensor-27 FTIR spectrometer. Samples used in this 
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case were prepared by mixing the original sample powders with KBr. Raman spectra 
were recorded using a 532 nm laser excitation operating at 6 mW power. Zeta potential 
measurements were carried out using a colloidal dynamics zeta probe to identify the 
surface charge of GO as a function of pH, balanced in the acidic–basic ranges using 
10−1M HCl and KOH solutions, respectively. A Jenway 6715 UV/Vis spectrophotometer 
was used to obtain the UV–Vis diffuse reflectance spectra. 
 
4.2.2 Cell viability 
A549 and SKMES-1 lung cancer cells were seeded in 6 well plates at a density of 
350,000 per well. After overnight incubation, cells were treated with or without 5, 50, 
250 and 500 µg/ml of GO for 24 h. Then, cells were trypsinised and centrifuged at 200 
g for 5 min. Cell pellets were then re-suspended in 100 µl of annexin binding buffer 
containing annexin (BioLegend, UK) and propidium iodide (PI) (Sigma-Aldrich, UK), 
and incubated for 15 min in the dark. Flow cytometry was performed using a Guava 
flow cytometer. The data were analysed using Guava 3.1.1 software. The early and 
late apoptotic populations of the cells were analysed by flow cytometer Alexa Fluor647 
Annexin V (apoptosis) – F2, Propidium iodide necrosis –F3 YEL. The criteria for early 
and late apoptotic cells are Annexin V-positive, PI-negative and Annexin V-positive, 
and PI-positive, respectively. Signals were detected using Alexa Fluor® 647, a bright 
far-red–fluorescent dye with excitation ideally suited for the 594 nm or 633 nm laser 
lines. PI is yellow-fluorescent dye with excitation ideally suited to the 532 nm laser line. 
Toxicity assays were repeated 3 times. The data were analysed in GraphPad Prism 
5.04, and expressed as % cell count ± SD, Mann Whitney. P < 0.05 was considered 
statistically significant.  
 
4.2.3 Regression model 
We investigated the relationship between concentration of GO and cell death rate, so 
that the most appropriate concentration levels could be determined for biological 
applications. Standard non-linear regression methods will only capture the general 
trend without taking into account the uncertainties in measurements and predictions. 
Therefore, we used a Gaussian process (GP) to model the relationships and readily 
incorporate the uncertainties in measurements to produce a Bayesian posterior 
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predictive distribution [29, 30]. A GP is essentially a collection of random variables, and 
any finite number of these have joint Gaussian distribution. Given a dataset 𝐷 =
 {(𝑥𝑖, 𝑦𝑖)}𝑖=1
𝑛  with 𝑛 data points, where 𝑥𝑖 is the 𝑖th GO concentration and 𝑦𝑖 is the 
associated cell count, the posterior predictive distribution is 
𝑃(𝑦𝑛+1|𝑥𝑛+1, 𝐷, 𝜃) ~ ℵ(𝑦𝑛+1|𝜇(𝑥𝑛+1), 𝜎(𝑥𝑛+1)). Here, the mean prediction 𝜇(. ) and the 
standard deviation 𝜎(. ) are functions of the covariance matrix. The covariance matrix 
captures the covariance between observed concentrations, which is governed by the 
specific covariance function and the set of hyper-parameters 𝜃. In this study, we used 
the Matern52 covariance function. The hyper-parameters are set by maximising the 
likelihood of the data. 
 
4.2.4 Water contact angle measurements and surface energy calculations  
The wettability of GO, CathD and CathL were determined using a contact angle 
goniometer. A digital camera was used to record the images and the contact angle was 
calculated (using PolyPro). The surface of the sample was prepared for wetting by 
gently drop casting it onto a glass slide. The surface energy was determined by 
measuring the contact angle of a 10 µl drop of diiodomethane (DIIO) on the surface.  
From Young’s equation, the surface free energy of a solid (S), 
σS = σSL + σLcosθ ,         (1) 
where σL is the surface tension of the liquid (L), σSL is the interfacial tension between 
the liquid and the solid (SL), and θ is the contact angle formed by the liquid drop on 
the surface of the solid. Our aim is to determine σS using known σL and unknown σSL. 
Following the Fowkes method [45], the interfacial tension 
σSL = σL + σS – 2( (σLD σSD)1/2 + (σLP σSP)1/2 ) ,             (2) 
where the surface energies are composed of dispersive (D) and polar (P) components. 
We can use this to eliminate the unknown in equation 1. 
For diiodomethane (DIIO), the liquid polar component is zero, so 
σSD = σL(cosθ + 1)2/4,         (3) 
where σL = σLD = 50.8 mN/m. From this, we directly find the dispersive component of 
the surface free energy of the solid from a measurement of the contact angle. 
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Water has both a polar and dispersive component: σLD = 26.4 mN/m and σLP = 46.4 
mN/m. By rearranging equations 1 and 2 we can determine the polar component of the 
surface energy of the solid: 
σSP = ( σL(cosθ+1)/2 – (σLDσSD)1/2 )2/σLP ,      (4) 
Once we know the dispersive and polar components, the total surface energy of the 
solid 
σS = σSD + σSP . 
On pure samples of GO, DIIO formed a contact angle of 33.4° and water 20°. This 
gives surface energies of 42.8, 29.6 and 72.4 mN/m for the dispersive component, 
polar component and total, respectively [31]. The other surface energies were 
calculated in the same manner. 
 
4.2.5 CathD proteolytic activities pH experiment 
Citric acid monohydrate and Na2HPO4 pH buffer solutions were prepared ranging 
between 3, 5.6 and 7. Their composition is given in SI note 3. The final volume of each 
pH buffer was 50 ml containing 0.005% Tween 20 (2.5 µl, sigma). CathD fluorogenic 
substrate (Enzo Life Sciences) 1 mg was reconstituted in 570 µl DMSO to produce 10 
mM stock concentration. 3 µl of this stock was diluted with 2.997 µl of dH2O to produce 
10 µM working solution (3 ml). This 10 µM solution was further diluted into 100 nM 
(final concentration) by adding 50 µl (10 µM) to 4.950 µl individual pH buffer. Substrate 
and substrate-pH buffer solution were kept away from light. Pepstatin A 5 mg was 
reconstituted in 363.5 µl DMSO, producing a stock solution of 20 mM (stored at -20 
ºC). A working solution (20 µM) was made by diluting the stock (2 µl) with 1.998 ml 
dH2O. The final concentration was 1 µM (110 µl of 20 µM in 2 ml of each substrate+pH 
buffer) which was recommended by the supplier (Calbiochem, Millipore) to be the 
effective concentration. Pepstatin A was added to substrate+buffer solution to produce 
the final concentration 1 µM. A final concentration of 50 ng/ml CathD was prepared 
from the stock solution (50 µg/ml). Firstly, 28 µl stock was diluted 10 times in 252 µl 
dH2O to produce 5 µg/ml intermediate stock. This was further diluted to 300 ng/ml. 20 
µl of 300 ng was dispensed into test wells containing 100 µl buffer (+substrate, +- 
pepstatin A) to give a final concentration 50 ng/ml. The experiment was carried out in 
4, 96 well black opaque plates (greiner bio-one): 2 plates were for CD+substrate and 
2 for CathD+Substrate+pepA.  Therefore, in the former 2 plates,  substrate+buffer 
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solution (100 nM) was dispensed in each well, and in the latter 2, 100 µl of 
pepstatin+substrate pH buffer solution was dispensed per well. Each condition was run 
in quadruplets per plate. Next, 20 µl of corresponding pH buffer (only) was dispensed 
in the control wells. Finally, 20 µl of corresponding buffer was added to control wells 
and 20 µl enzyme solution was added to test wells. Plates were read immediately and 
up to 10 mins of incubation at room temperature on bench top. Plates were read at 
Ex/Em: 320/393 and the data normalised to control and represented as a percentage 
of the control. 
 
4.2.6 CathL proteolytic activities pH experiment 
Citric acid monohydrate and Na2HPO4 pH buffer solutions were prepared ranging 
between 5.6 and 7. Their composition is given in SI note 3. CathL fluorogenic substrate 
Z-Val-Val-Arg-AMC (ZVA) 10mg was reconstituted in 150.6 µl DMSO to produce 100 
mM stock solution. An intermediate solution (100 µM) was made by adding 2 ul (100 
mM) stock to 1.998 ml pH buffer 5.5. This was further diluted to produce final 
concentration of 5uM substrate solution in individual pH buffer (100 µl substrate + 1900 
µl pH buffer) to make 2 ml. CathL inhibitor Z-Phe-Tyr-CHO (FY-CHO) 2 mg was 
reconstituted in 45 µl to produce a stock solution of 100 mM. The stock solution was 
diluted further to make 1 mM working solution by adding 5 µl to 450 µl pH 5.5 buffer. 
Final concentration was 10 µM in substrate pH solution. CathL 274 µg/ml (pH 5.5, 
Sigma) was diluted 10 times to produce 27.4 µg/ml intermediate solution in 5.5 pH 
buffer. Further dilution was made to produce 300 ng/ml concentration in individual pH 
buffer before dispensing in to the test wells (100 µl/well), to give final concentration of 
50 ng/ml (120 µl). The experiment was carried out in 4, 96 well black opaque plates 
(greiner bio-one). Two of these plates were used to test CathL proteolytic activity in the 
presence of ZVA. The inhibitory effect of FY-CHO was tested in the other two plates. 
Firstly, 100 µl of substrate pH buffer solution was dispensed in each corresponding 
well (both control and test wells) of the former 2 plates. The latter 2, contained 
substrate + FY-CHO buffer solution (100 µl-both control and test wells). Each condition 
was run in quadruplets per plate. Finally, 20 µl of corresponding pH buffer was added 
to each control well and 20 µl of enzyme solution (300 ng/ml) was added to all test 
wells. Plates were read immediately and up to 10 min of incubation at room 
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temperature on bench top. Plates were read at Ex/Em: 365/440 using Matt’s plate 
reader.    
 
4.2.7 Enzyme interaction with GO 
An interaction between CathD or CathL (50ng/ml) and GO (50, 500 and 1000 µg/ml) 
was tested in pH buffers (pHs 3.6 and 7 for CathD, and pHs 5.5 and 7 for CathL). pHs 
values of 3.6 and 5.5 are optimum for CathD and CathL activity, respectively. CathD 
and/or CathL was incubated with GO at different concentrations for 2, 5, 10, 15 and 20 
min. The experiment was carried out in x4 96 well black opaque plates (greiner bio-
one). Plates were read at the aforementioned time points of incubation at room 
temperature to measure absorbance at 280 nm for CathD and CathL using a 
SpectraMAX plate reader. Plates were read at Ex/Em: 485/530 nm and 490/520 nm to 
measure fluorescence intensity of CathD and CathL respectively and the data 
normalised to the control (and represented as a percentage of this control). The 
fluorescence intensity of the GO hydrolysis was detected kinetically using a 
SpectraMax plate reader. The same procedure was repeated (n=4) with CathL at 
various concentrations (50, 500 and 1000 µg/ml). The control wells contained GO only 
(dispersed in distilled water). FTIR, Raman spectroscopy, water contact angle and 
diiodomethane contact angles were measured in the same way as described in the 
previous section.  
To verify the adsorption of CathD and CathL, an intra-particle diffusion model with the 
experimental data of this study was used. 
Fick's second law was used to find out if intraparticle diffusion is a rate-controlling step 
during the adsorption experiment [32,33]: 
𝑞𝑡 = 𝑘𝑖𝑑√𝑡 + 𝐼,  
where I represents the boundary layer effect (a large value corresponds to a larger 
boundary layer thickness) and kid is the intraparticle rate constant. Such plots may 
present a multi-linearity [34,35], indicating that two or more steps take place. The first, 
sharper portion is the external surface adsorption or instantaneous adsorption stage. 
The second portion is the gradual adsorption stage, where intraparticle diffusion is rate-
controlled and from it Kint is obtained. The third portion is the final equilibrium stage 
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where intraparticle diffusion starts to slow down due to extremely low adsorbate 
concentrations in the solution. 
4.2.8 Statistical analysis 
Statistical analysis was performed between two groups by an unpaired Student’s t-test, 
and between multiple treatment groups by one-way analysis of variance (ANOVA) with 
Tukey post-hoc testing or two-way ANOVA with Bonferroni post-hoc test, using 
Graphpad Prism 5 software. Results are presented as mean ± s.d, unless otherwise 
indicated. The value of p < 0.05 was considered significant. 
 
4.3 Rsults 
 
4.3.1 Synthesis and in vitro toxic effects of GO on lung cancer cells 
 Similar to our previously reported work, exfoliated GO has been synthesized 
following the modified Hummer’s method [26-28]. The basic characterization is given 
in Supplementary note 2 and SI Figures 4.1-4.7. The TEM image showed the flake-
like shapes of GO (SI Figure 4.1). The Raman spectrum of GO (SI Figure 4.2) 
exhibited a D band at 1358 cm−1 and a G band at 1595 cm−1, highlighting the presence 
of defects and the in-plane stretching motion of pairs of sp2 atoms, respectively [36,37]. 
The surface area of the GO was measured by the N2 absorption 
Brunauer−Emmett−Teller (BET) method and found to be 25 m2/g with a pore volume 
of 0.07 cm3/g (SI Figure 4.3). The zeta potential of the GO sheet was determined as 
a function of pH to evaluate the effect of GO sheet concentration on the surface charge 
of the samples. The GO sheets are highly negatively charged when dispersed in water 
due to the deprotonation of surface carboxylic acid and phenolic hydroxyl groups (SI 
Figure 4.4). GO exhibited the lowest zeta potential value (−63.54 mV) due to the 
presence of a significant amount of free carboxylic groups. Furthermore, the FTIR 
spectrum of GO (SI Figure 4.5) shows the following characteristic functional groups of 
GO: C−O−C (∼1000 cm−1), C−O (1230 cm−1), C C (∼1620 cm−1) and C O (1740–
1720 cm−1) bonds. The O−H stretching vibrations in the region of 3600–3300 cm−1 are 
attributed to the hydroxyl and carboxyl groups of GO and residual water between the 
GO sheets [37]. The dispersibility of GO was examined from the linear relationship 
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between the absorbance (A) and the concentration (C) of a compound in a solution, 
given by the Lambert–Beer law. A calibration line was constructed by measuring the 
absorbance at 232 nm of nine different concentrations of the GO (0.039-10 mg/ml) 
solution which has given good water dispersibility of GO (SI figure 4.6) [39]. The XRD 
pattern of as-prepared GO gives a (001) reflection peak at 2θ = 13.7° (SI Figure 4.7), 
corresponding to a d-space of 0.75 nm, indicating an increased interlayer distance 
compared to that (3.34 Å) (2 theta ¼ 26.7º) in the graphite structure [40] and complete 
disintegration of graphite structure to form GO under ultra-sonic vibration.  
 
 In vitro toxic effects of GO were determined by measuring cell viability, early and 
late apoptosis, and necrosis in two cell lung cancer cell lines at different concentrations 
of GO (5-500 µg/ml). Early apoptosis is defined by an increase in phosphatidylserine 
(PS) expression on an intact cell membrane (detected by annexin V). In late apoptosis, 
however the membrane loses its integrity and PI permeates into the cells and flags 
these cells as late apoptotic/necrotic. Figure 4.2A demonstrates that after 24-h 
exposure to GO, the cell viability of both A549 and SKMES cells exhibited a slight but 
significant (p < 0.05) reduction at concentrations of 250 and 500 µg/ml, compared to 
control (0 µg/ml). Significant early apoptosis was also detected (Figure 4.2B), in A549 
cells at 500 µg/ml (p < 0.05) compared to control (0 µg/ml), and in SKMES-1 cells 50, 
250 and 50 µg/ml (p < 0.05) of GO. Late apoptosis (Figure 4.2C) and necrosis (Figure 
4.2D) measurements were consistent for A549 cells. Interestingly, in SKMES-1 cells, 
250 and 500 µg/ml of GO significantly induced late apoptosis while necrotic cells were 
detected at concentrations of 50-500 µg/ml. Figure 4.2E shows the representative 
FACS images and analysis of one experiment. GO induced apoptosis and necrosis a 
concentrations higher than 50 µg/ml in both cell lines. However, the percentage count 
of apoptotic cells remained higher compared to necrosis, suggesting that GO may not 
cause significant damage to the cell membrane allowing only annexin V to bind to PS 
on cell surface membrane. This indicates that cell death observed at higher 
concentrations of GO is probably due to apoptosis rather than necrosis.  
For the toxicity exposures undertaken, GO has been shown to be less toxic than other 
forms of graphene such as reduced graphene oxide, we recently reported for similar 
cell lines [29]. However GO has proven to be more toxic than graphene quantum dots 
as reported by Zhu et al where it was demonstrated that dots have little toxicity to 
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MG63 (80 ∼ 90% of cell viability at low dose) [41]. This may be due to the fact that 
such dots are smaller than GO, and hence cause less damage to the cell membrane. 
GO has been proven to have less toxic effects on cellular viability, oxidative stress, 
and cell death compared to reduced GO because of two dimensional thin sheets, 
functional groups and surface charge which facilitate its improved cellular uptake [42]. 
Oxidative stress is thought to be one of the key factors leading to graphene toxicology, 
reducing the viability of cells and hindering uptake of essential proteins and nutrients 
[43]. We also investigated the relationships between concentration of GO and cell 
death rate, so as to determine the most biocompatible concentrations. For this 
purpose, we used a Gaussian process (GP) to model the relationships and readily 
incorporate the uncertainties in measurements to produce a Bayesian posterior 
predictive distribution [29]. Interestingly, the model for A549 cells indicates that 
concentrations below 200 µg/ml are likely to be have better biocompatibility than higher 
concentrations. In contrast, in the model for SKMES-1 cells, indicated that 
concentrations between 250 and 500 µg/ml are likely to yield lower cell death. These 
predictions match with the experimental results. (The details of this model and 
modelling results are presented in SI note 2 and SI Figure 4.8). 
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Figure 4.2:  The percentage of living and dying A549 and SKMES-1 lung carcinoma cells before and after graphene oxide 
treatment. (A-D) The percentage of dead, living, early-stage apoptotic, and late-stage apoptotic cells in response to different 
concentrations of graphene oxide (GO). Flow cytometry for A549 and SKMES-1 lung carcinoma cells stained with annexin V 
(apoptosis) and propidium iodide (PI; late apoptosis and necrosis) following 24 h of treatment with varying concentrations of GO  (0–
500 µg/ml). (A) Percentage of living cells (B) early apoptosis (C) necrosis, (D) late apoptosis (flow cytometry) in response to rGO. 
Data are represented as mean ± SD, n.s., *p < 0.05 vs control (0 µg/ml). (E) The effect of graphene oxide on cell apoptosis (early and 
late) and necrosis as quantified by flow cytometry using Annexin V and PI. (Upper panel)  A549 and (lower panel) SKMES-1 lung 
carcinoma cells.The binding of AnnV and PI to the cells was measured by flow cytometry using Guava 3.1.1 software. Experiments 
were performed and interpreted as follows: cells that were Annexin V-ve/PI-ve (lower left quadrant) were considered as living cells, 
AnnV+ve/PI-ve cells (lower right quadrant) as early apoptotic cells, AnnV+ve/PI+ve (upper right quadrant) cells as late apoptotic cells, and 
AnnV−ve/PI+ve (upper left quadrant) as necrotic cells.  
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4.3.2 Basic characterization of enzymes 
 
The proteolytic activity of CathD was investigated using a specific fluorogenic substrate 
(1µM pepstatin A) over a range of two pHs 3.6 and 7 while the proteolytic activity of 
CathL was investigated using a specific fluorogenic substrate ZVA (5µM) over a range 
of two pHs 5 and 7. It is evident that CathD is mostly active at its physiological pH (3.6). 
As pH was increased to 7, fluorescence signals were observed to be reduced (Figure 
4.3 A). The result suggests that CathD is not active at pHs higher than its optimum and 
CathD is active as a mitogenic factor in non-proteolytic manner when used in the cell 
culture media. Fluorescence signals from the substrate hydrolysis did not rise 
significantly from their control. This suggests that pepstatin A is active and efficiently 
blocks CathD-mediated proteolysis. On the other hand, CathL is mostly active at its 
physiological pH 5 (Figure 4.3 B). Fluorescence signals remain almost two times 
higher than the control at pH 7 (pH of the cell culture media). The data suggested that 
CathL is proteolytically active at pHs above the physiological optimum level. CathL-
mediated ZVA proteolysis were inhibited by 10µM FY-CHO. This suggests that FY-
CHO is an efficient inhibitor of CathL’s proteolytic activity and that CathL is a 
proteolysis-independent mitogenic factor in cell media.  
The representative FTIR spectra of CathD and CathL are given in Figure 4.3C for the 
spectral range (3200–500 cm−1). The most prominent band assignments of the CathD 
at 1100, 1243, 1280, 1413, 1713, and 2050-2150 are C-O stretch, CH wagging, C-O 
stretch, Carboxylate ion (COO−) symmetry, C O stretch carboxylic acid and C-H alkyl 
stretch respectively [44,45]. The most prominent band assignments of CathL at 1100, 
1243, 1280, 1413, 1713, and 2050-2150 cm-1 are C-O stretch, CH wagging, C-O 
stretch, carboxylate ion (COO−) symmetry, C O stretch carboxylic acid and C H 
alkyl stretch respectively [44-46]. These bands were not observed in control 
experiments without CathD/CathL and substrate agents (data not shown). The regions 
with the widest ranges and their corresponding spectral signatures have been given in 
SI Table 4.1. The representative Raman spectra of CathD and CathL are given in 
Figure 4.3 D for the spectral range (2500–500 cm−1). The most prominent band 
assignments of the CathD are 2243, 2024 and 1603 cm−1 while assignments of CathL 
are 2024 and 1603 cm−1. The strong peak at 1608 cm-1 corresponds to the known 
bands for the Fmoc group as reported earlier [47]. The Raman bands at 2024 and 2243 
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cm-1 could be assigned to the C≡C stretching vibration, which was present in the 
propargyl group [47]. The surface free energy and its polar and dispersive parts were 
calculated to investigate the binding capacity and weight of electrostatic and/or van der 
Waals interactions between GO and the enzymes. The binding capacity of GO, CathD 
and CathL were calculated using the contact angle method and their respective contact 
angles have been shown in Figure 4.3 E. The surface free energies, polar and 
dispersive parts of GO, CathD and CathL are shown in Figure 4.3 F. CathD has the 
highest total surface energy of 77.4 mN/m, although GO, CathD and CathL have similar 
trends of surface energies of total and their respective parts because of the similar 
amount and weight of functional groups. As a result, the use of GO as an adsorbent 
could allow enzymes to be adsorbed and substituted to improve the binding of 
CathD/CathL with GO. It could also allow the rearrangement of the binding pocket in 
response to the substitutions. As a result of this process, it appears that the amino 
substitution at edge positions of GO ought to result in a more tightly binding ligand. 
(See set of “snapshots” in Figure 4.3 G). 
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Figure 4.3: Characterization of cathepsin D (CathD) and cathepsin L (CathL). (A) 
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CathD is highly active at pH 4 (optimum) and inactive at pH 7 and above. A specific 
fluorogenic substrate (10µM) was incubated with CathD (50ng/ml) in 96 well plates at 
different pHs ranging from 3 to 7.6 as shown. Fluorescence signals were measured 
using plate reader at Ex/Em: 320/393. Control wells contained pH buffer and substrate. 
The data is represented as percentage of control. (B) CathL is highly active in ionic 
buffer. A specific fluorogenic substrate ZVA (5 µM) was incubated with CathL (50ng/ml) 
in 96 well plates at different pH ranging from 3 to 7.6 as shown. Fluorescence signals 
were measured using a plate reader at Ex/Em: 365/440.  Control wells contained pH 
buffer and substrate. The data are presented as percentage of control. (C) FTIR of 
CathD and CathL. (D) Raman spectra of CathD and CathL shows bands at 1602 and 
2024 cm-1. (E) Water contact angle profile of GO, CathD and CathL gives the values 
of 20º, 9º and 11.5º. (F) Surface energy profile of GO, CathD and CathL. (G) 
Representative images and quantification of wettability, as measured by water and 
diiodomethane contact angles of GO, CathD and CathL. A digital camera was used to 
record the images and their contact angles were calculated by PolyPro software 
package. 
 
 
4.3.3 Enzyme interaction with GO 
 
Batch adsorption studies were conducted to measure the adsorption properties of 
CathD and CathL on GO. Figure 4.5 shows that an increase in adsorption capacity 
occurred for both enzymes over a 20 min time period, reaching a maximum capacity 
of above 90%. The capacity was found to be slightly greater for higher concentrations 
of GO with both kinetic models showing a good agreement with the experimental data 
(Figure 4.6 A and B). Figure 4.4 shows absorbance variations at different 
concentrations of GO (0, 50, 500 and 1000 µg/ml) exposed to CathD and CathL over 
different time scales (0-20 mins). The decrease in absorbance signals of CathD and 
CathL at pH of 3.6 and 5, respectively revealed the adsorbed amount of CathD and 
CathL to GO. With increase of time and concentration, CathD and CathL were almost 
fully adsorbed onto the GO surface. CathD and CathL adsorption was pH dependent, 
with the highest concentration of GO, which demonstrated highest adsorbed amounts 
at more acidic pHs (3.6 and 5). For pH 3.6, the amount of CathD adsorbed increased 
from 50 to 1000 µg/ml over a time scale of 0 to 20 mins. It is evident that adsorption 
capacity of 1000 µg/ml of GO is above 90 % after 20 mins. CathL adsorption on the 
GO surface followed a similar pattern in pH of 5 and 1000 µg/ml concentration of GO 
attained the highest value of efficiency after 20 min.   
87 
 
 
Adsorption kinetics are useful to investigate the adsorption mechanism and adsorption 
rate. In this study, we have used an intraparticle diffusion model which has clearly 
shown three linear segments to explain the adsorption stages: the first stage is 
attributed to the instantaneous adsorption onto the GO’s surface;, the second to 
intraparticle diffusion; and the third to the final equilibrium stage for which the 
intraparticle diffusion started to slow down because of the extremely low adsorbate 
concentration left in the solution. Figure 4.6 A-B show that none of the intraparticle 
diffusion plots passed through the origin,  which showed that the intraparticle diffusion 
was part of the adsorption but was not the only rate-controlling step and indicates the 
effect of film diffusion (boundary layer diffusion) on the adsorption of CathD and CathL. 
(The intraparticle diffusion constant values are shown in SI Table 4.2). Gaussian 
process regression models for CathD and CathL relating independent variables (time 
and concentrations) to the dependent variable of adsorption are shown in Figure 4.5 
(C-F). In Figure 4. 5 C and E, the mean predictions for CathD and CathL are depicted 
respectively and the uncertainty in these predictions has been shown in Figure 4.5 D 
and F. The mean predictions for CathD indicate that promising (lower) absorption can 
be achieved with a concentration around 100 µg/ml when it is active for 15 to 20 min. 
The models also revealed that concentrations greater than 900 µg/ml which is active 
for about 18 min could also be promising.  Additionally, the uncertainty in the model is 
relatively low in these areas. Figure 4.5 E and F shows similar trends CathL. 
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Figure 4.4: Effect of different concentrations of GO on CathD and CathL activities. 
Absorbance of CathD (A-D) and CathL (E-H) by GO at different concentrations (50, 
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500, and 1000 µg/ml) incubated in 96 well plates at different time-points (2, 5, 10, 15, 
and 20mins) Absorbance signals were determined using plate reader at Ex/Em: 
355/460nm. 
  
 
Figure 4.5: (A-B) Kinetic models fitting to the data for CathD and CathL using 
piecewise linear regression analysis of the adsorption experiments of (A) CathD and 
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(B) CathL on GO. (C-F) Gaussian process regression models to find prediction and 
uncertainty in CathD (C, D) and CathL (E, F) relating independent variables, (time and 
concentration), with dependent variable (absorption). In C and E, the mean predictions 
are depicted and the uncertainty in predictions is shown in D and F.  
 
 
Supplementary Figure 4.9 illustrates normalized fluorescence intensities of different 
concentrations of GO (0, 50, 500 and 1000 µg/ml) exposed to CathD and CathL over 
different time scales (0-20 min). The ability of both CathD and L to enzymatically cleave 
a fluorescent GO is reduced at increasing concentrations of GO (0, 50, 500 and 1000 
µg/ml). GO dose dependently increase the catalytic activity of CathD and CathL at both 
pH tested. A slight difference in emission spectra also occurs, suggesting that lowering 
the pH to more acidic values triggers an increased solvent exposure of non-polar sites 
in the enzymes. Fluorescence loss was observed in the case of CathL at pH 7 due to 
the reversible nature of CathL inhibition. No significant difference in fluorescence could 
be due to uptake of enzymes induced by GO. This uptake allows localization of 
internalized GO under different pH conditions [48, 49]. This could be attributed to the 
large size of GO which blocks fluorescence signals. This suggests that the CathD and 
CathL were adsorbed onto the surface of GO via physiochemical interaction and hence 
block the emission of fluorescence signals from the GO. CathD and CathL bonding 
speeded up with increasing the concentration of GO. This behaviour could indicate that 
both the enzymes and GO surface had to adapt their structures to form a stable 
interface. At high enzyme coverage of the GO surface, one could also envisage that 
rearrangements of protein molecules already bonded to the GO were required to make 
room for an incoming protein molecule. This crowding effect would contribute 
significantly to the self-fluorescence properties of GO. Understanding the respective 
effects of these factors to allow the design and uptake of pro-tumourigenic and pro-
metastatic enzymes released in extracellular matrix from malignant tumors will be the 
focus of further studies.  
 
 
FTIR and Raman spectroscopic findings can be used to monitor the macromolecular 
movements and vibrational/rotational states of specific chemical groupings which bind 
target biomolecules with high specificity during the formation of the nano-bio-interface 
of CathD- and CathL-GO. Figure 4.7(A-B) shows FTIR spectra of GO linked to CathD 
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and CathL at the concentrations of 50, 500 and 1000 µg/ml of GO after 20 mins. The 
FTIR spectrum of CathD-linked GO exhibited a variety of CathD and CathL absorption 
features such as C=O (ʋC=O at 1714 cm-1), and the peak of the C–N stretch mode (ʋC=O 
at 1100 cm-1) in all the concentration represents the CH stretching and NH bending. 
The spectra of CathD after interaction with 500 and 1000 µg/ml GO (Figure 4.6 A) 
showed the characteristic peak of alkoxy group at 980 cm-1 which arose from the C=O 
functional groups of GO and CathD. The peaks at 1413 cm-1 ascribed to NH bending 
and CN stretching also confirmed the existence of CathD and CathL. These results 
confirmed that CathD and CathL have been successfully covalently bonded onto the 
surface of GO. Figure 4.7(C-D) shows Raman spectra of CathD and CathL-linked GO. 
In the spectra of 500 and 1000 µg/ml concentrations of GO, the amide-I vibration at 
1590 cm-1 arose mainly from the ʋC=O stretching vibration. The band in the range of 
2020-–2250 cm-1 was caused by the C-H3 and C-H2 deformation vibrations from the 
side chains of different amino acids. The amide-III was the combination of the N-H 
bending and C-C stretching vibration in the region 1200-1340 cm-1 [30, 31]. Slight shifts 
can be observed between the two Raman spectra of GO and CathD and CathL 
adsorbed on GO. In the spectrum of GO (SI Figure 4.2) there were two typical peaks 
at ca. 1355 cm-1 and 1580 cm-1. The bands at 1600-1620 cm-1 can be assigned to the 
C=O stretching of carboxylate and C-H2 deformation vibration. In the Raman spectra 
of GO and CathD/CathL- GO, the prominent amide band at 1600-1620 cm-1 of 
Cathepsins was shifted to 1590 cm-1 at the CathD/CathL-GO interface. Based on these 
facts, it could be inferred that the CathD and CathL interacted with GO through its 
amide bonds. However, the amide bonds might not be the only force that bonded 
CathD and CathL to GO. Both Cathepsins have a deep bonding pocket with the binding 
groups identified by FTIR, at the bottom which provides the space and electrostatic 
attractions. 
  
The functional groups existing at the surface of GO readily make its surface passivated 
covered with inert molecules, which increases surface hydrophilicity and subsequently 
enhances the bonding strength of these nanostructures [32]. Several site-specific 
variants of GO have made an attempt to alter the surface-inactivation of ‘wild-type’ 
enzymes. The extent of this change and mechanistic insight of protein interaction with 
surfaces have been probed by water contact angle (WCA) measurements and surface 
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energy (Figure 4.6E-F). The CathD and CathL displayed higher binding activity 
towards GO, as demonstrated by the WCA values. Upon CathD and CathL interaction, 
the WCA profiles of GO shifted to higher values, suggesting that a good level of surface 
hydrophilicity was achieved (Figure 4.6F). The effect was more pronounced for the 
higher concentrations, whose average WCA value increased by 8.5 and 15.02 for 
CathD and CathL, respectively. The changes in diiodomethane contact angle (Figure 
4.6F) revealed the surface energy profile, which is quantitatively shown in Figure 4.6G-
H. The binding free energies of GO to CathD and CathL are shown in Figure 4.6G-H. 
When one group is replaced with an amino group, the intermolecular vdW and 
electrostatic interactions become more favorable, while more desolvation penalty is 
paid. The total free energy is improved due to the charge distribution of nano-bio-
interface substituent changed completely after introducing the amino group and 
carboxyl bond network to the ring, the conformation of the whole ligand changed 
accordingly. However, the polar penalties upon binding of these two proteins to GO 
was decreased. As a result of this process, it appears that the amino and carboxyl 
substitutions at the interface position ought to result in a more tightly binding ligand.  
 
Overall, the results have addressed a couple of key features related to the surface 
interaction of GO substrates with CathD and CathL: (i) the effect of the functional 
groups existing on the surface of GO and CathD/CathL; (ii) hydrophobicity driven by 
the adsorption of CathD/CathL onto the GO surface to form a nano-bio-interface. (The 
WCA of CathD and CathL is shown in Figure 4.3). Furthermore, the rise in total and 
dispersive surface energy caused by the CathD/L-GO interaction revealed that 
differences in functional group content, conformational flexibility, and shape and 
distinct bonding affinities released a higher free surface energy. Higher concentrations 
of GO readily covered the surface of the CathD/CathL to initiate the formation of a 
protein ‘soft’ corona, while lower concentrations with lower yield of functional changes 
took over to form a corona. The low polar and high dispersion parts (Figure 4.6 G-H) 
of the surface energy revealed that the polar and nonpolar side-chains of CathD/CathL 
facilitate conformational changes in the CathD/CathL structure and which in turn leads 
to high adsorption capacity of CathD/CathL into GO. 
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Figure 4.6: (A-B) FT-IR spectra of CathD/CathL-linked graphene oxide (GO) at 50, 
500,and 1000 µg/ml concentrations of GO. (C-D) Raman spectra of CathD/CathL-
linked GO at 50, 500, and 1000 µg/ml GO concentrations (E-F) Contact angle profiles 
of CathD/CathL-linked GO interfaces at 50, 500 and 1000 µg/ml concentrations of GO. 
Diiodomethane contact angle was measured to calculate the surface energy of 
enzymes, GO and their interfaces. (G-H) Surface energy profile of GO- CathD/CathL 
interfaces which have three segments of total surface energy, dispersive surface 
energy and polar surface energy of 50, 500 and 1000 µg/ml concentration of GO 
treated with CathD and CathL. 
 
4.4 Discussion 
 
The complexities of cancer entail the innovation of treatment modalities that are 
capable of clearing out the pro-tumourigenic enzyme by developing a novel platform 
based on biocompatible adsorbents. The currently available mainstream treatment 
options have resulted in improved survival and quality of life, although ovarian and 
breast cancers remains progressive diseases. Thus, there is an ever growing need for 
the development of alternative approaches. Conventional biological drug therapies 
have limitations due to inherent risk of abnormality and unwanted side effects on 
normal tissues/cells that adversely affect the efficacy and safety of the treatment. An 
emerging paradigm in cancer therapy suggests that adsorption of these enzymes in 
the local tumour environment can be compromised by using porous adsorbents. 
Enzyme-targeted therapy holds great promise for this by addressing the mechanisms 
of their clearance and treatment escape. In this study, we developed GO that breaks 
down and uptakes such enzymes which promote increased invasiveness and 
metastasis. The surface charge, surface area, chemical reactivity and electronic 
characteristics of GO were used to target these enzymes with sustained release of its 
active functional groups, free radical and porous sites for entrapment of CathD and 
CathL. The inhibition of CathD and CathL was observed at specific pH values which 
supports metastasis also verified by enzyme activity using specific substrates. The 
analysis of the released CathD and CathL libraries are carried out using a wide variety 
of analytical tools such as FTIR, Raman, WCA and surface energy profiles (see 
Figures 4.2 and 4.6) , thus offering a greatly accelerated identification process and 
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much higher throughput compared with conventional tools to analyse nanoparticle 
interactions with proteins. In this manner, the characterization of the studied enzymes 
for their binding and bioactivity is carried out to better understand their structural and 
functional behaviours. 
 
The current approach of enzyme targeting offers a number of important advantages. 
First, it allows the facile tagging of cathepsins with very high transformation/removal 
efficiencies using GO, which significantly increases the chances of identifying 
biomolecular fractions. Second, the clinical safety of this approach would further 
benefit from using a GO system that is already used in clinical trials to introduce 
drug/gene carrier vehicles. Finally, and very importantly, our approach is highly 
versatile and can be applied broadly for the discovery of therapeutic rescuers of 
disease-associated proteins. Here, we have used it to target two prominent ovarian 
and breast cancer-associated enzymes. The two-dimensional and adsorbing nature of 
GO could reduce the likelihood of abundance of these enzymes to induce tumor cell 
invasion and metastasis, and thereby maximize its broad applicability. Furthermore, 
the GO not only allows for robust interaction with enzymes but also enables the 
compact packaging of the GO within dissolvable capsules, facilitating non-invasive oral 
administration to track these proteins, which could be used as a diagnostic tool. 
Despite the obvious advantages presented by enzyme-targeted therapy (compared 
with the blunt instruments of chemotherapy, radiation and surgery), the cost-
effectiveness involved in producing GO is another advantage for implementing this 
material as a standard-of-care in the treatment of cancer. Currently, clinical-scale 
manufacturing of GO requires a variety of elaborate protocols to modify, deliver and 
selectively accumulate and administrate into the living systems. Future work will 
address cell based and pre-clinical metastatic disease models and will potentially 
involve further developments to incorporate targeted and achievable delivery of GO to 
the tumor sites with sufficient selectivity to facilitate the removal of disseminated 
enzymes. New drug delivery systems are needed to facilitate such combinations that 
may deliver adsorbent, and further studies are warranted to investigate the long-term 
impacts on cure rate, survival and potentiation of this therapy regimens. 
 
 
96 
 
4.5 Conclusions 
 
In summary, this chapter represents a straightforward and highly adaptable strategy 
for the rapid and facile removal of pro-metastasis enzymes that effectively rescue the 
disease. GO with its variable zeta potential, variety of functional groups and very large 
(and in principle fully accessible) surface area, is an extremely promising candidate for 
the adsorption of such enzymes. Results show that this material is compatible with 
cells. In addition, the adsorbent preparation is based on abundantly available and cost-
effective graphite as main precursor. GO nanostructures are easy to manufacture and 
are stable, which simplifies long-term storage and correspondingly reduces the cost. 
Thus, if implemented in the clinic as a new form of active enzyme therapy, this 
technology could provide a practical, low-cost and broadly applicable way to treat 
cancer. 
 
4.5 Supplementary information 
Supplementary note 1: We first characterized graphene oxide (GO) with a wide range 
of characterization tools such as Fourier-transform infrared spectroscopy (FTIR), 
Raman spectroscopy, transmission electron microscopy (TEM), scanning electron 
microscopy (SEM), Zeta potential analyser,, X-ray diffraction (XRD) and 
Brunauer−Emmett−Teller (BET) surface area method. 
 
The surface area of the GO as measured by the N2 absorption 
Brunauer−Emmett−Teller (BET) method is 25 m2/g having a pore volume of 0.07 cm3/g 
(SI Figure 4.3). However, it is still lower than the theoretical specific surface area for 
completely exfoliated and isolated graphene sheets (∼2,620 m2/g), potentially because 
it measures the outer surface of GO grains. The nitrogen molecules are inaccessible 
to the interlayer and interlamellar spaces of GO and as a result acid-base processes 
in aqueous GO dispersions take place on much greater surfaces. According to the 
Ruess model, graphite oxide consists of wrinkled carbon sheets composed of trans-
linked cyclohexane, and the fourth valencies of the carbon atoms are bound to axial 
OH-groups and ether oxygen atoms in 1,3-positions. As a result, this geometrical 
network, functional groups existing at the edges and basal planes of GO sheets, 
degree of exfoliation and dispersion, and surface chemistry of GO hinders nitrogen 
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access/adsorption to inner surfaces of GO, which is generally opened up upon 
exfoliation. The hydrophilic oxygen-containing functional groups provide GO sheets 
with a good dispersibility in water. The GO obtained shows good water solubility (SI 
Figure 4.6) and exhibits ultraviolet-visible (UV/Vis) absorption spectra of the GO at 
absorption peak at 232 nm, which is attributed to π−π∗ transition of the C C bonds.  
 
 
SI Figure 4.1: Transmission electron microscopy image of graphene oxide. 
 
 
SI Figure 4.2: Raman spectrum of the graphene oxide sample shows intense D (1358 
cm-1) and G peaks (1595 cm-1) of defects and the in-plane stretching motion of pairs 
of sp2 atoms, respectively. 
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SI Figure 4.3: BET surface area of graphene oxide measured by nitrogen sorption 
isotherms measured at -196 ºC. The BET surface area value obtained for this sample 
using the BET method is 25 m2/g.  
 
SI Figure 4.4: Representative zeta potential of graphene oxide over a range of different 
pH values.  
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SI Figure 4.5: Fourier transformer infrared (FTIR) spectrum of graphene oxide shows 
vibrations of functional groups of C−O−C (∼1000 cm−1), C−O (1230 cm−1), C C 
(∼1620 cm−1), C O (1740–1720 cm−1) bonds and O−H (3600–3300 cm−1).  
 
 
 
SI Figure 4.6: (A) UV/Vis absorption spectra of graphene oxide solutions with different 
concentrations (from 0.039-10 mg/ml) show the main peak around 232 nm. (B) The 
plot of the absorbance (λex = 232 nm) divided by the cell length, versus the 
concentration, given by the Lambert–Beer law (A = αlC), which determined the 
absorption coefficient (α) related to the absorbance per unit path length A/l. This linear 
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relationship fits well with the Lambert-Beer Law, indicating the good water solubility of 
the GO product.  
 
SI Figure 4.7: XRD pattern recorded for graphene oxide shows a (001) peak at 
2θ of 13.7°. 
 
 
Supplementary note 2: Regression model analysis of cell viability: The resulting 
predictive distributions from the trained GP models for A549 and SKMES-1 cells are 
shown in SI Figure 4.8. The models not only capture the measurement noises, but 
also indicate how much confidence may be derived from the predictions through the 
associated standard deviation. Most interestingly, GP models can predict cell-specific 
toxicity levels of concentrations. As such, we may exploit this knowledge to run further 
experiments to find out optimal levels of concentrations. This approach is better known 
as Bayesian optimisation: a sequential design method that may locate near-optimal 
solutions with limited number of time consuming and computationally expensive 
experiments. 
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SI Figure 4.8: Gaussian process (GP) regression models for cell survival rates of A549 
(left) and SKMES-1 (right) cells interacted with various concentrations of reduced 
Graphene Oxide (rGO). The green solid lines show the mean GP prediction, while the 
light green areas around the mean show the uncertainty (one standard deviation) in 
prediction. The models are trained with the data indicated by the red crosses.  
Supplementary Note 3: Different ranges of pHs were prepared to investigate the 
proteolytic activities of CathD and CathL. 21.01 g of citric acid was mixed to 1 ltr distilled 
water and 28.40 g of Na2HPO4 in 1 ltr distilled water. Citric acid monohydrate and 
Na2HPO4 pH buffer solutions were prepared ranging: 3.6, 5, and 7. Final volume of 
each pH buffer was 50 ml containing freshly prepared 1 mM DTT for CathL. Final 
volume of each pH buffer was 50 ml containing 0.005% Tween 20 (2.5 µl, sigma) for 
CathL. 
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SI Table 4.1: Characteristic IR bands of the protein linkages. 
 
Approximate 
frequency (cm-1) 
Vibrational modes References 
1610-1695 CO stretching 
 
C O: Amide I (C O stretching mode of proteins) 
[50] 
1480-1575 NH bending and CN stretching 
 
CH2: Asymmetric CH3 bending and CH2 scissoring 
C N H: Absorption of amide II, predominately β-sheet; an  
N H bending attached to a C N stretching modes, C N H bending  
or/and C N stretching vibrational modes. 
[50-54] 
1220-1320 CH stretching and NH bending, 
 
C N H: (ν(CN), δ(NH) amide III, α-helix collagen, tryptophan; and  
PO2 − asymmetric phosphate stretching associated with  
the phosphodiester groups of nucleic acids. 
C N H: Symmetric stretch: Amide III and CH3/CH2 twisting 
[50-54] 
625-765 OCN bending, mixed with other vibrational modes of amide II and III [53, 55]  
640-800 Out-of-plane NH bending [53, 55] 
535-605 Out-of-plane CO bending [53, 55] 
 
SI Table 4.2: Kinetic parameters obtained for CathD and CathL for GO using 
intraparticle diffusion model 
 
Adsorbent Enzyme Y R2 
 
GO (50 µg/ml) CathD 0.0087 ± 0.0071 0.9592 
 
CathL 0.0094 ± 0.0138 0.9068 
GO (500 µg/ml) CathD 0.0073 ± 0.0084 0.9939 
 
CathL 0.0073 ± 0.0011 
 
0.9323 
GO (1000 µg/ml) CathD 0.0071 ± 0.0008 0.8094 
 
CathL 0.0078 ± 0.0002 0.8741 
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SI Figure 4.9: Effect of different concentrations of GO on CathD and CathL 
fluorescence activities. GO at different concentrations (50, 500, and 1000 µg/ml) were 
incubated with CathD(A, B) and CathL (C, D) in 96 well plates at different time-points 
(2, 5, 10, 15, and 20 min) as shown. Data (symbols) are shown together with guides to 
the eye (connecting lines). Fluorescence signals were determined using plate reader 
at Ex/Em: 355/460nm. 
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Chapter 5  
In Vitro Toxic Effects of Reduced Graphene 
Oxide Nanosheets on Lung Cancer Cells 
 
The intriguing properties of reduced graphene oxide (rGO) have paved the way for a 
number of potential biomedical applications such as drug delivery, tissue engineering, 
gene delivery and bio-sensing. Over the last decade, there have been escalating 
concerns regarding the possible toxic effects, behaviour and fate of rGO in living 
systems and environments. This chapter reports on integrative chemical-biological 
interactions of rGO with lung cancer cells, i.e. A549 and SKMES-1, to determine its 
potential toxicological impacts on them, as a function of its concentration. Cell viability, 
early and late apoptosis and necrosis were measured to determine oxidative stress 
potential, and induction of apoptosis for the first time by comparing two lung cancer 
cells. We also showed the general trend between cell death rates and concentrations 
for different cell types using a Gaussian process regression model. At low 
concentrations, rGO was shown to significantly produce late apoptosis and necrosis 
rather than early apoptotic events, suggesting that it was able to disintegrate the 
cellular membranes in a dose dependent manner. For the toxicity exposures 
undertaken, late apoptosis and necrosis occurred, which was most likely resultant from 
limited bioavailability of unmodified rGO in lung cancer cells. 
 
5.1 Introduction 
 
The potential applications of graphene are rapidly expanding with a global industry 
estimated to be worth more than 1790.7 Million USD by 2020, which is reflective of its 
wide range of application domains including, electronics, supercapacitors, energy 
storage and medicine [1, 2]. The development of real-world applications of graphene 
is fuelled by its unique and superior properties such as high electron mobility, high 
mechanical strength and high specific surface area [3]. Although some effort has been 
made to investigate the biosafety profile of graphene, a significant lack of viable data 
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on biocompatibility hinders the precise forecast of the potential of graphene to solve 
real-world clinical problems. 
 Pristine graphene, graphene oxide and reduced graphene oxide (rGO) have been 
investigated as potentially hazardous materials when used in healthcare  because they 
could exert acute toxic effects on a wide range of living organisms including human 
cells, Gram-positive and Gram-negative bacteria, viruses, and plants, eukaryotic 
mammalian and in vivo animal models [4,5]. Current knowledge on their toxicological 
implications indicates the demand for further systematic investigations including a 
detailed basic physicochemical characterisation of the graphene-based materials 
exploited in each case. It has been demonstrated that graphene nanostructures cause 
harmful cellular effects when they enter the body, as they can pass through 
physiological barriers, encounter immune systems and trigger normal cellular 
responses and significantly enhance toxic potential in living systems [6]. Single and 
few-layered graphene having sharp edges may infiltrate cell membranes resulting in 
membrane damage and leakage of cytoplasmic substances. DNA damage, cell cycle 
arrest and oxidative stresses inside the cell are the main cytotoxicity responses to GO 
and rGO when they are exposed to different cell lines, which are likely due to the 
generation of reactive oxygen species, and deregulation of antioxidant genes [7]. The 
biocompatibility of graphene varies from their counterparts owing to their size, shape, 
lateral dimensions, high specific surface area and surface chemistry [8]. Most of the 
studies to date have focused mainly on the toxicity induced by pristine graphene and 
GO but the biocompatibility of rGO has not been fully understood. Recently, rGO has 
been evaluated for biological applications, for example, as drug delivery carriers, 
diagnostic sensors, biomarkers and antimicrobial agents [9]. However, it has been 
shown to cause several adverse effects in vitro including reactive oxygen species 
formation, cell apoptosis, inflammatory cytokine, loss of membrane integrity, 
membrane distress induced by direct contact with sharp edges of rGO, and 
inflammatory cell infiltration [10]. Recent studies also have shown that rGO is likely to 
be toxic and could integrate cell membranes and induce programmed cell death in a 
dose-dependent manner, particularly in concentrations higher than 50 µg/L [11-13]. In 
order to address these issues and to improve the bioavailability of rGO, it is essential 
to investigate its implications on the safety of living systems and develop a better 
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understanding of toxicological mechanisms, which would facilitate the existing 
methods for rGO preparation (with minimal toxicity for safer biomedical applications).  
 The current study is motivated by the requirements for a better understanding of the 
mechanisms and in vitro efficacy of graphene-induced degradation of cells. The in vitro 
toxicity of rGO against two lung cancer cells, A549 and SKMES-1, has been assessed 
and compared for the first time without premodification of rGO. We conducted the cell 
viability tests and measured the implications of early and late apoptosis and necrosis 
pathways to investigate the oxidative stress potential, and induction of apoptosis. We 
also showed the general trend between cell death rates and concentrations for cancer 
cells using a Gaussian process regression model. Our results demonstrated that a low 
concentration of rGO significantly produced late apoptosis and necrosis rather than 
early apoptotic events, though rGO was still able to disintegrate the cellular 
membranes in a dose dependent manner. Given the evolving field of graphene-based 
nanomedicine, our findings regarding the toxicity of graphene presented in this chapter 
using in vitro models would play a significant role in paving a new way to future 
biomedical applications of graphene. 
 
5.2 Materials and methods 
 
5.2.1 Synthesis and characterization 
 
The method of preparing exfoliated graphene oxide (GO) flakes is the same as 
described in the previous chapter (section 4.2.1) using the Modified Hummers method 
[14]. The resultant GO was dispersed in water under stirring to the concentration of 
0.25 mg mL−1. 75 mL GO (0.25 mg/mL) was mixed with 1.5 mL hydrazine (35 wt%) 
under magnetic stirring in a flask heated (in an oil bath) to 100 ºC. The resultant rGO 
powder was then washed with distilled water for further characterization. Transmission 
electron microscope (TEM), X-ray diffraction (XRD) analysis, Fourier-transform 
infrared (FTIR) spectra, Raman spectra and zeta potential measurements of rGO 
samples were carried out in the same manner as described in chapter 4 (section 
4.2.1). 
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5.2.2 Cell viability 
The methods used for the preparation of seed cultures, preparation of suspensions for 
seeding, techniques for cell viability and flow cytometry have been described in chapter 
4 (section 4.2.2). Cells were treated with or without 5, 50, 250, 500 and 1000 µg/ml of 
rGO for 24 h. 
5.2.3 Regression model 
 
The relationships between concentration of rGO and cell death rate were investigated 
to determine the most appropriate concentration levels for therapeutic purposes [15]. 
The details of this method were given in chapter 4 (section 4.2.3). 
 
5.3 Results and discussion 
 
As well-known, reduction of GO in an aqueous suspension results in agglomerated 
graphene nanosheets [16]. Similarly to that reported previously [17,18], as-prepared 
rGO nanosheets from the present work also exhibited typical wrinkled and scrolled 
structures (Figure 5.1 a, b). They consisted of a few-layers (typically 6–8 layers), and 
had an average thickness of 1.5 nm, as revealed by HRTEM (Figure 5.1b). XRD 
(Figure 5.2 A) further shows a diffraction peak at 26.40o (2θ) corresponding to the 
(002) lattice plane of rGO with interlayer spacing of 3.37 Å, indicating the formation of 
sp2 network of carbon [19]. As shown in Figure 5.2B, rGO exhibited a D band at 
1358 cm−1 and a G band at 1595 cm−1, showing a series of defects and the in-plane 
stretching motion of pairs of sp2 atoms, respectively [20]. FTIR peak at 3434 cm-1 was 
assigned to the O–H stretching vibration (Figure 5.2C). The weak peaks at 1622 cm-
1, 1399 cm-1, 1240 cm−1, and 1071 cm-1 arose from C=C stretching vibration, O–H 
deformation, C=O (epoxy) stretching vibration, and C=O (alkoxy) stretching, 
respectively, implying that the original functional groups were largely removed [21]. 
Zeta potential is a key parameter in the evaluation of stability of colloidal dispersions 
and prediction of the mobility/reaction of nanoparticles inside the cells [17]. 
Nanomaterials are generally considered to be fairly stable in a solution if the 
corresponding zeta potential is sufficiently high (more positive and negative than +30 
mV and −30 mV respectively) [22]. As depicted in Figure 5.2D, as-prepared rGO 
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nanosheets showed a maximal zeta potential of −49.2 mV at pH 12, which was resulted 
from the reduction of different functional groups existing on the surface of the original 
GO. 
 
Figure 5.1: (A)- TEM and (B) HRTEM images of as-prepared exfoliated rGO sheets. 
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Figure 5.2: (A)- XRD pattern, (B)- Raman spectrum, (C) FTIR spectrum, and (D) Zeta 
potential-pH curve of as-prepared rGO. 
 
As demonstrated in Fig. 3A, after 24-h exposure to rGO, the cell viability in the case of 
A549 cells decreased by virtue of increasing the concentration of rGO from 5 to 1000 
µg/ml. For example, the percentage of living cells was reduced to 70, 50 and 40% at 
concentrations 5, 50 and 250 µg/ml respectively, compared to the controls (0 µg/ml, 
~90%). However, in SKMES-1 cells, rGO-induced toxicity was reduced significantly at 
a concentration of 50 µg/ml or above. Cell viability was reduced to 70, 60, 42  and 42% 
at concentrations of 50, 250, 500 and 1000 µg/ml, respectively, compared to the 
controls (0 µg/ml, ~80%). Cells undergoing early apoptosis significantly increased 
when treated with 50 µg/ml in a dose dependent manner up to 500 µg/ml (both in A549 
and SKMES-1 cells) (Figure 5.3B). A dose-dependent increase in late apoptosis 
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(Figure 5.3C) and necrosis (Figure 5.3D) was also observed in both cell lines, where 
rGO demonstrated a greater toxic effect on A549 cells compared to SKMES-1 cells. 
 
Figure 5.3.  Bar graphs quantifying the percentage of dead, living, early-stage 
apoptotic, and late-stage apoptotic cells in response to different concentrations of 
reduced graphene oxide (rGO). Flow cytometry for A549 and SKMES-1 lung 
carcinoma cells stained with annexin V (apoptosis) and propidium iodide (PI; late 
apoptosis and necrosis) following 24 h of treatment with various concentrations of rGO  
(0–1000 µg/ml). (A) graphic representation of percentage of living cells (B) early 
apoptosis (C) necrosis, (D) late apoptosis (flow cytometry) in response to rGO. Data 
were represented as mean ± SD, n.s., *p<0.05 vs control (0 µg/ml). 
The resulting predictive distributions from the trained GP models for A549 and SKMES-
1 cells are shown in Figure 5.4. The models not only capture the measurement noises, 
but also indicate how much confidence may be derived from the predictions through 
the associated standard deviation. Interestingly, the model for A549 cells indicates that 
concentrations below 200 µg/ml are likely to be better than higher concentrations. In 
contrast, the model for SKMES-1 cells, concentrations between 600 and 800 are likely 
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to yield lower cell death. These predictions match with the experimental results 
presented in Figure 5.3. 
 
Figure 5.4. Gaussian process (GP) regression models for cell survival rates of A549 
(left) and SKMES-1 (right) cells interacted with various concentrations of reduced 
Graphene Oxide (rGO). The green solid lines show the mean GP prediction, while the 
light green areas around the mean show the uncertainty (one standard deviation) in 
prediction. The models are trained with the data indicated by the red crosses.  
Most interestingly, GP models can predict cell-specific toxicity levels of concentrations. 
As such, we may exploit this knowledge to run further experiments to find out optimal 
levels of concentrations. This approach is better known as Bayesian optimisation: a 
sequential design method that may locate near-optimal solutions with limited number 
of time consuming and computationally expensive experiments [23]. 
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Figure 5.5: Representative FACS images and analysis of one experiment. Data were presented as percentage of the cell population. Cell viability 
of A549 (upper panel) and SKMES-1 (lower panel) at selected concentrations. Experiments were performed and interpreted as follows: Annexin 
V-ve/PI-ve cells (lower left quadrant), AnnV+ve/PI-ve cells (lower right quadrant), AnnV+ve/PI+ve (upper right quadrant) and AnnV−ve/PI+ve (upper left 
quadrant) were considered as living, early apoptotic, late apoptotic, and necrotic cells respectively.
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Cell viability, early and late apoptosis and necrosis were also measured under similar 
conditions to those mentioned above. Early apoptosis is typically defined by an 
increase in phosphatidylserine (PS) expression on an intact cell membrane (detected 
by annexin V). In late apoptosis, however the membrane loses its integrity allowing PI 
into the cell and flags these cells as late apoptotic/necrotic. This study showed that 
rGO induced apoptosis and necrosis above the concentration of 5 µg/ml in A549 and 
above the concentration of 50 µg/ml in SKMES-1 cell lines (Figure 5.5). Even at lower 
concentrations, rGO was shown to significantly produce late apoptosis and necrosis, 
suggesting that rGO was able to disintegrate cellular membranes (PI staining) at lower 
concentrations. Interestingly, the effect was more pronounced in A549 cells compared 
to SKMES-1 cells upon exposure of rGO. Kumar et al [11] recently reported the high 
toxicity of rGO on A549 cancer cells arising from its reduced lateral size, and showed 
alteration of mitochondrial homeostasis upon rGO exposure. Hu et al. [10] found that 
rGO caused a dose-dependent decrease in A549 cell viability to 47% (20 mg/mL) and 
15% (85 mg/mL). Toxicity screening of engineered nanomaterials is always 
accomplished in concentration-dependent manner to develop safety profile and risk 
management strategies for their real-world applications. In the case of graphene, low 
concentrations are generally not toxic in mammalian cells but high concentrations play 
a role in plasma membrane internalization and induction of programmed cell death 
[24]. Liao et al. [25] reported toxicity of graphene sheets in dose-dependent manner 
which showed chronic hemolysis activity to suspended erythrocytes owing to its good 
electrostatic interactions with the erytrocyte membrane. Also high concentrations of 
graphene sheets (200 µg/ml) produced higher reactive oxygen species in human skin 
fibroblast cells than low concentrations (3.125 µg/ml) of graphene sheets due to their 
strong interaction and binding to the cell surface. Comparable results were reported in 
A549 cell line [10, 11] suggesting that higher concentrations of graphene sheets 
damage membrane integrity and block the localization of sheets with cell barriers and 
produce high yield of reactive oxygen species. rGO has pronounced effects on cellular 
viability, oxidative stress, and cell death compared to GO because of its sharp edges, 
functional groups, surface charge and nanosheets which facilitate its improved cellular 
uptake [26]. The combined effect of early and late apoptosis and necrosis events 
produced by rGO implies a threat to clinical utility of rGO. rGO induced toxicity 
potentially causes the poor delivery of essential nutrients to cancer cells by blocking 
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the immune tolerance of the host cells to recruit blood vessel factories for their survival. 
Oxidative stress is one of the key paradigms leading to graphene toxicology that 
reduces the viability of cells and also hinders the uptake of essential proteins and 
nutrients into cells [12, 27]. Production and abolition of reactive oxygen species are 
well-adjusted inside the cells, and altering the balance could induce lipid peroxidation, 
dysfunction of mitochondria, and apoptosis and necrosis [28]. The toxic transformation 
of graphene, irrespective of the specific structure/assembly of graphene used, relies 
on its bioaccumulation, the structural and chemical morphology of graphene as well as 
the generation of reactive oxygen species in both dark and photo toxicity environments 
[29]. The excessive reactive oxygen species generation may induce the mitochondrial 
membrane damage from lipid peroxidation, DNA damage and apoptosis (at low dose) 
[30]. The generation of reactive oxygen species to induce oxidative stresses is 
considered to be a leading cause of toxicity for graphene nanocomposites [28]. 
Furthermore, the rGO revealed necrosis was more profound and prevalent at high 
doses, which is likely due to gene deregulation and encoding, demolition phase of 
apoptosis process, whereas, apoptosis events induced by low dose of rGO might be 
triggered due to death-receptor medicated pathways and mitochondrial-driven intrinsic 
pathways [31]. Furthermore, based on the existing literature work and this chapter, it 
is revealed that cellular membrane distress, oxidative stresses and direct contact of 
the sharp edges with the cells are considered to be majorly responsible for the toxicity 
of rGO. Direct contact of sharp edges and lateral dimensions of rGO may induce 
genotoxic lesions and genomic instability through their interactions with the DNA 
sequence and structure in target cells [32]. In addition, the presence of impurities and 
toxic chemicals during the fabrication of graphene nanocomposites may have adverse 
effects on their bioavailability to living systems. Diversity in size, shape, surface 
chemistry, lateral dimensions and fabrication routes of rGO make it impossible to 
establish clearly the comparison of biological and toxicological impacts of rGO between 
different studies. As different preparation methods produce different quantities of 
functional groups and free radicals on the surface of rGO, this subsequently induces 
oxidative stresses. Therefore, terminology, nomenclature and preparation methods 
need to be reconciled and standardized to validate analytical methods for measuring 
toxicology impacts, bio distribution and physicochemical characteristics of rGO in living 
systems. With the rapid growth and expansion of the graphene market, it is necessary 
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to assess the risk management strategies related to the fabrication processes and 
clinical settings which can potentially minimise the environmental and clinical risks of 
graphene. Furthermore, an important benefit of graphene over other nano-assemblies 
is that its physiochemical properties such as hydrophobicity/hydrophilicity, surface 
charge, size, and surface area could be tuned by adjusting synthesis conditions. 
Moreover, a variety of post-preparation methods may be introduced to graphene 
sheets targeting the efficient reduction of graphene oxide. Surface functionalization, 
reduction strategies, doping, and introduction of biocompatible coatings are another 
promising and intriguing window of opportunity to improve the bioavailability of rGO to 
living systems. This is of a particular importance in relation to bio-persistence and long-
term toxicity of this material, since there is a lack of long term in vivo monitoring in this 
area. 
 
 The results from this study confirmed that rGO poses higher biological risks than 
GO and other derivatives of graphene. In order to improve the bioavailability of rGO, 
several significant challenges remain to be addressed such as translating its 
toxicological mechanisms and preparation of safer and modified rGO sheets. Further 
toxicological studies should take into consideration the facile preparation of the sample 
such as the intermixing of debris from sample impurities, residues of strong acids and 
reducing agents, which may profoundly revise and improve the surface features of 
rGO. Further in vivo investigations are also required to trace the bioavailability of rGO 
and to clarify the clinical effects of this ‘miracle material’. 
 
5.4 Conclusions 
 
This chapter describes the in vitro toxic effects of rGO on lung cancer cells (A549 and 
SKMES-1) as a function of its concentration. The results indicated that rGO caused 
significant late apoptosis and necrosis rather than early apoptotic event at lower 
concentrations, suggesting that rGO was able to disintegrate the cellular membranes 
in a dose dependent toxicity manner. For the toxicity exposures undertaken, late 
apoptosis and necrosis occurred, which was likely resultant from the limited 
bioavailability of unmodified rGO in lung cancer cells.  
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Chapter 6 
Investigation into the Toxic Effects of Graphene 
Nanopores on Lung Cancer Cells and Biological 
Tissues 
 
As an inexpensive monolayer archetypal member of carbon family, graphene has 
triggered a new ‘gold rush’ in nanotechnology for achieving unique properties that were 
not available in many traditional materials. Owing to these unique features, graphene-
related materials are finding new uses in nanomedicine and synthetic biology in 
addition to their diverse applications in electronics, optoelectronics, photonics and 
environmental clean-up. The increased production of graphene nanostructures and 
increased likelihood of exposures to these substances in environmental and 
occupational settings has raised concerns about adverse health outcomes. In 
particular, the biological effects of these materials needs to be assessed to ensure risk 
free, sustainable development of graphene for widespread applications. In this chapter, 
for the first time, we study the in vitro and in vivo interactions of a relatively new 
derivative of graphene, graphene nanopores (GNPs) in mammalian systems, to 
systematically elucidate the possible mechanism of their toxicity over time. This study 
shows that GNPs induce early apoptosis in both SKMES-1 and A549 lung cancer cells, 
however, late apoptosis is only induced at concentrations higher than 250 µg/ml, 
suggesting that, although GNPs at lower concentrations induces upregulation of 
phosphatidylserine on cell surface membrane (i.e. early apoptotic event), it does not 
significantly disintegrate the cell membrane. In this chapter, we also show that rats 
intraperitoneally injected with GNPs suffer sub-chronic toxicity in a period of 27 days 
when tested at single and multiple doses of GNPs (5 and 15 mg/kg) as evidenced by 
blood biochemistry, organo-somatic index, liver and kidney enzymes functions 
analysis, oxidative stress biomarkers and histological examinations. In vivo toxicity 
results reveal that GPNs mainly accumulate in the liver and lungs after intravenous 
administration and can be gradually cleared through kidney. In sum, our results show 
that GNPs are likely to have a low bioavailability in SKMES-1 and A549 lung cancer 
cells in rats. Nevertheless, this must be considered against the context of a wider lack 
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of knowledge regarding the bioavailability, fate and behaviour of this type of new 
porous frameworks of graphene in natural systems. Therefore, a more long-term GNPs 
exposure regime more realistic to real-life environmental consequences is needed to 
fully determine the transport capacities of GNPS in living systems. 
 
6.1 Introduction 
 
Graphene has become a ‘superstar’ in nanomedicine with applications to help improve 
diagnostics, therapeutics, and genetic risk factors, owing to their multifaceted 
properties such as small size, large surface area-to-volume ratio, quantum size effects, 
and unique physicochemical properties [1-3]. One important advantage of graphene-
based materials is their ability to effectively cross biological barriers such as the blood 
brain barrier highlighting their potential as a drug delivery vehicle for anticancer 
therapeutic agents. In particular, the combined enhanced permeability and retention 
effect would facilitate their accumulation in tumors, releasing the therapeutic levels of 
drugs into the target cells with the reduced side effects [4]. Typically, graphene 
quantum dots have many properties far superior to conventional quantum dots such 
as photoluminescence, low toxicity and interplay between size and optical features 
which have been utilised as diagnostic imagining tools as well as 
photodynamic/photothermal therapy [5]. Similar use of three-dimensional graphene 
foam for stem cell therapy of stroke and its bioconjugates in regenerative medicine has 
been described in recent literature [6]. Recently, graphene nanopores (GNPs) have 
also been used for DNA sequencing [7-9] and water treatment [10,11] and GNPs have 
provided unique porous frameworks [12]. One drawback of the use of GNPs is that 
very few synthesis techniques are available. However, techniques such as electron 
beam irradiation, ion bombardment, doping, templating, chemical etching, chemical 
vapour deposition and other chemical methods have been utilised for their preparation 
[9, 13-16]. The drawbacks of these methods are the low production yield and the 
problems associated with their separation/purification. To address this omission, we 
have demonstrated a novel and facile approach to GNPs synthesis via thermal 
treatment of reduced graphene oxide without using any catalyst and template-based 
approach [17].  
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GNP, a thin, flexible material with excellent electrical addressability and robust 
mechanical properties is promising for label-free protein detection, DNA sequencing 
and high throughput wastewater based-micropollutant decontamination [7-11]. The 
high specific surface area and nanoporous framework allows direct sensing and 
sequencing of atomic-scale biomolecules. In recent years, cellular internalization and 
trans-barrier transport of micro/mesoporous graphene nanosheets have been the 
subject of major development in nanobiotechnology. It is evident that nanoscale 
materials with diameter less than 100 nm can enter cells, while nanoparticles smaller 
than 40 nm in diameter can reach the cellular nuclei. Particles with diameters below 
35 nm are able to reach the brain by passing through the blood–brain barrier [18], while 
larger nanoparticles are excluded which in turn reduces the delivery of theranostic 
nanoparticles [19]. A better understanding of the physiochemical properties of 
graphene, the interaction between graphene and cells, and possible toxicity 
mechanism is of critical importance to outline potential biomedical applications of these 
materials. The proposed mechanism of GNPs toxicity is depicted in Figure 1. The 
widespread use of graphene- based materials and their potential toxic effects are likely 
to exacerbate several health concerns [20, 21]. Most laboratory experiments 
investigating the potential applications of GNPs in life sciences have not considered 
the toxicity associated with GNPs in their testing regimes. Recently, however, a few 
studies have examined the in vitro and in vivo toxic implications of three dimensional 
graphene foam to investigate the bioavailability and subsequent toxicity potential [22, 
23]. The pre-clinical risks, and adverse effects of GNPs exposure and approaches to 
minimize their health hazards still remains undefined. However, inhalation of graphene 
structures is believed to be a risk for cardiorespiratory disease. For example, graphene 
nanoplatelets can be transported deep within the distal regions of lungs and trigger a 
chronic inflammation in the respiratory tract [24]. It is generally thought that the 
placenta, lung, gastrointestinal tract and skin act as major barriers for many 
nanostructures entry into living organisms [25]. Indeed, a recent study on mice 
demonstrated that intratracheally delivered few-layered graphene was mainly retained 
in the lung with 47 % remaining after 4 weeks, resulting in dose-dependent acute lung 
injury and pulmonary edema [26]. An in vitro study of the effects of graphene and 
graphene oxide on human skin HaCaT keratinocytes demonstrated that oxidized 
graphene was the most cytotoxic, inducing mitochondrial and plasma-membrane 
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damages, suggesting low cytotoxic effects at the skin level [27]. Reduced graphene 
oxide is more toxic than graphene oxide as evident by many studies reported recently 
which is primarily due to its sharp edges and structural morphology [28, 29]. In contrast 
to the typically soluble nanoparticles examined in conventional toxicology 
investigations, graphene nanostructures have different shapes and surface areas, and 
which in turn can significantly influence their diffusion, dispersion, aggregation and 
agglomeration in plasma. Importantly, these “tunable” characteristics of graphene 
account for the varying toxic outcomes on the tissues. In vivo toxicity testing of 
graphene, at post-mortem histological examinations of liver alterations have revealed 
hypertrophy of hepatocytes, necrosis and inflammatory cell infiltration in liver and 
kidney tissues [30]. The level of organ functions and oxidative stress have been 
reported to affect the fate, transport and toxicity of graphene in organs but there is 
currently a lack of consistency in this regard [30]. Liver enzyme functions can be used 
to reveal the biodistribution, metabolism, and excretion patterns of graphene. Similarly, 
investigation of oxidative stress indicators, is a commonly acknowledged mechanism 
adopted to investigate cellular injuries in mammals. Antioxidants act as a defence 
system to reinstate the cellular redox balance, when oxidative stress are generated as 
a result of excess production of reactive oxygen species. Disruption of this critical 
balance in the presence of excessive reactive oxygen species triggers the activation 
and promotion of pro-inflammatory cascade, cytokine and chemokine which in turn 
causes mitochondrial release of proapoptotic factors potentially leading to cell death. 
Since hepatocytes are key targets for reactive oxygen species damage and therefore 
liver function and biomarkers of oxidative stresses should be investigated with great 
care. Clearly, in vitro and in vivo investigations into the toxicity of graphene 
nanostructures is becoming increasingly important. In response to this, the present 
study investigates the toxic effects of GNPs on lung cancer cells (SKMES-1 and A549) 
in vitro and rat in vivo, specifically, biochemical, serum enzyme analyses, complete 
blood count as well as histological analysis have been used in this chapter. 
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Scheme 6.1: Scheme of the potential mechanisms of action of graphene nanopores 
(GNPs). When graphene reach the exterior membrane of a cell, they interact with the 
plasma membrane or extra- cellular matrix and enter the cell, mainly through diffusion, 
endocytosis and/or binding to receptors. The potential toxic effects of graphene mainly 
depends on its physicochemical characteristics, nature of its interaction with cell and 
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its accumulation in specific organs. Upon interaction with light, graphene can generate 
reactive oxygen species, which in turn can cause oxidative stress, loss in cell 
functionality, proinflammatory response and mitochondrial damage. Uptake of 
graphene into the nucleus may cause DNA-strand breaks and induction of gene 
expression via the activation of transcription factors, cell death and genotoxicity. 
 
6.2 Materials and methods 
 
6.2.1 Synthesis of graphene nanopores 
 
The method of preparing exfoliated graphene oxide (GO) flakes and reduced GO is 
the same as described in chapters 4 and 5 (sections 4.2.1 and 5.2.1) using the 
Modified Hummers method. The resultant rGO was allowed to settle, washed with 
distilled water and filtered until the supernatant became clear. To obtain porous 
nanosheets, the filtered product was oven-dried in vacuum overnight and then 
thermally treated at 200 ºC in Ar for 12 h under a slow ramp rate of 3 ºC min-1. 
Transmission electron microscope (TEM), X-ray diffraction (XRD) analysis, UV–Vis 
absorbance, Fourier-transform infrared (FTIR) spectra, Raman spectra and zeta 
potential measurements of GNP samples were carried out in the same manner as 
described in chapter 4 (section 4.2.1). Microstructures of GNPs, graphite flakes and 
GO samples were taken on a Philips XL-30 scanning electronic microscope (SEM) 
under high vacuum conditions with accelerating voltage 20 kV and the samples were 
mounted onto carbon sticky tape. Nitrogen gas sorption analysis was conducted using 
a Quantachrome Autosorb-iQ gas sorptometer. Prior to the sorption measurements, 
sample was heated at 200 °C under vacuum conditions for 3 h. Surface area was 
calculated by using Brunauer–Emmett–Teller (BET) theory method. The total pore 
volume (Vt) was measured from the amount of adsorbed nitrogen (at P/Po = ca. 0.99).  
 
6.2.2 Cell viability 
The methods used for the preparation of seed cultures and preparation of suspensions 
for seeding have been described in chapter 4 (section 4.2.2). Cells were treated for 
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24 h with and without various concentrations of GNPs (5, 50, 250, 500 and 1000 µg/ml) 
in culture medium and cells cultured without GNPs were taken as control. 
6.2.3 Regression model analysis 
 
The relationships between concentration of rGO and cell death rate were investigated 
to determine the most appropriate concentration levels for therapeutic purposes [31]. 
The details of this method were given in chapter 4 (section 4.2.3). 
 
6.2.4 Cell apoptosis and necrosis 
 
Cell apoptosis and necrosis were examined using flow cytometery as previously 
described in chapter 4 (section 4.2.2). Data were expressed as % cell count ± SD and 
analysed by Mann Whitney. P < 0.05 was considered statistically significant. 
 
6.2.5 Animals 
 
All animal experiments were performed in compliance with the institutional ethics 
committee regulations and guidelines on animal welfare (Animal Care and Use 
Program Guidelines of Government College University), and approved by Government 
College University, Faisalabad, Pakistan. Sprague-Dawley adult male rats (average 
age of 6-7 weeks, 230-250 g weight) were obtained from the animal house of 
Government College University, Faisalabad, housed in groups in ventilated cages 
under standard lighting conditions and natural day/night cycle after approval from the 
ethical committee of the institution. They were given free access to water and food and 
the surrounding humidity and temperature (25 °C ± 2 °C) was controlled. After a period 
of acclimatization for 7 days, the animals of similar mean initial body weights were 
randomly divided into five groups, n=8 per group. The body weights of the control group 
and all the experimental groups were observed and recorded weekly to note weekly 
changes in body weights. The body weight and behaviour were recorded every day 
after the first exposure. Organo-somatic index was calculated by the following formula: 
(Weight of the organ (g)/Total body weight (g)) X100. A control group was fed by usual 
water and food, while the other group was treated with various doses of GNPs (5 
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mg/kg, 15 mg/kg single and multiple doses) intraperitoneal injections for 27 days. The 
treatment continued on alternate days for a period of 27 days. Animal exposure 
schedule was also schematically represented in Supplementary information Figure 
6.1. At the end of the experimental period, animals were fastened overnight, 
anaesthetized the next day, by administering ketamine hydrochloride (30 mg/kg body 
weight) and sacrificed. Blood samples were collected at the start of the experiment and 
after 27 days of the treatment, from the marginal ear vein, and used for the analysis of 
complete blood count (CBC), selected serum biochemical parameters, haematology, 
liver function tests and oxidative stress enzymes. 
 
6.2.6 Complete blood count (CBC) and clinical biochemistry panel analysis 
 
Hematological parameters: Red blood cell count (RBC); Lymphocytosis (LYM); 
Lymphocytosis (LYM %); mid-range absolute count (MID); total % of granulocytes 
GRA; Hemoglobin (HBGL); mean corpuscular haemoglobin (MCH); Mean corpuscular 
hemoglobin concentration (MCHC); Mean corpuscular volume (MCV); hematocrit 
(HCT); Red cell distribution width (RDW); Platelet count (PLT); mean platelet 
component (MPC); large platelet concentration ration (LPCR); and White blood cell 
count (WBC), were analysed in blood samples by using Hitachi 902 automatic analyser 
(Japan) using a haematology autoanalyser. Blood samples (of approximately 7 ml) 
were collected into heparinised tubes and centrifuged at low speed of 2000×g for 5-
10 min to separate plasama. The vital organs were collected, weighed immersed in 
fixative sera for further process of histology and for evaluation of enzyme activities, 
antioxidants and biomarkers. 
 
6.2.7 Liver and kidney function analysis 
 
To evaluate the liver function, the activities of alanine aminotransaminase (ALT), 
aspartate aminotransferase (AST) and alkaline phosphatase (ALP) and to assess the 
activities of kidney function, the activities of creatinine was measured. Concentration 
of these enzymes were determined using marketed reagent kits (CHEMELEX, S.A Pol. 
Ind, Barcelona, Spain) and autoanalyser system (Hitachi Ltd., Tokyo, Japan) following 
the IFCC method [32]. 
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6.2.8 Histological analysis 
 
The harvested heart, liver, kidney, brain, small intestine and testis were fixed with 4% 
paraformaldehyde for 5 h and then dehydrated and processed for histology. 6 µm 
sections were cut from paraffin blocks using a Reichert microtome and stained with 
eosin (cytoplasm staining). The stained slides were examined by light microscopy 
through a 20X and 40X objective lens. A histological analysis of vital organs was 
performed to determine the toxic effects and the degradation of GNPs to inducing 
tissue damage or any histopathologic changes. 
 
6.2.9 Oxidative stress biomarkers 
 
The activities of biomarkers of oxidative stress, i.e. catalase activity, superoxide 
dismutase activity, glutathione-S-transferase activity and lipid peroxidation, were 
measured. To determine these parameters in the liver, the liver was separated and 
washed in standard ice-cold isotonic saline solution. Then, the tissues were 
homogenized in 0.1 M Tris-HCl buffer solution at 4 °C following by the centrifugation 
(10,000 rpm for 15 min at 4 °C) and the supernatant was stored at −20 °C for the 
evaluations of enzyme activities. This procedure was followed by previously reported 
method [33]. The activity of lipid peroxidation was evaluated by quantifying the 
malondialdehyde (MDA), following by the thiobarbituric acid reactive substance 
(TBARS) method. This procedure was followed by previously reported method [34]. 
The concentration of MDA TBA compound was evaluated by using a 
spectrophotometer at 532 nm using blank as control. The reduced glutathione (GSH) 
was estimated according to the method described in ref [35]; catalase [36]; and 
hydroperoxide [37]. 
 
6.2.10 Statistical analysis 
 
The results was statistically analysed in GraphPad Prism 5.04 to investigate the 
impacts of GNPs injected groups for complete blood count parameters, body weight, 
liver and kidney function tests, and oxidative stress biomarkers, as compared to 
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control. P < 0.05 was considered as statistically significant. Data were presented as 
the mean ± standard deviation (SD). 
 
6.3 Results 
 
6.3.1 Basic characterization 
 
Figure 1 shows basic characterization of as-prepared GNPs. Scanning electron 
micrographs enable the visualization of wrinkles and corrugations in the graphene 
sheets, and induce the formation of nano-sized channels or pores on the surface 
(Figure 6.1a). As seen in Figure 6.1a, the GNPS had an irregular, folded structure 
with sheets entangled with each other. This is further seen in the high-resolution 
transmission electron micrographs shown in Figure 6.1(b). To further clarify the growth 
process of the GNPs structure, the raw material and intermediate product were 
investigated by XRD, FTIR and Raman spectroscopy. A comparison of the XRD 
patterns of graphite flakes, GO and GNPs reveals that the (002) peak of GNPs was 
broadened and had a markedly reduced intensity, indicating that they were composed 
of single-layer graphene sheets (Figure 6.1 c). The introduction of pores on graphene 
sheets resulted in a change of the D/G Raman peak intensity ratio (Figure 6.1 d) [38, 
39]. For graphene-based materials, the Raman G-peak (ca. 1590 cm-1) corresponded 
to the sp2-hybridized hexagonal lattice of carbon atoms, and the D-peak (ca. 1350 cm-
1) was indicative of sp3-hybridized carbon atoms in the lattice structure, which was 
categorised as defects on the edges of the graphene. In addition, the coexistence of 
D-peak revealed the sp2 hybridized carbon atoms which were slightly reduced as a 
result of oxidation. However, as indicated in Figure 6.1d, as-prepared GNPs had a 
higher D/G intensity ratio than graphite and GO, correlating to the reduction in the 
average size of the sp2 domains after the reduction of exfoliated GO. The increased 
amount of sp3-hybrdized carbon atoms indicated the activation of nanosheets for the 
formation of pores and edges in the nanosheets [40, 41]. The FTIR peak of GO was 
centred at about 1615 cm–1, which was shifted to the absorption peak of a carbonyl 
group at about 1730 cm–1 for PG, indicating that the thermal treatment of rGO left more 
edged carbon atoms in the form of oxygen containing groups (Figure 6.1 e). To further 
analyse and quantify the pore structure, nitrogen adsorption–desorption isotherms for 
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the GNPs sample were determined. Figure 6.1f shows the isotherms and Barrett–
Joyner–Halenda pore size distributions of PG. According to the IUPAC classification, 
the nitrogen adsorption–desorption isotherm curves of these samples exhibited a type 
IV with a H3 hysteresis loop, which is a characteristic feature of mesopores [42]. 
Furthermore, the adsorption segment of the nitrogen isotherms at P/P0 displayed a 
steady increase, suggesting the formation of large mesopores and small macropores 
with the average pore size in the GNPS calculated as 3–5 nm.  
133 
 
 
Figure 6.1: Basic characterization of as-prepared GNPs. (a) Low-magnification 
SEM images of as-prepared GNPs. (b) TEM images of a representative GNPS 
showing holes in the nanosheet. (c) X-ray diffraction, (d) Raman spectroscopy, and (e) 
Fourier transform Infrared spectroscopy of graphite flakes (black), GO (red) and GNPS 
(blue). (f) Measurement of specific surface area. The pore size distribution of GNPS 
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was calculated using Barrett–Joyner–Halenda method presented in Figure f as an inset 
at 77 K, pore size 1-4 nm. 
 
6.3.2 In Vitro toxic effects of GNPs on lung cancer cells 
 
Figure 2A demonstrates that after 24-h exposure to GNPs, the cell viability of A549 
cells exhibited a significant dose-dependent reduction from 50 to 500 µg/ml. For 
example, reduction in the percentage living cell were 52.8%, 42.5% and 33.2% at 
concentrations 50, 250 and 500 µg/ml respectively, compared to control (0 µg/ml, 
~80%). A similar observation was made in SKMES-1 cells where GNPs concentrations 
50 and above induced significant reduction of living cells. However, the reduction was 
not dose dependent (Figure 2A). For example, at 50, 250 and 500 µg/ml of GNPs, 
percentage count for living cells were 50.8%, 46.5% and 47.4% respectively, 
compared to control (0 µg/ml, 70%). Early apoptosis showed a significant increase in 
signals from 5 µg/ml in a dose dependent manner up to 500 µg/ml both in A549 and 
SKMES-1 cells (Figure 6.2B). A dose-dependent increase in late apoptotic (Figure 
6.2C) and necrotic cells (Figure 6.2D) was also observed in A549 cell line, although 
no significant increase in necrosis was observed in the SKMES-1 cell line. The 
resulting predictive distributions from the GP models for A549 and SKMES-1 cells are 
shown in Figure 6.2 (E & F). The models not only capture the measurement noises, 
but also indicate how much confidence may be derived from the predictions through 
the associated standard deviation. Interestingly, the model for both cells indicate that 
concentrations above 50 μg/ml are likely to be toxic than lower concentration, which 
yields lower cell death. These predictions match with the experimental results 
presented in figure 6.2 (A-D). 
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Figure 6.2.  Bar graph quantifying the percentage of dead, living, early-stage apoptotic, 
and late-stage apoptotic cells in response to different concentrations of graphene 
nanopores (GNPS). Flow cytometry analysis of A549 and SKMES-1 lung carcinoma 
cells stained with annexin V (apoptosis) and propidium iodide (PI; late apoptosis and 
necrosis) following 24 h of treatment with varying concentrations of GNPs  (0–500 
µg/ml). (A) graphic representation of percentage of living cells (B) early apoptosis (C) 
late apoptosis, (D) necrosis (flow cytometry) in response to GNPS. Data are 
represented as mean ± SD, n.s., *p<0.05 vs control (0 µg/ml). n.s. denotes not 
significant. (E-F) Gaussian process (GP) regression models for cell survival rates of 
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A549 (E) and SKMES-1 (F) cells interacted with various concentrations of GNPs. The 
green solid lines show the mean GP prediction, while the light green areas around the 
mean show the uncertainty (one standard deviation) in prediction. The models are 
trained with the data indicated by the red crosses. 
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Figure 6.3: Representation of FACS images and analysis of one experiment. Data are presented as percentage of the cell population. 
Cell viability of A549 (upper panel) and SKMES-1 (lower panel) at selected concentrations. Experiments were performed and 
interpreted as follows: Annexin V-ve/PI-ve cells (lower left quadrant), AnnV+ve/PI-ve cells (lower right quadrant), AnnV+ve/PI+ve (upper 
right quadrant) and AnnV−ve/PI+ve (upper left quadrant) were considered as living, early apoptotic, late apoptotic, and necrotic cells. 
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6.3.3 Effects of GNPs on body and relative organ weights 
 
In vivo toxicity of GNPs was assessed in rats following 27-day repeated dose 
intraperitoneal injections. GNPs treatment did not affect the body weight of the treated 
rats during the 27-days exposure period for treatment with 5 mg/kg body weight either 
once or multiple doses (Figure 6.4). No significant decrease in body weight was 
observed in rats administered GNPs up to 5 mg/kg. Rats in the high repeated dose 
group (15 mg/kg body weight) showed lower body weights after 27 days (Figure 6.4) 
compared to the control group. The analysis showed that rats did not differ statistically 
significantly in the dose–response for body weight (apart from high repeated dose). 
Organo-somatic indices demonstrated that organ weight did not change by the 
treatment of GNPs, compared to the control, supporting its low toxicity 
(Supplementary information Figure 6.2).  
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Figure 6.4: Daily body weight (g) of control groups and treated groups exposed to 
GNPs along with intraperitoneal injection of rats for 27 days. 
 
6.3.4 Effects of GNPs on complete blood count in the rat 
 
To examine the in vivo cytotoxicity of GNPs, we performed a complete blood count 
(CBC), liver and kidney function enzymes, biomarkers of oxidative stress and 
histological study of vital organs of control and treated rats in a dose-dependent 
manner (14 doses spread over a 27 day period of either 5 or 15 mg/kg body weight). 
Toxic effect of GNPs on CBC was observed (Figure 6.5 a-o) although there was a 
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slight (6%) reduction in platelet numbers in the 15 mg/kg group (Figure 6.5 K), 
although the proportion of lymphocytes remained stable (Figure 6.5 B) and total white 
cell count was unaffected (Figure 6.5 N). 
 
 
Figure 6.5: (A-N) Complete blood count in rats after 27 days of GNPs administration. 
Rats (n=8 per group) were intraperitoneally injected with single doses of 5 mg/kg body 
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weight (group 1), 15 mg/kg body weight (group 2) and multiple doses of 5 mg/kg body 
weight (group 3) and 15 mg/kg body weight (group 4). Results are presented as mean 
± standard deviation (SD), for: A) Red blood cell count (RBC); B) Lymphocytosis (LYM 
%); C) mid-range absolute count (MID); D) total % of granulocytes GRA; E) 
Hemoglobin (HBGL); F) mean corpuscular haemoglobin (MCH); G) Mean corpuscular 
hemoglobin concentration (MCHC); H) Mean corpuscular volume (MCV); I) hematocrit 
(HCT); J) Red cell distribution width (RDW); K) Platelet count (PLT); L) mean platelet 
component (MPC); M) large platelet concentration ratio (LPCR); and N) White blood 
cell count (WBC). Data are represented as mean ± SD., *p<0.05, **p<0.01, ***p<0.001 
vs control. n.s. denotes not significant. 
 
 
6.3.5 Liver and kidney function analysis 
 
In general minor alterations were observed in liver and kidney functions (Figure 6.6) 
i,e, the results showed that activities of ALT, AST, ALP and creatinine enzymes 
increased in all groups. This increase in comparison to the control group in the second, 
third and fourth groups, is significant from the statistical point (p˂0/05). The increased 
ALP, ALT and AST are indicative for liver damage. Liver function tests such as ALT, 
AST and ALP were carried out to study liver damage of GNPs treated groups as 
compared to control. After 27 days of exposure, the activities of ALT, AST and ALP 
were increased significantly in 15 mg/kg of GNPs repeated doses, while at the highest 
dose (15 mg/kg) of GNPs, the activity of kidney enzyme creatinine gradually 
decreased. The single low and high doses (5 and 15 mg/kg body weight of rats) were 
least effective in ameliorating the alterations in the concentrations of the creatinine 
induced, while the repeated dose (5 and 15 mg/kg body weight of rats) showed 
significant ameliorative effects on the blood levels of creatinine. 
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Figure 6.6: Liver and kidney enzyme functions results in rats after 27 day post GNPs 
administration. Rats (n=8 per group) were intraperitoneally injected with single doses 
of 5 mg/kg body weight (group 1), 15 mg/kg body weight (group 2) and multiple doses 
of 5 mg/kg body weight (group 3) and 15 mg/kg body weight (group 4). Values are 
expressed as mean ± standard deviation, for: A) Alanine transaminase (ALT), B) 
Aspartate transaminase (AST), C) alkaline phosphatase (ALP) and D) Creatinine. Data 
are represented as mean ± SD., *p<0.05, **p<0.01, ***p<0.001 vs control. n.s. denotes 
not significant. 
 
6.3.6 Histopathological changes 
 
A comprehensive post mortem histological study was then performed to assess any 
tissue interactions with GNPs. Sections of heart, kidney, liver, small intestine, brain 
and testis were examined for histopathological changes 27 days after GNPs 
administration (at single and multiple doses of 5 and 15 mg/kg of body weight of rats). 
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The histology photographs of the liver, kidney, heart and small intestine tissues were 
shown in Figure 6.7 and 6.8. GNPs for 27 days showed significant pathological 
changes, vacuolation, dilation of central vein and haemorrhage, vacuolation and 
dilation of central vein, damage of vacuolation, haemorrhage and degeneration of 
central vein, dilation of epithelial lining and hydropic degeneration edema in liver 
tissues. Kidney tissues of treated group showed acute vacuolization, dilation of epithial 
lining, vacuolation and nucleus degeneration, nucleus damage, necrosis and epithelial 
degeneration. Heart showed the chemodectoma, toxic myocarditis, reddish brown 
atrophy; yellowish brown pigments lipofuscin, the lipofuscin granules as remnants of 
cell organelles and cytoplasmic material. Brain showed effects of carcinoma, 
oligodendrocytoma small thin walled blood vessel and cryptococcosis. Testicular 
tissue of treated groups showed spermatogenesis and vacuolation, dilation of germinal 
layer, degeneration of secondary spermatocytes, damage in germinal layer, 
vacuolation and low process of spermatogenesis. The lung showed damage of 
vacuolation, degeneration of central vein, inflammation, hemorrhage, d-shaped cells 
structure, hemosidophroages and lesion. The multiple-dose of GNPs exposed to rats 
induced histopathological changes that indicates the accumulation of GNPs in the liver. 
The histopathological alterations of these organs at 14 days in the rats were shown in 
Supplementary information Figures 6.3 and 6.4. All the rats were in normal 
condiation at end of experiment. No clinical abnormality or death was observed in the 
treated rats. 
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Figure 6.7: Representative histopathological changes of the liver, kidney, heart and 
small intestine of the GNPs-exposed and control rats in the haemotoxyline-eosin (H&E) 
stained sections. The doses of GNPs were 5 and 15 mg/kg for the single-dose 
exposure and 5 and 15 mg/kg (every other day, in total fourteen injections) for the 
multiple-dose exposure. Control group liver showed normal histology while single low 
dose group (5 mg/kg) showed vacuolation (circle), dilation of central vein (DCV 
indicated by arrow) and haemorrhage (H indicated by arrow). Single high dose group 
(15 mg/kg) showed haemorrhage (H), vacuolation (V) and dilation of central vein (DCV) 
and Karyolysis (K). Multiple low dose group (5 mg/kg) showed the high frequency of 
vacuolation (circle), haemorrhage (H) and degeneration of central vein (DCV), Nuclear 
damage (N), Karyolysis (K) and epithelial damage (ED). Multiple high dose group (15 
mg/kg) in rats caused destructive effects on liver haemorrhage (H), massive 
vacuolation (circle), complete dilation of epithelial lining  (ED), dilation of central vein 
(DCV indicated by arrow) and hydropic degenerative edema (HDE). Kidney tissues of 
control group showed normal histology, single low dose group showed acute 
vacuolization (arrow) and single high dose group caused dilation of epitheliail lining 
(DEL), vacuolation (circle) and nuclear damage (ND). Kidney tissues of group treated 
with multiple low dose group showed nucleus degeneration (ND), vacuolation (circle), 
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while high dose group showed acute necrosis (N), epithelial degeneration (E) and 
vacuolization (V). Control group heart showed normal histology of heart muscle tissues 
and single low dose treated group showed the chemodectoma, an ovoid mass, the 
tumors were enclosed in a fibrous capsule. Single high dose group indicated toxic 
myocarditis, in this heart muscle fibers showed varying degree of damage, ranging 
from loss of striation to complete necrosis and fragmentation, whereas multiple low 
dose group caused acute rheumatism heart, which is the collection of pleomorphic 
histocytes with large basophilic nuclei which having prominent nucleolus that give the 
cell an ‘owl-eye’ appearance. While rats treated with multiple high dose group showed 
reddish brown atrophy; yellowish brown pigments lipofuscin tends to accumulate in 
many tissues, the lipofuscin granules are remnants of cell organelles and cytoplasmic 
material. When the parenchymal cells of an organ have atrophied because of increase 
age or presence of wasting diseases it causes the condition of brown atrophy. 
Histology of control group small intestine showed the normal cell of serosa (s), 
muscular layer (M), sub mucosa (‘S), intestinal glands (I.G) and villus (V) and single 
low dose treated group showed the damage of submucosa and muscular layer (arrow) 
and enlargement of lacteal (circle). Single high dose treated group showed reduction 
in villi length (thin arrow), distortion of lamina propria (thick arrow), and intestinal crypts 
destruction (circle). Multiple low dose treated group indicated moderate villus atrophy 
(big arrows) and crypt hyperplasia (small arrow) and multiple high dose group showed 
total distortion of villi and villus atrophy flat mucosa and no visible microvilli (arrows). 
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Figure 6. 8: Representative histopathological changes of the brain, testis and lung of 
the GNPs-exposed and control rats in haemotoxylin-eosin (H&E) stained sections after 
27 days. The doses of GNPs were 5 and 15 mg/kg for the single-dose treatment and 
5 and 15 mg/kg (every other day, in total fourteen injections) for the multiple-dose 
treatments. Control group brain showed normal cells, while rat treated with a single 
dose (5 mg/kg body weight) exhibited reduced motor neurons and the degenerated 
sparse neurons (thin arrows). The single high dose treated group exhibited tumors 
(arrow) and cords of tumor. Rat treated with multiple dose (5 mg/kg body weight) 
suffered oligodendrocytoma with numerous small thin walled blood vessels (arrow). 
Rats treated with the multiple high dose group exhibited crytococcosis and a flask 
shaped depression (arrow). Testicular tissue of the control group of rats exhibited 
normal histology. Rats treated with a single dose (5 mg/kg body weight) showed 
spermatogenesis (thin arrow), vacuolation (circle) and primary spermatids (thick 
arrow).The single high dose treated group showed  the dilation of germinal layer 
(circle), degeneration of secondary spermatocytes (thick large arrow), production of 
primary spermatids (small arrow), and  vacuolation (circle)  Rats treated with the 
multiple low dose group showed dilation of the germinal layer (circle), the degeneration 
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of secondary spermatocytes (thick large arrow), the production of primary spermatids 
(small arrow), and the vacuolation (circle). The multiple high dose treated group 
showed vacuolation (circle), damaged basement membrane (B), damaged primary 
spermatocytes (DS shown by large arrow) and damaged sertoli (st). Control group lung 
showed normal cells, while rat treated with a single dose (5 mg/kg body weight) 
exhibited damages of vacuolation, degeneration of central vein and acute 
inflammation. The single high dose treated group showed damage of vacuolation, 
hemorrhage and hemosidophroages.    Rat treated with multiple dose (5 mg/kg body 
weight) showed damage of vacuolation, vein and artery damages, disruption, 
hemorrhage and d-shaped cells structure and hemosidophroages. Rats treated with 
the multiple high dose group showed damage of vacuolation, vein and artery damage, 
hemorrhage, d-shaped cells structure, hemosidophroages and lesion. 
 
 
6.3.7 Biomarkers of oxidative stress 
 
The oxidative stress induced by GNPs exposures in the vital organs was evaluated to 
disclose the potential toxic effects. However, as shown in Figure 6.9, the MDA activity 
in the liver of rat treated with low single and multiple dose (5 mg/kg body weight of rat) 
remained unaffected among the treatments. Hence, there was no obvious oxidative 
damage observed in the liver in response to the low dose. The activities of GSH inflated 
after 27 days of both single and multiple doses exposures. Catalase activity (CAT) is 
the crucial enzyme in antioxidant defence systems which transform the species H2O2 
to water and oxygen [43]. As prepared GNPs triggered a reduction in the CAT activity 
in treatments whereas a notable reduction was seen at the dose of high multiple dose 
group. Results indicated that under stress, the CAT activity was reduced. MDA and 
GSH activities were assessed by the difference of optical density of the compound at 
365 nm.  
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Figure 6.9: Biomarkers of oxidative stress results in rats after 27 days of GNPs 
administration. Rats (n=8 per group) were intraperitoneally injected with single doses 
of 5 mg/kg body weight (group 1), 15 mg/kg body weight (group 2) and multiple doses 
of 5 mg/kg body weight (group 3) and 15 mg/kg body weight (group 4). Values are 
expressed as mean ± standard deviation, for: A) MDA, B) hydroperoxide, C) GSH, and 
D) catalase. Data are represented as mean ± SD., *p<0.05, **p<0.01 vs control. 
 
6.4 Discussion 
 
Since the isolation of graphene in 2004, research has been conducted to elucidate the 
potential toxic effects of graphene exposure in in vitro and in vivo environments. Much 
research has been carried out on pristine graphene, graphene oxide, reduced 
graphene oxide, graphene quantum dots, and graphene nanoribbons and has showed 
that these single or few-layered structures are capable of inducing adverse effects in 
the cell lines and animal models [44]. These early investigations initiated a whole raft 
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of pre-clinical toxicity studies on graphene nanostructures designed to inform the 
potential use of these structures in clinical settings. The results of these studies 
suggest that graphene nanostructures such as graphene oxide and reduced graphene 
oxide, have the capacity to induce toxicity to mammals both as a function of their 
chemistry by inducing oxidative stress and lipid peroxidation, and as a result of their 
aggregation causing physical blockages [45]. Indeed, 3D porous graphene frameworks 
have shown various effects from acute lethally to sub lethal toxic effects including 
histological, and oxidative stress responses. However, GNPs, one of the most 
prominently used derivatives of graphene, e.g. used in DNA sequencing, drug delivery 
cargos and water treatment have not been investigated for their potential toxicity [46]. 
GNPs have different properties from their bulk counterparts based on their size, 
surface area and porosity. In terms of toxicity a size related increased surface area can 
lead to an enhanced dissolution of materials and thus lead to the release of potentially 
toxic ions and increase in toxic sites. Additionally due to small pore and sheet sizes, 
graphene nanopores might retain in many cells and organs compared to larger 
structures. Many studies have shown a size-dependent increase in toxicity as a 
function of particle size decrease as well as more specific size dependent generation 
in reactive oxygen species [47]. Although, size is an obvious intitial determinant of 
graphene toxicity, many other factors have important contributions to make. Surface 
charge, stability and aggregation behaviour of graphene nanopores within various 
exposure environments, are determined both by the physiochemical properties of the 
surrounding media and the properties of GNPs themselves. A variety of parameters 
relating to the physiochemical features of GNPs have been shown to influence their 
toxicity. Their parameters are poorly understood with many studies producing 
contradictory results, making predicting effects difficult. Graphene nanostructures can 
cross either para-cellularly or transcellulalry, and can travel within circulatory system 
and to subsequently accumulate within tissues and organs [48]. These nanostructures, 
depending on their composition and physiochemical properties can produce severe 
damages to cells by inducing oxidative stresses [49]. An understanding of the toxicity 
mechanism is vital to attaining a more uniform understanding and comparison of 
observed effects. Here we investigated in vitro and in vivo toxic effects of GNPs. Our 
data indicate that GNPs have acute toxicity in SKMES-1 and A549 lung cancer cells 
cultured in vitro. Due to poor solubility and superhydrophobicity, GNPs aggregate, non-
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specifically bind to proteins on cell surface membrane and disintegrate membrane 
integrity, and thus measuring cellular membrane integrity is an effective way to detect 
cell toxicity [50]. However, PI enters the cell that has lost its membrane integrity, and 
subsequently flags the cell as late apoptotic/necrotic. This chapter shows that GNPs 
induce early apoptosis in all cells, however, late apoptosis is only induced at 
concentrations higher than 250 µg/ml, suggesting that although GNPs at lower 
concentrations induce upregulation of phosphatidylserine on cell surface membrane 
(i.e. early apoptotic event), and they do not significantly disintegrate the cell membrane. 
Also, none of the GNPs concentrations were found to induce necrosis in SKMES-1 
cells, although concentration higher than 50µg/ml significant induced necrosis in A549 
cells. This is probably due to the different proteome profile and morphologies of the 
two cell lines. Also, generation of reactive oxygen species in response to graphene 
induces oxidative stress which is considered to be te leading cause of cellular toxicity. 
Thus, a number of factors can be involved in the induction of cellular toxicity by GNPs 
and therefore, testing toxicity in animal models is comprehensive and more 
physiologically relevant. Hence, we investigated effect of GNPs at different 
concentrations in rats, particularly examining toxicity in key organs such as liver, 
kidney, heart, small intestine, brain and testis. 
 
Body weight and organ indices are generally considered as significant toxicity 
parameters to investigate the acute exposure of foreign materials in animals [51]. In 
this study, the first sign of toxicity recorded for the rats given intraperitoneal injection 
of GNPs was an observed decrease in body weight.  GNPs also induced 
histopathological changes in small intestine, live and kidney. The increased levels of 
AST, ALT, AMP and decreased levels of creatinine observed after 27 days are 
indicators of toxicity that appear in the rats receiving both single and multiple doses of 
GNPs, compared to control groups. Severe organ damage can generally increase the 
activities of ALT and AST and enhanced activities of both are observed when disease 
processes affect liver cell integrity. Importantly, increased serum ALT activity reflects 
specific hepatocellular injury. Some of the histopathological alterations associated to 
these injuries were also evident in liver, where GNPs induced in dose- and time-
dependent histological alterations of the liver tissues, including congestion, prominent 
vasodilatation. Histopathological changes in the liver at 27 days was higher than that 
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of rats sacrificed at 14 days following both single and multiple doses of GNPs. 
Nevertheless, GNPs treatment groups also revealed GNPs accumulation in the lung, 
compared to their control groups. The impact of GNPs in these organs could be due to 
agglomerated states of GNPs which is dependent on physiochemical synthesis 
process of GNPs. Furthermore, GNPs accumulated in Kupffer cells did not induce any 
inflammatory response. Similarly, GNPs are not involved in the inflammatory 
responses in lymph nodes. Minor inflammatory responses can be observed in other 
organs particularly in the lung which shows isolated areas with a granulomatous 
inflammation. Interestingly, GNPs did not induce any significant histopathological 
variations in the kidney compared to their control groups, which suggests their rapid 
clearance from the renal tissues. Our data support previous studies that have 
demonstrated the accumulation of graphene nanosheets in the liver, lung, kidneys, and 
spleen after intraperitoneal, intravenous, or dermal administration [52]. After inhalation 
exposure in rats, graphene has been found to accumulate in the lung, leading to 
phagocytosis [24]. In this chapter, the acute intraperitoneal exposure of GNPs at 15 
mg/Kg for 27 days leads to significant liver damage. This was evident by the elevated 
ALT and ALP serum levels and pathological alterations in the liver. Increasded levels 
of MDA, GSH and hydroperoxdise were observed in the liver of GNPs-treated rats. 
Interestingly, decreased levels of CAT were also found in the liver, suggesting that 
GNPs reduced the activity of this endogenous antioxidant enzyme, contributing to 
oxidative stress and hepatocyte damage. This study suggests that more studies are 
needed to determine the relatively long-term toxicity of porous graphene frameworks 
via variety of administration routes to detect any possible serious side effects from such 
materials. 
 
 
6.5 Conclusions 
 
This chapter was aimed to assess the in vitro and in vivo interactions of relatively new 
derivative of graphene, graphene nanopores (GNPs) in mammalian systems, for the 
first time and to elucidate the possible mechanism of their toxicity. In vitro results show 
that GNPs induce early apoptosis in both SKMES-1 and A549 lung cancer cells, 
however, late apoptosis is only induced at concentrations higher than 250 µg/ml, 
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suggesting that, although GNPs at lower concentrations induce upregulation of 
phosphatidylserine on cell surface membrane (i.e. early apoptotic event), it does not 
significantly disintegrate the cell membrane. Subsequent, in vivo studies indicated   
damage in the main organs of rats (liver, kidney, lungs, heart, brain and testis) but the 
possible fast clearance of GNPs through kidney. We also showed that GNPs can 
induce oxidative stress in the liver. Blood markers remained within normal ranges 
following treatment. Our results show that changes in liver and kidney functions of 
these treatments can be minimal. GPNs cause sub-acute toxicity at our tested dose (5 
and 15 mg/kg) to the treated rat in a period of 27 days as evidenced by blood 
biochemistry, liver and kidney enzymes functions, oxidative stress biomarkers and 
histological examinations. We for the first time investigated the in vitro and in vivo toxic 
effects of any porous graphene nanostructure and found the time and dose dependent 
toxicity of GPNs in lung cancer cell lines and rat. These findings will help elucidate how 
GNPs induces time-course toxicity that may facilitate the modified and biocompatible 
development of porous graphene-based systems for industrial applications. Therefore, 
long-term, high dose, and careful selection of administration route using different 
animal models are crucial before seeking any clinical application of this ‘wonder 
material’. 
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6.6 Supplementary information 
 
 
SI Figure 6.1: Exposure schedule of graphene nanopores (GNPs) administration in 
rats. Rats were intraperitoneally injected with GNPs in a period of 27 days to test at 
single and multiple doses of GNPs (5 and 15 mg/kg) to analyse blood biochemistry, 
organo-somatic index, liver and kidney enzymes functions analysis, oxidative stress 
biomarkers and histological examinations. All of these testing has been carried out at 
day 27. 
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SI Figure 6.2: Organosomatic indices of organs in different groups of rats at 14 days 
after intravenous administration. All treated groups showed statistically no significant 
differences from the control group. 
 
HSI = Hepato-somatic Index 
GSI = Gonado-somatic Index 
SSI = Spleeno-somatic Index 
CSI = Cardio-somatic Index 
RSI = Renato-somatic Index 
SISI = Small Intestino somatic Index 
 
 
 154  
  
 
 
SI Figure 6.3: Representative histopathological changes of the liver, kidney, heart and 
small intestine of the GNPs-exposed and control rat in the haemotoxyline-eosin (H&E) 
section. The doses of GNPs were 5 and 15 mg/kg for the single-dose exposure and 5 
and 15 mg/kg (every other day, in total fourteen injections) for the multiple-dose 
exposure. Control group liver showed normal histology while single low dose treated 
group showed vacuolation, dilation of central vein and haemorrhage. A group treated 
with single high dose showed the damage and the healing process while a group 
treated with multiple low dose caused liver injury alongwith vacuolation, hemorrhage, 
dilation and epithelial damage. Multiple high dose treated group showed considerable 
destruction of epithelial lining, vacuolation, karyolysis degeneration of central vein, 
dilation of blood sinusoid and netrophilic and lymphocytic infiltration. Control group 
showed normal histology section of kidney while group treated with single low dose 
showed shrinked and d-shaped glomerulus. A group treated with single high dose 
indicated glomerulus constriction, nucleus distortion, epithelial degeneration and 
vacuolization. Multiple low dose group showed epithelial degeneration and d-shaped 
glomerulus. Multiple high dose treated group induced necrosis, nucleus distortion, 
epithelial lining degeneration and vacuolization. Control group of heart tissue showed 
normal histology of heart muscle tissues and single low dose treated group showed 
the chemodectoma. Single high dose group indicated toxic myocarditis. Whereas 
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multiple lose dose group caused acute rheumatism heart, which was the collection of 
pleomorphic histocytes with large basophilic nuclei. Multiple high dose treated group 
showed reddish brown atrophy; yellowish brown pigments lipofuscin. Histology of 
control group of small intestine showed the normal goblet cell at epithelial of the villus, 
absorptive epithelial and lamina propria. Single low dose group showed the damage of 
sub mucosa and muscular layer (arrow) and enlargement of lacteal (circle) and single 
high dose group showed puncture goblet cell (  G) atepithelial of the villus, 
absorptive epithelial and lamina propria. Multiple low dose treated group indicated the 
destructive and distorted villus (left side arrow) and ruptured crypts and intestinal 
glands (right side arrow) and multiple high dose group indicated the complete shrinking 
of lamina propria and lacteal (small arrows) and showed mild or to some extent no 
shrinking of lamina propria (big arrows). 
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SI Figure 6.4: Representative histopathological changes of the brain, testis and lung 
of the GNPs-exposed and control rat in the haemotoxyline-eosin (H&E) section after 
14 days. The doses of GNPs were 5 and 15 mg/kg for the single-dose exposure and 
5 and 15 mg/kg (every other day, in total seven injections) for the multiple-dose 
exposure. Control group showing normal histology of brain tissue of rats. Rats treated 
with single low dose (5mg/kg body weight) causes astrocytoma, brain shows the cells 
are pleomorphic, with wide variation in the size and shape of their nuclei which are 
also deeply basophilic. Rats treated with single high dose (15mg/kg body weight) 
causes hemangioblastoma; the pleomorphism of the nuclei of the closely packed large 
cells. Rats treated with multiple low dose (5mg/kg body weight) causes meningioma, 
a meningioma may invade the overlaying skull bone and cause it to thicken. The tumor 
cells have uniform ovoid vesicular nuclei and abundant eosinophilic cytoplasm which 
is vacuolated in some cell. There is no pleomorphism of nuclei and no mitosis in tis 
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tissue. Rats treated with multiple high dose (15mg/kg body weight) causes 
meningioma, which are lobulated tumors attached to the dura. A control group of testis 
shows the normal histology. Rats treated with single low dose showed vacuolation, 
less number of primary, secondary spermatocytes, damage in germinal layer. Rats 
treated with single high dose showed degeneration of germinal layer, damage in 
primary and secondary germ cells. Rats treated with multiple low dose showed that 
vacuolation, spermatogenesis completely stopped. Rats treated with multiple high 
dose showed massive damage in complete germ cell d-shaped completely destruction 
in spermatogenesis.Control group brain showed normal cells, while rat treated with a 
single dose (5 mg/kg body weight) exhibited showed damage of vacuolation, vein and 
artery damage, disruption, hemorrhage and edema. The single high dose treated 
group showed damage of vacuolation, vein and artery damage and inflammation. Rat 
treated with multiple dose (5 mg/kg body weight) showed damage of vacuolation, vein 
and artery damage, hemorrhage and hemosidophroages.   Rats treated with the 
multiple high dose group showed damage of vacuolation, vein and artery damage, 
hemorrhage and d-shaped cells structure and hemosidophroages. 
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Chapter 7 
Influence of Luminescent Graphene Quantum 
Dots on Trypsin Activity 
 
Protein-graphene interactions have the potential to play a pivotal role in the future 
directions of nanomedicine. These interactions lead to the diverse processes such as 
generation of protein coronas, nano-bio-interfaces, particle wrapping and biocatalytic 
processes that could determine the ultimate fate of graphene nanocomposites in 
biological systems. However, such interactions and their effects on the bioavailability 
of graphene have not yet been widely appreciated, despite the fact that this is the 
primary surface in contact with cells. This chapter reports on the integrative 
physiochemical interaction between trypsin and graphene quantum dots (GQDs) to 
determine their potential biological identity in enzyme engineering. This interaction was 
measured by a wide range of analytical methods. Definitive binding and modulation of 
trypsin-GQDs was demonstrated for the first time by use of vibrational spectroscopy 
and wetting transparency, which revealed that trypsin was absorbed on GQDs’ surface 
through its cationic and hydrophilic residues. Our finding suggested that trypsin’s active 
sites were stabilized and protected by the GQDs, which was likely to be responsible 
for the high bioavailability of GQDs in enzymes. Our work demonstrated the efficacy of 
GQDs as an enzyme modulator with high specificity, and their great application 
potential in enzyme engineering as well as enzyme-based therapies. 
 
7.1 Introduction 
 
 The regulation of enzyme activity plays diverse roles in catalytic activity adjustments 
and modulation of cellular events such as signal transduction, DNA replication, 
metabolism, gene expression, immune responses, metastasis, and metabolism [1, 2]. 
Various types of enzyme dysfunction cause a wide variety of human diseases and 
disorders associated with inborn errors of metabolism and specific mutations within the 
enzymes [3-5]. The regulation of enzyme function provides a promising direction for 
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the development of therapeutic interventions [6]. Hence, regulation of enzyme activity 
and stability have attracted a great deal of attention. Recently, luminescent quantum 
dots (QDs) have emerged as a promising system for enzyme modulation [7]. These 
QDs have several advantages over conventional regulators: for instance, they can 
enter cells easily, and have unique luminescent features, surface charge, 
hydrophilicity, and geometry and surface properties for the binding of enzymes [8, 9]. 
Recent developments in graphene nanocomposites indicate promising new pathways 
to control the binding and activation of protein structure and cell behaviour [10]. Several 
derivatives of graphene, such as graphene oxide, reduced graphene oxide and pristine 
graphene, have been reported to show their interactions and influences on enzymes 
activities [10-12]. In the past few years, graphene oxide with different functionalization 
and modifications has been extensively investigated to understand its interaction with 
proteins [10-15]. The electrostatic bonding and π-π stacking interactions and 
covalent/non-covalent bonding are considered to be the major mechanisms of 
graphene-protein interactions. Graphene-biomolecule interactions have been shown 
to underpin clinical diagnostic tools for cancer biomarker detection, which demonstrate 
that graphene based enzyme modulators are becoming an increasingly relevant 
alternative to traditional techniques [10].  
 Graphene quantum dots (GQDs) have widely been explored in biological 
applications but their interaction with enzymes has not. They are photoluminescent 
nanoparticles with excellent optical characteristics, unique physiochemical properties, 
excellent photo stability and minimal toxicity [16, 17]. These characteristic features 
make them an ideal system for biomedical applications, including drug delivery 
systems, diagnosis and therapy, bio-imaging and sensing [18]. Their interactions with 
biomolecules form the basis of a variety of clinical and real world applications. For this 
field to evolve, we need to understand the dynamic forces, surface chemistry and the 
biophysiochemical nature of both components that shape these interactions. Chemical 
or electrostatic attachment of enzymes to GQDs could enhance the rate of nano-bio-
interface formation and/or cause an enzyme to denature. GQD-induced changes in 
biomolecular behaviour and morphology would help us to better understand the 
bioavailability and implications of GQDs on human health and the environment. 
As a biologically relevant target enzyme we selected trypsin, which is a pancreatic 
serine protease involved in the digestive systems of food proteins and number of 
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important biological activities. Trypsin is a medium-sized globular protein with 
applications in, e.g., wound healing machineries, in washing agent involved in many 
biotechnology activities. The bonding forms a nano–bio-interface that defines the role 
of the QD and can induce damage in the interacting trypsin. Features of the QD that 
contribute to the formation of the interface in a biological environment are surface 
charge, electronic states, size, shape, functional groups, free radicals, surface 
roughness and wetting properties. Features of trypsin that may influence its interaction 
with the QD are size, ionic strength, temperature, surface hydrophobicity, surface 
charge, sequence and conformation. The trypsin-QD interactive profile may lead to 
dynamic changes in the living system. The interface can form when trypsin moves 
towards QDs. As a result, QDs can also induce potential changes to trypsin such as 
function and conformation as a result of surface energy release. We define how the 
interaction modifies the nano-bio-interface and probe the trypsin activity over a range 
of GQDs concentrations (25, 50, 75, 100, 125 and 150 µg/ml). The changes in surface 
and physiochemical properties as a result of enzymatic interaction of graphene are 
also unknown. Therefore, we utilised Raman spectroscopy, Fourier transform infrared 
spectroscopy (FTIR) and wettability tests to investigate the chemical, structural and 
surface hydrophilicity/hydrophobicity changes encountered by GQDs towards the 
stability of trypsin. Different levels of inherent surface oxygen containing functional 
groups of GQDs were found to be the reason behind the tuning of trypsin’s specific 
activity. A fluorogenic substrate for trypsin was used to carry out control experiments 
of trypsin activity. 
7.2 Materials and methods 
7.2.1 Synthesis and basic characterization of GQDs 
 GQDs were prepared by tuning the carbonization degree of citric acid (CA) as 
previously reported [19]. In a typical procedure, 2 g CA was put into a 5 ml beaker and 
heated to 200 ºC using a heating mantle. About 5 min later, the CA was liquated. 
Subsequently, the colour of the liquid changed from colourless to pale yellow, and then 
orange in 30 min, implying the formation of GQDs. The resultant orange liquid was 
added dropwise into 100 ml of 10 mg/ml NaOH solution, under vigorous stirring. After 
neutralization to pH 7.0 with NaOH, an aqueous suspension of GQD was obtained. 
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 Transmission electron microscope (TEM), X-ray diffraction (XRD) analysis, Fourier-
transform infrared (FTIR) spectra, Raman spectra and zeta potential measurements of 
GQD samples were carried out in the same manner as described in chapter 4 (section 
4.2.1). The photoluminescence (PL) features were obtained by using an Edinburgh 
Instruments Spectrofluorometer FS5 at 350 nm of excitation wavelength. The 
wettability of GQDs was determined using a contact angle goniometer. A digital camera 
was used to record the images and the contact angle was calculated (using PolyPro). 
The surface of the sample was prepared for wetting by gently drop casting it onto a 
glass slide. The surface energy was determined by measuring the contact angle of a 
10 µl drop of diiodomethane (DIIO) on the surface. The equations used in the surface 
energy calculations are given in the chapter 4 (section 4.2.4). 
 
7.2.2 Trypsin proteolytic activity on substrates and GQDs 
 A fluorogenic substrate, Boc-Gln-Ala-Arg-AMC (kcat/Km=2.0 x 107 M-1sec-1; Km=6.0 
µM) at different concentrations (0, 0.1, 0.25, 0.5 and 1µM) was used to examine 
trypsin-mediated enzymatic activity at 37 ºC at various time-points (2, 5, 10, 15, 30 and 
60 mins). The trypsin (trypsin-EDTA solution 1X) was purchased from sigma-Aldrich, 
Dorset United Kingdom and used without further purifications. The substrate stock 
solution was prepared in DMSO and was further diluted. The test wells within a black 
opaque 96 well plate (Greiner Bio-one) contained 1% trypsin and various 
concentrations of the substrate: controls were 1% (V/V) trypsin + distilled water and 
substrate (v/v) only in distilled water. Plates were read at the aforementioned time 
points of incubation at room temperature. Plates were read at Ex/Em: 355/450nm and 
the data normalised to the control (and represented as a percentage of this control). 
The fluorescence intensity of the substrate hydrolysis was detected kinetically using a 
SpectraMax plate reader. The same procedure was repeated (n=4) with GQDs at 
various concentrations (0, 25, 50, 75, 100, 125 and 150 µg/ml). The control wells 
contained GQDs only (dispersed in distilled water). Statistical analysis was performed 
between the concentration of GQDs/substrate and trypsin by unpaired Student’s t-test 
(using GraphPad Prism). Results were presented as mean ± s.d. unless otherwise 
indicated. Values of p < 0.05 were considered significant. FTIR, Raman spectroscopy, 
water contact angle and DIIO contact angles were measured in the similar way as 
described in Section 7.2.1.  
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7.3 Results and discussion 
 
7.3.1 Basic characterization 
 TEM was used to observe the microstructure of GQDs (Supplementary Figure 7.1). 
Dark spots shown in SI Figure 7.1(A) were GQDs which had regular diameter, circular 
shape and were not aggregated. TEM image shows a relatively identical size 
distribution between 5 and 10 nm. As shown in Supplementary Figure 7.1(B), an 
absorption peaks centered at 1637 and 3402 cm-1 revealed C=C and O-H bonding 
appeared in the FTIR spectrum. The absorptions at 1255 and 1078 cm-1 indicated the 
existence of C-H and C-O, respectively. Furthermore, the GQDs exhibited stretching 
vibrations of C–H at 2950 and <1350 cm−1, suggesting that the GQDs contained some 
partially carbonized CA [20]. . As shown in Supplementary Figure 7.1(C) the Raman 
spectrum of GQDs exhibited a D band at 1355 cm−1 and a G band at 1580 cm−1, which 
are related to a series of structure defects and the in-plane bond-stretching motion of 
the pairs of sp2 atoms, respectively [21]. PL spectra of GQDs was almost excitation-
independent, with the maximum excitation and emission wavelengths at 365 and 
455 nm, respectively (Supplementary Figure 7.1D). PL spectra of GQDs at the 
excitation wavelengths of 340, 350, 360, 370 and 380 nm are shown in 
Supplementary Figure 7.2. Figure 7.1 shows that the GQDs had good water solubility 
(Figure 7.1A) and droplets of water on the surface (Figure 7.1C) exhibited a typical 
water contact angle (WCA) of 14º indicating a strongly hydrophilic nature. The water 
wettability data were combined with wettability measurements of diiodomethane 
(Figure 7.1D) to determine the surface energy (see Supplementary Note 1 in the SI). 
A dispersive surface energy of 36.5 mN/m and polar surface energy of 35.7 mN/m led 
to a total surface energy of 72.2 mN/m. 
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Figure 7.1: Water solubility, wetting transparency and surface energy of GQDs. (A) 
The absorbance (λex = 275 nm) as a function of concentration. The experimental data 
(symbols) are well described by the Lambert-Beer Law (line), which indicates good 
water solubility of the prepared GQDs. (B) UV/Vis absorption spectra of GQD having 
concentrations of 150, 125, 100, 75, 50, 25, 12.5 and 6 µg/ml indicate band around 
260 nm. (C) Photograph of a 10 µl drop of water on the GQDs, showing a water contact 
angle of 14º. (D) Photograph of a 10 µl drop of diiodomethane on the GQDs with a 
contact angle of 46º. 
7.3.2 Trypsin activity with substrate and GQDs 
 Fluorogenic substrate concentration and trypsin activity assays were conducted in 
order to determine the substrate breakdown and activity. Figure 7.2 shows that the 
highest concentration of substrate (1 µM) had the highest enzyme activity. In trypsin-
substrate interaction, highest concentration of substrate was also active over different 
time points (Figure 7.2e). Figure 7.2e shows the increase in enzymatic activity over 
the varying concentration of substrate. 
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Figure 7.2: Fluorescence intensity of trypsin, substrate and trypsin+substrate as a 
function of time and substrate concentration. Fluorogenic substrate, Boc-Gln-Ala-Arg-
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AMC at different concentrations (0, 0.1, 0.25, 0.5, 1uM) was incubated with 1 % trypsin 
in 96 well plates at different time-points (2, 10, 30 and 60 mins). (A-D) Different 
concentration of substrate over different time-points compared to only trypsin and 
substrate. (E) Highest concentration of substrate compared to substrate and trypsin 
only.  Fluorescence signals were measured using plate reader at Ex/Em: 355/450nm.  
Control wells contained H2O+substrate and H2O+trypsin. 
 
Figure 7.3 shows normalized fluorescence intensities at different concentrations of 
GQDs (25, 50, 75, 100, 125 and 150 µg/ml) exposed to trypsin over different time 
scales (0-60 mins). Trypsin was active at all the concentrations of GQDs but most 
active at 150 µg/ml. As the concentration was decreased from 150 to 25 µg/ml, the 
fluorescence signals reduced. This could suggest that the trypsin was adsorbed onto 
the surface of GQDs via physiochemical interaction and hence block the emission of 
fluorescence signals from the GQDs. Decreased fluorescence intensity is also relevant 
to increased trypsin quenching. This may be due to the fact that water molecules are 
surrounded between the enzyme and the hydrophilic GQDs surface, and hence, the 
adsorption-induced conformational reshuffles result in revealing trypsin to water 
molecules. Trypsin bonding speeded up with increasing the concentration of GQDs. 
This behaviour could indicated that both the trypsin and GQDs surface had to adapt 
their structures to form a stable interface. At high enzyme coverage of the GQDs 
surface, one could also envisage that rearrangements of protein molecules already 
bonded to the GQDs were required to make room for an incoming protein molecule. 
This crowding effect would contribute significantly to the self-fluorescence properties 
of GQDs.  
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Figure 7.3: Effect of different concentrations of GQDs on trypsin activity. GQDs at 
different concentrations (150, 125, 100, 75, 50 and 25 µg/ml) were incubated with 1 % 
trypsin in 96 well plates at different time-points (2, 5, 10, 15, 30 and 60mins) as shown. 
(A-D) Comparison of different concentration of GQDs on trypsin activity over 0-60 mins. 
(E) Influence of the highest concentration of GQDs on trypsin activity compared to the 
case of GQDs only. Trypsin was highly active at 150 µg/ml concentration of GQDs and 
 170  
  
slightly active at other concentrations. Fluorescence signals were determined using 
plate reader at Ex/Em: 355/460nm.  Control wells contained H2O and GQDs, H2O and 
trypsin. 
 The nano-bio-interface resulting from the trypsin-GQDs interaction can be confirmed 
by FTIR. The changes/shifts in the functional groups of interfaces were identified by 
using FTIR. Figure 7.4(a-f) shows FTIR spectra of GQDs linked to trypsin at 
concentrations of 25, 50, 75, 10, 125 and 150 µg/ml of GQDs. The FTIR spectrum of 
1% trypsin is given in Supplementary Figure 7.3. The FTIR spectra of trypsin-GQDs 
interfaces exhibited a variety of trypsin absorption features such as C=O (ʋC=O at 1639 
cm-1). In particular, the C–N stretching mode peak in 100 µg/ml concentration trypsin-
linked GQDs appeared at 1366 cm-1 (ʋC–N receptor binding with an aromatic  
compound) [22]. The spectra of trypsin after interaction with 50 µg/ml GQDs (Figure 
7.4b) showed not only the characteristic peaks of C=N at 1629 cm-1, which arose from 
the amino groups of trypsin and the aldehyde groups of GQDs, but also the 
characteristic bands of the GQDs, 1255 and 1637 cm-1 (C–N, stretching vibration), and 
1078 cm-1 (C–O–C, antisymmetric vibrations) (Figure 7.4c). The peaks at 1102 cm-1 
assigned to the stretching vibration of O–H and C–O–C confirmed the presence of 
GQDs. Furthermore, the peak appeared at 1736 cm-1 (150 µg/ml, the highest 
concentration of GQDs), can be assigned to C=O which did not appear at other 
concentrations except 25 µg/ml. These spectra also showed the presence of C= O 
(ʋC=O at 1736 cm-1), C=C (ʋC=C at 1629 cm-1), and at 1228 /1055 cm-1 in carboxyl, epoxy 
and alkoxy groups, respectively (Figure 7.4f).  These results confirmed that trypsin 
had been successfully covalently bonded onto the surface of GQDs. 
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Figure 7.4: FT-IR spectra of trypsin-linked GQDs. (A) 25, (B) 50, (C) 75, (D) 100, (E) 
125, and (F) 150 µg/ml GQDs concentration. 
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Figure 7.5: Raman spectra of trypsin-linked GQDs. (A) 25 and (B) 150 µg/ml. 
 
 Figure 7.5 shows Raman spectra of trypsin-linked GQDs. In the spectra of 25 and 
150 µg/ml concentrations of GQDs, the amide-I vibration at 1625 cm-1 arose mainly 
from the ʋC=O stretching vibration. The band in the range of 1250-–1340 cm-1 was 
caused by the C-H3 and C-H2 deformation vibrations from the side chains of different 
amino acids. The amide-III was the combination of the N-H bending and C-C stretching 
vibration in the region 1200-1340 cm-1 [23, 24]. Slight shifts can be observed between 
the two Raman spectra of GQDs and trypsin adsorbed on GQDs. In the spectrum of 
GQDs (Fig S1e) there were two typical peaks appeared at ca. 1355 cm-1 and 1580 cm-
1. The bands at 1600-1625 cm-1 and 1250-1340 cm-1 can be assigned to the C=O 
stretching of carboxylate and C-H2 deformation vibration. After combining with GQDs, 
the strong amide band at 1629 cm-1 in the FTIR spectrum of trypsin appeared and 
merged with the band of GQDs at 1637 cm-1 (C=C group). Additionally, in the Raman 
spectra of GQDs and trypsin-GQDs, the prominent amide band at 1580 cm-1 of GQDs 
was shifted to 1625 cm-1 in trypsin-GQDs interface. Based on these facts, it could be 
inferred that the trypsin interacted with GQDs through its amide bonds. However, the 
amide bonds might not be the only force that bonded trypsin to GQDs. Trypsin has a 
deep bonding pocket with an aspartic acid at the bottom. This provides the space and 
electrostatic complementarity to specifically bond long basic side chains, such as 
lysine and arginine. These are positively charged amino acids and, therefore, could be 
conjugated to the negatively charged surface of the GQDs through the electrostatic 
interaction. 
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 The functional groups of GQDs act as a passivating layer and contribute to the 
increased hydrophilicity. To evaluate the extent of surface modification induced by 
trypsin, WCA measurements were carried out on the samples before and after 
treatment and also at different time-points of trypsin-GQDs interaction (Figure 6). The 
trypsin displayed higher hydrolytic activity towards GQDs, as demonstrated by the 
decrease in the WCA values. The decrease in WCA confirmed that the reaction 
proceeded effectively. Upon trypsin interaction, the WCA of GQDs was moved to lower 
values of CAs, which indicates an increase in the surface hydrophilicity (Figure 6a). 
This effect was distinct and noticeable in the case of the higher concentrations, for 
which the average WCA value was decreased by about 30º. A decrease of 6.5º was 
recorded at 25 µg/ml. The decrease in DIIO contact angle (Figure 7.6b) revealed the 
surface energy profile, which is quantitatively shown in Figure 7.7. Overall, the results 
addressed a couple of key features related to the surface interaction of GQDs 
substrates with trypsin: (i) the effect of the functional groups existing on the surface of 
GQDs and trypsin; (ii) hydrophobicity driven by the adsorption of trypsin onto the GQDs 
surface to form a nano-bio-interface (the WCA of trypsin is shown in Supplementary 
Figure S4.). Furthermore, the rise in total and dispersive surface energy caused by the 
trypsin-GQDs interaction revealed that differences in functional group content, 
conformational flexibility, and shape and distinct bonding affinities released higher free 
surface energy. Higher concentrations of GQDs readily covered the surface of the 
trypsin to initiate the formation of a protein ‘soft’ corona, while lower concentrations 
with lower yield of functional changes took over to form a corona. Polar part of total 
surface energy enhanced dispersion of liquid on the surface, while the dispersion 
section improved the hydrophobic nature and consequently increased the CA profile 
(Figure 7.7). Low polar part (Figure 7.7 c) and high dispersion part (Figure 7.7 d) of 
surface energy exhibited different trends were evident because of the polar and 
nonpolar side-chains of trypsin facilitating conformational changes in the trypsin 
structure and consequently leading to high adsorption capacity of trypsin into GQDs. 
A recent study conducted by Gupta et al. showed the similar surface energy profile for 
carbon nanotubes [25].  
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Figure 7.6: Contact angle profiles of trypsin-GQDs interfaces at 25 and 150 µg/ml 
concentrations of GQDs. (A) water contact angle of interface from 5 to 60 mins. (B) 
DIIO contact angle of interface from 5 to 60 mins. DIIO contact was measured to 
calculate the surface energy of trypsin, GQDs and their interfaces. 
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Figure 7.7: Water contact angle and surface energy profile of GQDs-trypsin interfaces 
from 0 to 60 mins. (A) water contact angle (B) total surface energy (C) dispersive 
surface energy and (D) polar surface energy of 25 µg/ml, 50 µg/ml, 75 µg/ml, 100 
µg/ml, 125 µg/ml and 150 µg/ml concentration of GQDs treated with trypsin. 
 The entrapment of enzyme immobilization is generally carried out by ionic/covalent 
interaction, encapsulation and adsorption. The process of adsorption is considered to 
be a simple, effective and economical method for enzyme immobilization. Enzyme 
interactions with nanoparticles surfaces occur upon adsorption [24] and the adsorbed 
enzyme molecules in facilitating these interactions display the structure of the 
nanoparticle-enzyme interface. However, a key challenge in understanding the 
enzyme-nanoparticle interaction is to characterize the nano-bio-interfaces to analyse 
their bulk properties such as release of surface energy, functional changes in enzyme 
conformation, nature of bonding and change in wettability. The turn-over product of 
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interfacial homogeneity comes from the transfer, localization and distribution of 
proteins amide groups towards nanoparticles. In this regard, vibrational spectroscopic 
analytical methods can define the undergoing continuous changes as a result of 
bonding and interaction. The increased enzymatic activity of trypsin adsorbed on 
GQDs surface are ascribed to a definite adsorption conformation/arrangement where 
trypsin were adsorbed with their active site toward the surface of GQDs.  
 The changes identified by analytical methods in this study revealed the biosafety of 
GQDs. GQDs are biocompatible and more likely not to induce oxidative damage. The 
interaction between GQDs and trypsin is very important to reveal the influence of 
GQDs on enzyme activity. Vibrational spectroscopic methods and wetting 
transparencies have been utilised to characterize possible bonding between GQDs 
and trypsin. Electrostatic weak interactions may contribute to their interaction, and 
these weak interaction may change the conformation of trypsin which makes its activity 
decreased. This work highlighted that the interactions of graphene nanocomposites 
with enzymes were associated with their surface chemistry. The role of tunable surface 
chemistry of GQDs could be exploited in the modulation and regulation of essential 
processes involved in cell differentiation and proliferation where trypsin plays the main 
role to hydrolyze proteins into smaller peptides or even amino acids. Addition of GQDs 
to trypsin activity could specifically and selectively favour the biocatalyst reactions, 
such as to improve the the functional properties of trypsin such as solubility, viscosity, 
emulsifying features, foaming and gelling properties and to produce protein 
hydrolysates and bioactive peptides that are used in infant formulas. Immobilization of 
trypsin on GQDs demonstrated that GQDs are an ideal enzyme carrier. The high 
surface area of graphene allows significant loadings of trypsin, which results in a higher 
ionic-strength and stability of enzymes. Further work is required to investigate the 
stability and thermostability of other relevant enzymes and graphene nanocomposites 
with specifically tailored surface properties, with the aim to further the understanding 
of enzyme–graphene interactions at the molecular level. 
7.4 Conclusions 
 We systematically studied the interactions of GQDs with trypsin to elucidate the 
general fate of GQDs in biological systems. GQDs exhibited a strong bonding capacity 
owing to their surface charge and surface functionalities. They were highly 
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biocompatible, as demonstrated by the fact that the trypsin was adsorbed onto their 
surface via chemical interaction and hence blocking the emission of fluorescence 
signals from the graphene molecule. Furthermore, FTIR, Raman spectroscopy and 
wetting transparencies of GQDs-trypsin interfaces were performed to understand the 
role of surface chemistry in the enzyme-GQD interactions. Detailed investigation 
illustrated that the GQD-induced acceleration was concentration-dependent. The 
results indicated that GQDs are a potential substrate for efficient enzyme 
immobilization. The nano-bio-interface between adsorbing enzyme and GQDs surface 
could have potential applications in the development of biocompatible nanomaterials, 
nanomedicine and for enzyme separation and purification approaches. 
7.5 Supplementary information: 
 
 
 
SI Figure 7.1: Basic characterization of GQDs. (A) Transmission electron microscopy 
image of GQDs showing their regular diameter, round shape and spatial distribution. 
Scale bar: 200 nm. (B) FTIR spectrum of the GQDs showing vibrations of different 
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functional groups. (C) Raman spectrum of the GQDs showing the D (1355cm-1) and G 
peaks (1580 cm-1). (D) Photoluminescence spectrum of the GQDs. 
 
 
SI Figure 7.2: Luminescence property and emission diagram of GQDs. PL spectra of 
GQDs at the excitation wavelength of 340, 350, 360, 370 and 380 nm. The strongest 
photoluminescence emission occurs at 460 nm. 
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SI Figure 7.3: FTIR of 1% trypsin showing vibrations of C=N at 1629 cm-1, stretching 
modes of O–H and C–O–C at 1100-1200 cm-1, and stretching vibration of C–H at 3300-
3550 cm−1 [26,27]. 
 
 
SI Figure 7.4: Trypsin contact angle measurements with water (left, 45º) and DIIO 
(right, 42º). 
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Chapter 8 
Tracing the Bioavailability of Three-Dimensional 
Graphene Foam in Biological Tissues 
 
Graphene-based materials with a three-dimensional (3D) framework have been 
investigated for a variety of biomedical applications because of their 3D morphology, 
excellent physiochemical properties, volume stability, and their controllable 
degradation rate. Current knowledge on the toxicological implications and 
bioavailability of graphene foam (GF) has major uncertainties surrounding the fate and 
behavior of GF in exposed environments. Bioavailability, uptake, and cell attachment 
could have potential effects on the behavior of GF in living organisms, which has not 
yet been investigated. This chapter describes the toxicological effects on 3D GF on 
human glioblastoma U87 cell line and common carps. Our results showed that GF did 
not show any noticeable toxicity in U87 cell line and common carps, and the antioxidant 
enzymatic activities, biochemical and blood parameters persisted within the standard 
series. Histological imaging revealed that GF remained within liver and kidney 
macrophages for 7 days without showing obvious toxicity. Furthermore, fluorescence 
imaging revealed cell attachment which could play a pivotal role in regenerative 
medicine. An in vitro and in vivo studies also demonstrated a direct interaction between 
GF and biological systems, verifying its eco-friendly nature and high biocompatibility. 
 
8.1 Introduction 
 
Recent development of three-dimensional graphene foams (3D GF) provides an 
effective route to uniform dispersion of graphene in a composite matrix [1-3]. The 
effective and homogeneous distribution of graphene has been the focus of substantial 
investigations, with the most critical changes in morphology and porous architecture 
[4]. 3D GFs form a united and continuous network of graphene sheets, thus fulfilling 
the requirement of uniform distribution [5]. 3D GFs could be potentially used in a variety 
of areas, such as in energy storage [6], Li ion batteries [7], supercapacitors [8], 
electrochemical sensing [9], and tissue engineering (as stem cell scaffolds) [10] owing 
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to their high surface area (ranging from a few hundred to ca. 2000 m2/g) and 
hierarchical (macro/meso/micro pores) structure in combination with the intrinsic 
properties of two dimensional (2D) graphene. 3D GFs are economical to produce and 
highly scalable for commercial and industrial applications [11]. Recently, the 
biocompatibility of GF in living systems has become a great concern [11], although it 
shows great potential in stem cells and some other applications. Regardless of these 
applications, studies on the direct biological interaction of GF with living and aquatic 
system are not available. So far, only a few studies have exploited GF’s porous 
morphology and architecture for neural and human mesenchymal stem cells, bioactive 
scaffolds and drug delivery system. Wang et al. used polycaprolactone-enriched GF 
(PCL/GF) as a promising scaffold for bone tissue engineering because of its excellent 
biomineralization rate and the presence of a hydroxyl group [12]. Nieto et al. fabricated 
a high strength biocompatible scaffold via forming a thin uniform PCL coating on GF 
using a dipping method [13]. Although these reports demonstrated in vitro applicability 
of GF in tissue engineering, the bioavailability and potential toxic effects of 3D GF in 
living models remains unclear. Assessing the potential impacts of GF on the human 
health is critical for the sustainable development of the graphene-industry. 
Bioavailability and uptake of GF to organisms are key determinants of toxicity, yet 
these features are useful and coherent modes of aquatic animals. This work addresses 
this omission by focusing on these important principles for GF. 
 
In this chapter, GFs were probed as a biocompatible materials for cellular attachment. 
Common carps (Cyprinus carpio) are a remarkable class of species in freshwater 
environments and are commonly used as an in vivo model. Common carp is 
fundamentally an important aquatic species for toxicology of nanomaterials (NMs) [14]. 
Compared to laboratory fishes, common carps are stronger against contaminants 
mainly due to the variety of their interaction routes, multiple exposure routes into 
organisms, physicochemical characteristics of water, and diversity of aquatic 
environment [15]. These are generally considered the most appropriate model to 
evaluate the properties of toxins and their implications on a biological system. GFs 
were shown to maintain remarkable biocompatibility, low responsiveness to toxicity 
screening, and very small fluctuations in enzymatic patterns of common carp [15]. In 
the present work, we investigated the interactions of GF with U87 cell line and fish, to 
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investigate the cell attachment and its effects on antioxidant enzymatic activities 
(superoxide dismutase (SOD), catalase (CAT), and glutathione-S-transferase (GST)) 
in vital tissues such as the liver, kidney, and heart), biochemical features in the blood 
and histological alterations in the liver, kidney, and heart, when exposed for 7 days. 
These findings would help explore and develop novel and facile GF-based approaches 
for tissue engineering and regenerative medicine. 
 
8.2 Materials and methods 
 
8.2.1. Fabrication and characterization of three-dimensional GF 
 
Graphene foams were prepared via a CVD route using styrene and a Ni foam template 
(supplied by Novamet, USA, with a 99% porosity and 1.6 mm thickness). Briefly, the 
Ni template was activated in a tube furnace at 1000 °C for 10 min under Ar flow of 180 
mL/min and H2 flow of 200 mL/min, followed by injecting the styrene carbon source 
into the furnace tube at a rate of 0.254 mL/h (controlled by a syringe pump (Razel 
Scientific Instrument, Inc.  USA)), still under the same mixture gas flow for 1 h. Finally, 
the sample was cooled down naturally to room temperature under a reduced Ar flow 
of 50 mL/min. The 3D graphene networks were obtained by overnight etching of the 
original Ni template in 3 M HCl, and the final product was characterized by using a 
scanning electron microscope (SEM), transmission electron microscope (TEM), X-ray 
diffraction (XRD) analysis, Raman spectra of GF samples were recorded in the same 
manner as described in chapter 4 (section 4.2.1). 
 
8.2.2 Cell viability and fluorescence imaging 
 
Human glioblastoma U87 cell line was purchased from the American Type Culture 
Collection (ATCC, USA) and were then cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) which was supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin streptomycin. Cells were incubated at 37 °C under humidified air with 5% CO2 
for three days to achieve 80% confluence and were then trypsinized with trypsin and 
suspended in DMEM. Cells were also cultured on 3D GF attached at the bottom of 24-
well plate for 28 days. The 3D GF sheet was 1 cm wide, 1 cm long, and 0.2 cm thick. 
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Alamar blue stock solution (0.1 mg/ml in phosphate buffered saline (PBS)) was diluted 
to 1:10 with DMEM serum-free medium. The solution was transferred to each well and 
then incubated under dark condition at 37 °C. The solution was dropped in 96-well 
plate to obtain the volume of 500 µl/well and was triplicated. Cytotoxicity was 
determined using AlamarBlue® cell viability assay (Thermofisher Scientific, Italy) 
following the guideline provided by manufacturer. Fluorescence (ʎex = 540 nm; ʎem = 
595 nm) was measured by using plate reader after 2 h of incubation at 37 °C. 
Experiments were repeated for 3 times and cell viability was presented as percentage 
of control cells. The cells were then washed with PBS and fixed with 4% 
paraformaldehyde for 15 min. A fluorescence microscope (Olympus MODEL 
BX51WIF) was employed for imaging assessment of cell attachment to 3D GF.  
 
8.2.3 Procedure for in vivo toxicity 
 
Common carp (Cyprinus carpio) (50 ± 2 g weight and 29 ± 0.9 cm in length) was 
procured from the Fish Hatchery Satiana Road Faisalabad Punjab, Pakistan and held 
there for two weeks in a stock aquarium with flowing aerated dechlorinated tap water. 
Stock fishes were fed with commercial fish meal, and maintained in the stock aquarium 
at 28 ± 2 °C and 12:12 light to dark period (after permission by the ethical committee 
of Government College University, Faisalabad, Pakistan). After 2 weeks 
acclimatization, fishes weighing around 50 g (n = 40) were transferred into four aerated 
experimental glass aquaria (10 fishes/tank) and further acclimated for 48 h. They were 
randomly divided into four groups having the non-significant difference in weight. The 
first group was used as the control group (without GF treatment), and the other groups 
were exposed to either 5 (low dose), 10 (medium dose) or 15 (high dose) mg·L−1 of 
sterile GF for 7 days. During the test period, the fishes were fed twice a day with 
artificial diet. Both blood and tissues (heart, kidney and liver) were collected after 24, 
48, 96 h and 7 days of exposure for each treatment, randomly. Blood samples were 
collected through cardiac puncture by using 2 mL heparinized needle flushed with 
EDTA and transferred to a tube containing EDTA. The tissues were frozen at −4°C for 
further analysis. For histological analysis, heart, kidney and liver tissues with a 
diameter of 3–5 mm were fixed in sera  
(60% ethanol + 30% formalin + 10% acetic acid) for 3–4 h [18]. The fixed samples were 
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dehydrated at room temperature with ethanol and toluene series and embedded in 
paraffin. These paraffin embedded tissues were sectioned into thin slices of 4–5 μm 
by using a microtome (SLEE Rotary Microtome CUT5062 by Nikon Instruments 
Europe), stretched in water and mounted on gelatin-coated marked glass slides. These 
sections were then stained with haematoxylin and eosin. The stained tissues were 
examined under an optical microscope (Nikon Eclipse 50i by Nikon Instruments 
Europe) fitted with a digital camera. 
 
8.2.4 Measurement of enzymatic activities and other biochemical parameters 
 
Liver, heart and kidney samples from the fishes were collected at different timescales 
after treatment, ice-covered, and kept separately at ~20°C. These sections were 
washed with 0.15 mM KCl solution and normalized on ice with 50 mM phosphate buffer 
(pH 7.0). The suspension was sonicated and then centrifuged (at rate of 10,000× g at 
4°C for 10 min). GST activity was measured using a GST Tag assay kit (Novagen, 
Germany). The reaction absorbance was monitored at 340 nm by using a UV 
spectrophotometer (Tecan Infinite F200, Austria). CAT activity was measured using 
the Abei method [19]. SOD activity was measured by using an SOD assay kit (Dojindo 
Laboratories, Kumamoto, Japan). Total protein concentration was calculated by using 
the Bradford method [20]. The biochemical parameters (total cholesterol (TCHO), 
alanine aminotransferase (GPT/ALT), albumin (ALB), alkaline phosphates (ALP), 
ammonia (NH3), glucose (GLU), ν-glutamyltransferase (GGT), glutamic oxaloacetic 
transaminase/aspartate aminotransferase (GOT/AST), blood urea nitrogen (BUN), 
creatinine (CRE), and total bilirubin (TBIL)) were examined in the current work. 
Statistical records were measured and analyzed using Excel software and plotted 
using the origin pro 2016 version. The differences between the samples and controls 
were assessed using one-way Anova. Data are presented as mean ± SE (n = 3). 
 
8.3 Results and discussion 
 
GFs were fabricated via chemical vapor deposition (CVD) of graphene on a Ni foam 
template. The Ni scaffold assisted CVD process is an effective way to obtain larger 
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grains for better quality growth and to produce GF with a controlled morphology. The 
porosity, grain size, and surface smoothness of three-dimensional (3D) Ni foam with 
visible grain boundaries make it suitable for GF growth. As-prepared GFs were 
characterized by scanning electron microscopy (SEM). Figure 8.1A, B presented 
together SEM images of an as-prepared GF. SEM images revealed that the as-
prepared GF had a porous interconnected 3D network. Figure 8.1 C showed a 
wrinkled piece of graphene foam. GFs were also characterized by Raman 
spectroscopy. As seen in Figure 8.2a, two strong peaks at 1574 cm−1 (G) and at 2720 
cm−1 (2D) appeared. The position and intensity of the Raman peaks give valuable 
information about the defect level, the number of graphene layers or the sp3 hybrid 
phase. The G peak is the E2g optical mode of graphite and this band arises from the 
C=C in-plane stretching vibration. Negligible effect of the D mode at 1300 cm−1 
indicates a perfect crystal structure of the foam, and a carbon monolithic-like structure 
[21–24]. As shown, the G peak (intensity: IG) is stronger than the 2D peak (intensity: 
I2D), suggesting the few layer feature of the GF (IG/I2D ~ 2.4). In a single layered 
graphene, I2D is greater than IG, whereas in a bilayered graphene, both are almost 
equal. Figure 8.2b shows the XRD pattern of a powder sample prepared from as-
prepared GF. The sharp peak at 26.5° (2) corresponds to the (002) plane of graphite, 
and the weak one at ca. 55° to the (004) plane. 
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Figure 8.1: Basic characterization of as prepared graphene foam (GF) (A, B) Scanning 
electron microscopy (SEM) images of GF representing its porous netwrok, (C) a 
photograph of a piece of GF. 
Figure 8.2: (A) Raman spectroscopy and (B) XRD of GF with Cu-Ka radiation (l ¼ 
0.154 nm) operated at 40 kV and 40 mA. 
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As-prepared GFs were further investigated for toxicity and spontaneous morphological 
and histological changes in common carp. The cytotoxicity of the 3D GF has been 
shown by cell viability over 24 h. The cell population is significantly increasing using 
GF-based scaffold (Figure 8.3 A). Hence, GF has capability to attach and grow cells 
in 3D microenvironment. It is also evident that 3D GF has a good cytocompatibility in 
U87 cell line over a period of 28 days. Cell attachment was further investigated by SEM 
and fluorescence imaging which revealed cell adhesion and cell confluent on 3D GF 
after 21 days of seeding as shown in Figure 8.3 (B-D). Cells shown in green exhibited 
their attachment in 3D scaffolds. Although, cell attachment was not uniform on GF, 
which was due to the porous network of scaffold. The results indicated cell 
maintenance in 3D culture, good cell viability and cell growth.  
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Figure 8.3: Cytotoxicity and fluorescence imaging of 3D graphene foam. (A) Alamar 
BlueTM cell viability assay test on U87 seeded on GF and polystirene samples over 
28 days, (B) SEM image of cells cultured on GF-based scaffold and (C-D) 
immunofluorescence image of U87 cells seeded on 3D GF for 21 days at 
magnifications of 200 and 100 µm. 
 
In this chapter, common carps were investigated for 7 days following treatments with 
low (5 mg/L), medium (10 mg/L) and high (15 mg/L) doses of GF. Animal models were 
distributed in four groups, three treated with low, medium, and high doses and one 
untreated as a control group, n = 8 per group. The control and treated animals were 
then euthanized for histological analysis, biochemical parameters, enzymatic activities, 
and further studies. There were some additional animal models involved in this 
experiment, as a safe side of the experiment. Body weights were supervised and 
measured every 48 h and the variations were very close between treated and untreated 
groups (SI Figure 8.1), suggesting insignificant systemic effects. The eating, drinking, 
experimental conduct, grooming, urination, and neural changes were normal 
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throughout the 30 day study. No nausea was detected before and after the treatment 
of GF formulation. 
 
The biochemical parameters of treated and control fishes were examined for any acute 
and appreciable marks of toxicity and their responses to GFs over 7 days. These 
features did not show any significant changes. Figure 8.4 A, B presents blood testing 
results of common carps exposed to GF in a dose-dependent manner after 7 days, 
including NH3: ammonia (μg/dL), GLU: glucose (mg/dL), TCHO: total cholesterol 
(mg/dL), ALP: alkaline phosphates (μ/L), GOT/AST: glutamic oxaloacetic 
transaminase/Aspartate Aminotransferase (μ/L), GPT/ALT: alanine aminotransferase 
(μ/L), GGT: ν-glutamyltransferase (μ/L), ALB: albumin (d/dL), BUN: blood urea 
nitrogen (mg/dL), CRE: creatinine (mg/dL), and TBIL: total bilirubin (mg/dL). Data 
represent the average ± SD (n = 3). No statistically significant changes were observed 
between different groups in a dose dependent manner except the BUN. The 
assessment of the biochemical parameters revealed that a higher dose of GF likely 
had a toxic effect because of its strong hydrophobic interface with cell membranes [20], 
although GF exhibited an insignificant hemolytic effect (up to 75 μg/mL) and minor 
intensities of coagulation. However, graphene oxide (GO) and their other counterparts 
at 2 μg/mL provoked persistent and severe injury in lungs [25]. GF did not induce 
appreciable toxic effects in serum biochemical levels because of its different 
morphology, chemical structure, higher surface area, and porous architecture as 
compared to other graphene-based counterparts. 
Figure 8.4 (A,B): Blood analysis of common carp exposed to GF as a function of dose 
level after 7 days. These results showed mean and standard deviations of ALB: albumin 
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(d/dL), BUN: blood urea nitrogen (mg/dL), CRE: creatinine (mg/dL), TBIL: total bilirubin 
(mg/dL) and B: NH3: ammonia (μg/dL), GLU: glucose (mg/dL), TCHO: total cholesterol 
(mg/dL), ALP: alkaline phosphates (μ/L), GOT/AST: glutamic oxaloacetic 
transaminase/Aspartate Aminotranferse (μ/L), GPT/ALT: alanine aminotransferase (μ/L) 
and GGT: ν-glutamyltransferase (μ/L). Data are presented as mean ± SE (n = 3). 
 
Next, we studied antioxidant enzyme activities before carrying out the histological 
analysis on the vital organs. It should be noted that the antioxidant enzyme expressions 
and levels are accountable for the removal of chemically induced oxidative stresses in 
the immune and defensive mechanism of a living system. Antioxidants include several 
enzyme classes such as glutathione-S-transferase (GST), catalase (CAT), and 
superoxide dismutase (SOD). Irregular abnormalities in these enzymatic repairs reveal 
the level of oxidative damages and defense. Variations in oxidative lesions have also 
recently been found to be a main factor for tumor growth in the liver as a result of 
polluted environment [26]. Exposure of nanoparticles (NPs) induces the mitochondria 
damage (via) depletion of glutathione, an endogenous thiol (SH–) group, and stress 
proteins. These antioxidants and free radicals are mediators of tissue and cellular 
related injuries and diseases [27,28]. Also the increased bioaccumulation of NPs 
causes a steady rise of hepatic and renal antioxidant activities, affecting the 
mitochondrial respirational system [29]. Hence, there must be a balance between 
generation of oxidants and antioxidants and the level of lipid peroxidation in vital 
tissues of the carps. Environmental stress is also involved in the functions of aquatic 
organisms. 
 
The antioxidant enzymatic activities (GST, CAT, and SOD) are presented in Figures 
5–7. As shown, enzymatic activities generally showed variation in a dose-dependent 
manner. GST actions in the liver, kidney and heart were normal regardless of the GF 
exposure after 48 h (Figure 8.5A). While at a higher dose, GST declined more 
significantly in the kidney than in the liver and heart at 96 h, and it was prominent in 
the liver at a higher dose (Figure 8.5B). GST plays a catalytic role in conjugation of 
toxic and harmful metabolites. Higher levels of GST cause the activation of enzymes 
involved in glutathione (GSH) synthesis. GSH indicates amplified detoxification 
activities in the main organs of fish [30]. The decline in GST levels was an effect of the 
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overuse of enzymes to resist the oxidative stresses instigated by GF, eventually GSH 
concentration was increased in vital tissues. In this work, the common carp revealed a 
substantial increase in GST over a 24 h and a 7 day timescale, but oxidative stresses 
decreased with increasing the GST concentration. Therefore, a rise in GST 
concentration can also be used for the analysis of reduced GSH dependent 
metabolism changes involved in redox and detoxification processes. 
     
Figure 8.5 (A–D): Glutathione-S-transferase (GST) activity in different organs of the 
common carp exposed to various concentrations of GF for different times: (A) 24 h (B) 
48 h (C) 96 h (D) 7 days. Data are presented as mean ± SE (n = 3). 
 
The key role of CAT is to protect the cells from accumulations of H2O2 by catalyzing its 
decomposition to H2O and O2, and to activate H2O2 as a peroxidase [31]. Its levels 
were similar among the control and treated groups, except a slight change in the kidney 
tissues of the common carp at a 7 day timescale indicated a reduced activity to protect 
the cells against H2O2 (Figure 8.6). It was reported that the enhanced SOD and CAT 
in the hepatocytes of the fish might be prompted by microcystin [32]. 
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Figure 8.6 (A–D): catalase (CAT), activity in different organs of the common carp 
exposed to various concentrations of GF for different times: (A) 24 h (B) 48 h (C) 96 h 
(D) 7 days. Data are presented as mean ± SE (n = 3). 
 
SOD levels were within the range observed for control and treated carps (Figure 8.7). 
SOD is a defensive free radical in enzyme systems that principally dismutase 
superoxide radicals [33]. This also reveals the greater requirement of proteins to 
protect the cells against the radicals. However, SOD activity was considerably lesser 
in the liver of fish exposed to high dose as compared to the liver in the control model 
(Figure 8.7A). The antioxidant resistance of the liver was affected at higher 
concentration, as evidenced by CAT and GST in the liver of carp exposed to a low 
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dose. Based on these results, we consider that GST and CAT were generated in 
appropriate capacities to neutralize the oxidative stress produced by GF. However, the 
relationships between GST, CAT, SOD and other antioxidant enzymes need to be 
established by further investigations. 
Figure 8.7 (A–D): Superoxide dismutase (SOD) activity in different organs of the 
common carp exposed to various concentrations of GF for different times: (A) 24 h (B) 
48 h (C) 96 h (D) 7 days. Data are presented as mean ± SE (n = 3). 
 
Histopathology of the heart, kidney, and liver of the common carp was also exploited 
and the results are shown in Figure 8.8 (in a dose dependent manner). Less damage 
was revealed in the low dose groups, but more damage was perceived in the high dose 
groups. Heart tissues showed normal histology in the control and low dose treated 
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common carps (Figure 8.8 A, B), whereas brown atrophy ( ) was found in the fish 
heart treated with medium dose (Figure 8.8 C) due to the deposition of pale golden 
brown ( ) (lipofuscin) granules in the heart muscle fibers. Common carp treated with 
a high dose showed degeneration of muscle fibers (*), vacuolization and thin fibers 
(Figure 8.8 D). Figure 8e–h show micrographs of the kidney of common carp treated 
with different doses of GF. Normal histology of the kidney was observed in the control 
and low dose treated groups (Figure 8.8 E, F). Atrophy and degeneration of 
glomerulus was found in the medium treated group (Figure 8.8 G). Necrosis and 
degeneration (ϕ) of kidney tubules was found in the high dose treated group (Figure 
8.8 H). Normal histology of the fish liver was found in the control and low dose treated 
groups (Figure 8.8 I, J) while degeneration of hepatocytes (#), pyknosis, karyolysis, 
and karyorrhexis in nuclei of hepatocytes and degeneration of the central vein in the 
liver lobule of common carp were found in the medium dose treated groups. High levels 
of hepatocytes degeneration (λ), karyorrhexis, and haemorrhage were also found in 
liver lobule of fish treated with a high dose of GF (l). The respective histopathological 
alterations in these vital tissues of both control and treated groups (Figure 8.8) are 
given in SI Table 8.1. Histological alterations in these organs after 5 days of GF 
treatment are also shown in SI Figure 8.2 and SI Table 8.2. 
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Figure 8.8 H & E stained light micrographs of Cyprinus carpio (heart (a–d), kidney (e–
h) and liver tissues (i–l)) treated with GF in a dose dependent manner. Figure 8a,b 
show normal histology of heart tissues, Figure 8c,d show histological alterations with 
deposition of lipofuscin granules (c) and degeneration/thinning of cardiac muscles (d) 
in high dose. Figure 8e,f show normal histology of kidney in the control and low dose 
treated groups while atrophy and constriction of glomerulus was found in the medium 
treated group (g). Necrosis and degeneration (ϕ) of kidney tubules was found in the 
high dose treated group (h). Normal histology of fish liver was found in the control and 
low dose treated groups (i,j) while degeneration of hepatocytes (#), pyknosis, 
karyolysis and karyorrhexis in nuclei of hepatocytes (k,l) and degeneration of central 
vein in liver lobule of Cyprinus carpio (k) were found in the medium and high dose 
treated groups. 
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No noticeable toxicity was found after breakdown of GF in vivo over a timescale of 7 
days. However, the biodistribution and toxicokinetics in the cells and animal model 
investigation revealed remarkable biocompatibility with GF, which could offer a new 
avenue for potential real-world applications of GF. Common carp treated with a high 
dose of GF survived without any sign of toxicity. The enzymatic and anti-oxidant 
activities were used to define the ultimate fate of GF in living systems. All results from 
this work suggested that as-prepared GF had excellent biocompatibility on the 
timescale investigated. These could unveil the potential risk associated with their 
bioaccumulation. The relative infancy of NMs begs for animal model investigations to 
shed light on in vivo interactions of NMs before translation to humans. Importantly, it is 
necessary to assess long term toxicity in other animal models to better understand the 
mechanism of toxicity and compatibility of such materials before clinical applicability. 
Although such toxicological investigations indicated the less toxic effects in such 
animal models and were useful for research, it is really hard to relate these responses 
and effects to those in humans. A cross-species comparative approach can 
significantly improve the prediction of human responses to practical and realistic 
applications. However, long term toxicology studies are needed to using such materials 
in clinical settings. 
 
A large number of in vivo studies based on histology changes of vital organs exposed 
to graphene have been carried out before. A non-biodegradable feature of GFs as 
implanted scaffolds was demonstrated in rat exhibiting good biocompatibility [34]. GO 
administration in some other animal models, such as rat, caused prolonged toxicity 
and lung granuloma death [35]. In another study, GO administration was found to 
induce dose-dependent lung toxicity, granulomatous abrasions and injuries, and 
inflammatory cell penetration [36]. Higher concentrations of graphene, GO and rGO 
(reduced graphene oxide) were reported to be toxic. Fortunately, the results from the 
present study indicated that toxicity of GF was very minor. This is probably because of 
its different porous structure, chemical and physical morphology, and architecture, 
compared to those of its other graphene-based counterparts. Synthesis routes, size, 
surface charge, colloidal stability, surface chemistry, and water solubility affect in vivo 
nano-formulations. No noticeable differences were found in the in vivo toxicity of GF in 
this study. Additionally, GF appeared to be non-biodegradable even after 7 days of 
 199  
  
treatment. Several factors might have contributed to the toxicity mechanism of GF, 
including the variety of exposure routes to living models, short or long term exposure 
periods, different chemiophysical properties, volume stability, and surface properties 
in vivo. To solve the real world clinical problems, these factors must be considered 
before evaluation of toxicology and bio-distribution of NPs. Hence, understanding the 
fundamentals of aquatic toxicology and bioavailability of GF would also provide insights 
into the validity of environmental fate and impacts of GF. Long term toxicological and 
biodegradability studies of GF rooted into the target tissue for regenerative engineering 
need to be carried out in the future. 
8.4 Conclusions 
 
The present work deals with the systematic toxicity assessment of GF in U87 cell line 
and common carp. High dose administrations did not clue to critical or prolonged 
toxicity in fish, but some variations in blood cells were observed. In terms of 
biochemical and blood parameters testing, values remained within standard series 
resulting in no morphological and metabolism changes in fish model. Histopathology 
imaging revealed that GF remained within liver and kidney macrophages for 7 days 
without showing obvious sign of toxicity. Fluorescence imaging probed the cell 
attachment with 3D microenvironment of GF. The findings from this work provide 
insights into the diverse biological effects of GF and open new opportunity for their 
biomedical applications as an interface and scaffold material. 
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8.5 Supplementary information 
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SI Figure 8.1: Mean and standard deviations of body weight of common carp treated 
with GF show no statistically substantial changes over a period of 7 days. Data are 
presented as mean ± SE (n = 3). 
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SI Table 8.1: Histological changes in fish after treatment with GF for 7 days. 
Histological changes were observed in both control and treated groups and indicated 
by + and – (where + means this is found in particular tissue, ++ means this is highly 
noted in particular tissue, and – means it is not found in the tissue). 
 
Histological alteration Control Low dose Medium dose  High dose 
Liver 
Karyolitic  nuclei in 
hepatocytes 
- - + ++ 
Karyorrhexis nuclei in 
hepatocytes 
- - + ++ 
Pyknosed nuclei in 
hepatocytes 
- 
- 
- 
- 
+ ++ 
Necrosis - 
- 
- 
- 
+ ++ 
Degeneration of central 
vein 
- - + ++ 
Degeneration of 
hepatocytes 
- - + ++ 
Inflammatory cells - - + ++ 
Hemorrhage - - - ++ 
Renal tissue 
Glomerlus shrinkage - - + ++ 
Pynknosed nuclei - - + ++ 
Congestion - - + ++ 
Necrosis - - + + 
Deposition of Lipofuscin 
granules 
- - + - 
Haemorrhage - - - ++ 
Heart 
Condensed pyknosed 
nuclei 
- - - - 
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Deposition of Lipofuscin 
granules 
- - + - 
Thinning and 
degeneration of 
myofibrils 
- - - + 
Haemorrhages - - - - 
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SI Figure 8.3: H & E stained light micrographs of Cyprinus carpio {heart (a-d), kidney 
(e-h) and liver tissues (i-l)} treated with GF in dose dependant manner after 5 days.  
Figures a-b, e-f and i-j show normal histology of heart, kidney and liver. Figures c-d, g-
h and k-l show histological alterations in dose dependent manner in selected tissues. 
Details of histological alterations are given in Table S2. All the images were taken at 
50µm scale bar. 
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SI Table 8.2: Histological findings in fish after treatment with GF for 5 days. Histological 
changes were observed in both control and treated groups and indicated by + and – 
(where + means this is found in particular tissue, ++ means this is highly noted in 
particular tissue, and – means it is not found in the tissue). 
 
Histological alteration Control Low dose Medium dose High dose 
Liver 
Karyolitic  nuclei in 
hepatocytes 
- - + + 
Karyorrhexis nuclei in 
hepatocytes 
- - + ++ 
Pyknosed nuclei in 
hepatocytes 
- 
- 
- 
- 
+ + 
Necrosis - 
- 
- 
- 
+ ++ 
Degeneration of central 
vein 
- - + + 
Degeneration of 
hepatocytes 
- - + ++ 
Inflammatory cells - - + + 
Hemorrhage - - - ++ 
Renal tissue 
Glomerlus shrinkage - - + + 
Pynknosed nuclei - - + ++ 
Congestion - - + + 
Necrosis - - + + 
Deposition of Lipofuscin 
granules 
- - + - 
Haemorrhage - - - ++ 
Heart 
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Condensed pyknosed 
nuclei 
- - - - 
Deposition of Lipofuscin 
granules 
- - + - 
Thinning and 
degeneration of 
myofibrils 
- - - + 
Haemorrhages - - - - 
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Chapter 9 
Conclusions and Future Outlook 
 
Although nanostructured graphene is physically tiny, it has a vast and growing impact 
on the economy. Nanostructured graphene could reap huge technological and 
economic advantages in nanomedicine. Nanomedicine, a multidisciplinary field that 
embraces biology, chemistry, physics and material sciences, is playing a key role in 
the treatment of human diseases such as cancer, neurological disorders and infectious 
diseases. The ‘war’ against cancer was declared in the early 1970s; there has been 
much research done on cancer diagnosis and treatment since then. More recently, 
considerable attention has been paid to developing graphene-based anticancer 
nanomedicine for the point-of-care management and treatment of these diseases. The 
leading payoff of nanomedicine lies in the realisation of nanostructured graphene-
based therapeutic platforms to potentially deal with the prevention and cure of cancer. 
Although nanostructured graphene is already used as an anticancer medicine, there 
is still uncertainty on the biological effects and bioavailability of graphene to facilitate 
a non-toxic and sustainable advancement of this technology. This thesis focused on 
biological effects of graphene-based materials (graphene oxide (GO), reduced 
graphene oxide (rGO), graphene nanopores (GNPs), graphene quantum dots (GQDs) 
and 3D graphene foam (GF)) as anticancer nanomedicines. The work reported here 
was motivated by the pressing need to understand the occupational, health and safety 
aspects of graphene-based nanosystems that could overcome a number of barriers to 
clinical translations. Taken together, all of these experimental works lay a foundation 
for subsequent adaptation of these materials into biomedical practices. 
 
9.1 Conclusions 
 
The main achievements and key findings for the work carried out in each chapter of 
this thesis are summarised below: 
 
1. Chapter 4 presents a straightforward and highly adaptable strategy for the rapid 
and facile removal of pro-metastasis enzymes that effectively rescue the disease. GO, 
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with its variable zeta potential, variety of functional groups and very large (and in 
principle fully accessible) surface area, is an extremely promising candidate for the 
adsorption of such enzymes. Overexpression and secretion of the enzymes cathepsin 
D (CathD) and cathepsin L (CathL) is associated with metastasis in several human 
cancers. As a superfamily, extracellularly, these proteins may act within the tumor 
microenvironment to drive cancer progression, proliferation, invasion and metastasis. 
We have conducted research into the potential of anti-metastatic target therapy using 
GO to adsorb these pro-tumourigenic enzymes. Definitive binding and modulation of 
CathD/L with GO revealed that CathD/L were adsorbed onto the surface of GO through 
its cationic and hydrophilic residues indicating non-toxic effects on cells. GO 
nanostructures are easy to manufacture and are stable, which simplifies long-term 
storage and correspondingly reduces the cost. This work could provide a roadmap for 
the rational integration of CathD/L-targeting agents into clinical settings. 
  
2. Chapter 5 reports on integrative chemical-biological interactions of rGO with lung 
cancer cells, A549 and SKMES-1, to determine its potential toxicological impacts on 
them, as a function of its concentration. The in vitro toxicity of rGO against these two 
lung cancer cells has been assessed and compared for the first time without 
premodification of rGO. Cell viability, early and late apoptosis and necrosis were 
measured to determine oxidative stress potential and induction of apoptosis. The 
general trend was shown between cell death rates and concentrations for different cell 
types using a Gaussian process regression model. At low concentrations, rGO was 
shown to significantly produce late apoptosis and necrosis rather than early apoptotic 
events, suggesting that it was able to disintegrate the cellular membranes in a dose-
dependent manner. Given the evolving field of graphene-based nanomedicine, our 
findings regarding the toxicity of graphene using in vitro models could play a significant 
role in paving a new way to future biomedical applications of rGO. 
 
3. In chapter 6, a cost-effective and facile method for the preparation of a relatively 
new derivative of graphene, graphene nanopores (GNPs) was presented along with 
their in vitro and in vivo interactions in the mammalian and non-mammalian systems 
to systematically elucidate the possible mechanism of their toxicity over time. This 
study showed that GNPs induce early apoptosis in both SKMES-1 and A549 lung 
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cancer cells; however, late apoptosis is only induced at concentrations higher than 250 
µg/ml, suggesting that, although GNPs at lower concentrations induces upregulation 
of phosphatidylserine on a cell surface membrane (i.e. early apoptotic event), it does 
not significantly disintegrate the cell membrane. Here, we also showed that rats 
intraperitoneally injected with GNPs exhibited acute toxicity in a period of 27 days 
when tested at single and multiple doses of GNPs (5 and 15 mg/kg) as evidenced by 
blood biochemistry, organo-somatic index, liver and kidney enzymes functions 
analysis, oxidative stress biomarkers and histological examinations. In vivo 
biodistribution results reveal that GPNs mainly accumulate in the liver and lungs after 
intravenous administration and can be gradually cleared through the kidney. Our 
results showed that GNPs are likely to have a low bioavailability in SKMES-1 and A546 
lung cancer cells and in rats.  
 
4. Chapter 7 demonstrates the integrative physiochemical interaction between trypsin 
and GQDs to determine their potential biological identity in enzyme engineering. We 
selected trypsin, due to its role as a biologically relevant target enzyme; trypsin is a 
pancreatic serine protease involved in digestion of proteins as well as playing a role in 
other important biological activities. Trypsin is a medium-sized globular protein with 
applications in wound healing machineries, and in washing agents. The bonding forms 
a nano–bio-interface that defines the role of the QD and can induce damage in the 
interacting trypsin. GQDs exhibited a strong bonding capacity owing to their surface 
charge and surface functionalities. They were highly biocompatible, as demonstrated 
by the fact that the trypsin was adsorbed onto their surface via chemical interaction 
and hence blocking the emission of fluorescence signals from the graphene molecule. 
Different levels of inherent surface oxygen containing functional groups of GQDs were 
found to be the reason behind the tuning of trypsin’s specific activity. A fluorogenic 
substrate for trypsin was used to carry out control experiments of trypsin activity. Our 
findings suggested that trypsin’s active sites were stabilised and protected by the 
GQDs, which was likely to be responsible for the high bioavailability of GQDs in 
enzymes. 
 
5. Chapter 8 presents a cytotoxicity study on 3D GF in human glioblastoma U87 cell 
line and common carps, which was measured by antioxidant enzymatic activities, 
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biochemical and blood parameters, and histological alterations in key organs (kidney, 
liver, heart, and spleen). High dose administrations did no cause any acute toxicity in 
fish, but some variations in blood cells were observed. In terms of biochemical and 
blood parameters testing, values remained within standard series, resulting in no 
morphological or metabolism changes in the fish model. Histopathology imaging 
revealed that GF remained within liver and kidney macrophages for 7 days without 
showing obvious signs of toxicity. Additionally, fluorescence imaging of U87 cells 
seeded on GF-based scaffolds probed the cell attachment with 3D microenvironment 
of GF. 
 
9.2 Future work 
 
Based on these research findings, a number of future recommendations can be made 
to benefit the discipline of anticancer nanomedicine with respect to the research and 
development work required for the progression of this ‘miracle material’. The following 
future studies for each derivate of graphene discussed in this thesis should be taken 
into consideration to further validate the fate of graphene-based materials in 
nanomedicine: 
 
9.2.1 Graphene-based anti-metastatic extracellular enzyme therapy 
 
The findings presented in Chapter 4 make a significant contribution towards the further 
development of anti-metastatic extracellular enzyme therapy.  
 One aspect that is worth investigating in the future is the in vivo testing of GO 
for the adsorption and subsequent removal of pro-metastatic enzymes from 
living systems. However, the other adsorbents for selective targeting of 
extracellular enzymes could also be investigated for a range of enzymes. 
 Further in vitro testing with enzyme suspensions and substrates, and using 
further cellular assays which explore potential mechanisms of other enzyme 
adsorption, could also be interesting to extend this novel therapy. Furthermore, 
testing the role of reactive oxygen species in adsorption and tuning the GO 
properties could give a wider insight into the interplay between in vivo activity–
structure relationships. 
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 Importantly, tumors tend to survive under hypoxic conditions, which are 
characteristic features of tumor metastasis and drug resistance. Low oxygen 
environments could also be taken into account while using GO as an anticancer 
therapeutic agent. Design of hypoxia-activated modulators and reductants with 
graphene-based materials could help improve the anticancer efficacy of such 
nanomaterials-based therapies to target/leverage tumor hypoxia. 
 
9.2.2 Bioavailability of reduced graphene oxide 
 
Future studies are desirable to investigate the in vivo structure–activity relationships 
for rGO (Chapter 5), using different cell lines with differing lateral and sheet sizes of 
rGO or differing chemical modifications, and preparation to make it biocompatible and 
less toxic for biological applications.  
 The release of untreated rGO to the animal models and their pro or antibacterial 
and inflammatory responses should be taken into consideration for the 
wellbeing of humans.  
 Further studies must be conducted in this field to exploit the role of redox 
signalling. Chemical preparation of rGO involves exfoliation using sodium 
nitrate which can in turn release reactive nitrogen species in the cells. For 
example, the chemical exfoliation of GO is commonly carried out by using 
graphite flakes in H2SO4 and NaNO3 to oxidise graphite flakes into graphite 
oxide. Oxidation by HNO3 may liberate gaseous NO2 and/or N2O4. The addition 
of NaNO3 increases the interlayer distance marginally with improved basal 
planes oxidation of graphite. As a result, graphite flakes are broken into the 
smallest possible sheets layer wise (e.g. single or few layers) with the maximal 
functionalisation on the basal plane. After the exfoliation of GO, hydrazine is the 
commonly used reducing agent to reduce the functional groups and to enhance 
surface area and porosity. As a result of using hydrazine, nitrogen tends to 
remain covalently bonded to the surface of graphene in the form of hydrazones, 
amines, aziridines and/or other analogous species. On this basis, it is important 
to quantify and analyse nitrogen-centred radicals present in graphene 
nanostructures. Elevated levels of reactive nitrogen species are involved in the 
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hyperactivation of cellular oxidases and mitochondrial dysfunction as a result of 
cell damage by inducing or repressing nitrosative stresses. 
 
9.2.3 Role of reactive oxygen species in oxidative stress and toxicity of 
graphene nanopores 
 
Chapter 6 presented the sub chronic levels of toxicity in rats when it was 
intraperitoneally administrated.  
 As part of future work, it will certainly be interesting to work on the role of 
reactive oxygen species in oxidative stress and in vivo toxicity by other routes 
of administration.  
 Testing other organs of interest, such as the liver and lung, for potential toxicity 
can also be adapted to look at the biosafety profile of GNPs. These 
superhydrophobic GNPs nanosystems can also be used to store and release 
therapeutic levels of nitric oxide for the disruption of biofilms with chronic 
wounds.  
 It is clearly evident that GNPs have a high specific surface area in which to store 
and release high amounts of nitrogen gas. A similar approach can be used for 
infectious diseases. Such wounds cannot be healed with antibiotics, hence 
these nanoporous systems could be a promising candidate for controlling 
wound biofilm infections.  
 
9.2.4 Graphene quantum dots in enzyme engineering 
 
The nano-bio-interface between the adsorbing enzymes and the GQDs surface could 
have potential applications in the development of biocompatible nanomaterials, 
nanomedicines, and for enzyme separation and purification approaches. It is clearly 
evident from our results presented in Chapter 7 that GQDs-trypsin interaction has 
shown consistency, time efficiency and the capability to tag chemically.  
 This work can be further extended to understand the kinetics of GQDs protein 
binding and affinities of GQDs for different proteins. Though we have shown 
that GQDs are able to bind to trypsin, the affinity and specificity for different 
proteins are unknown.  
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 Future studies can be directed towards understanding the dependence of size, 
charge, and amino acid composition of different proteins in GQDs-protein 
complex formation. However, a similar approach could be used to deliver high 
molecular drug within diseased cells. Exploring the potential biological 
applications of GQDs, such as drug delivery and imaging among many other 
applications. 
 
9.2.5 3D graphene in regenerative medicine 
 
It was demonstrated that development of biocompatible 3D GF-based scaffolds can 
be used for the attachment and growth of cells (Chapter 8).  
 Regeneration of stem cell and non-stem cell cultures within 3D 
microenvironments of GF-based scaffolds could be exploited in animal models 
for their clinical settings, hence when tested in in vivo models this can potentially 
open a new route for the realisation of 3D GF in regenerative medicine.  
 As part of future work, it will also be interesting to study other recently reported 
advanced functionalities of biodegradable GF for stem cell therapy. 
